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I. Primary Chondrosarcoma 
 
Primary bone tumors are rare, constituting 0.2% of all reported neoplasms (1). 
Malignant cartilage tumors of bone are classified as chondrosarcomas. After 
osteosarcoma, primary chondrosarcoma is the second most frequent high grade 
bone tumor in humans, and is most common in adults between the 3rd and 6th 
decade of life. Conventional chondrosarcoma is the most common variant, and 
constitutes about 85% of all chondrosarcomas  (fig 1) (2).  
Chondrosarcomas frequently occur in the bones of the pelvis, ribs and bones of the 
extremities, and are much more rare in the skull or small bones of the hands and 
feet. Patients often present with persistent swelling and/ or pain. Using 
conventional imaging, a radiolucent lesion with ring-like opacities can be observed 
due to calcifications, MRI imaging is helpful to determine matrix calcification and 
soft-tissue involvement. A central chondrosarcoma typically arises in the 
metaphysis or epiphysis and dynamic contrast enhanced MRI is a helpful tool in 
identifying malignancy. In the diagnosis of a peripheral chondrosarcoma, arising 
on the surface of the bone, an MRI scan can be particularly helpful as a cartilage 
cap >1.5-2cm is an indicator of malignancy (3;4). Histologically, conventional 
chondrosarcomas are divided into 3 grades (5). As the former grade I 
chondrosarcoma (CSI) (6) was rarely reported to metastasize, in the 2013 WHO 
classification CSI is reclassified as atypical cartilaginous tumor (ACT), being of 
the intermediate, locally aggressive category and will here be referred to as ACT/ 
CSI. High grade chondrosarcomas that are more prone to metastasize, are classified 
as grade II (CSII) and grade III (CSIII) chondrosarcoma (2). 
An important predictor for local recurrence is the margin status upon resection. The 
most important predictor of metastases is histological grade. So far no molecular 
markers have been identified that are independent from and better than histological 
grading, and correct assessment of histological grade requires an experienced 
pathologist. An ACT/ CSI will show ample hyaline cartilaginous matrix 
surrounding the cells that have small hyperchromatic nuclei, whereas CSII and 
CSIII will show increased cellularity, nuclear atypia, and nuclear size. Grade III 
lesions are more cellular than grade II lesions with high mitotic count, more 
myxoid matrix and spindle cell changes at the edge of the lobuli. The distinction 
between a benign enchondroma and an ACT/ CSI can prove difficult and a high 
interobserver variability has been established (7-9). For clinical management, the 
distinction between ACT/ CSI and CSII is more important, which is less subjected 
to interobserver variability (8). In ACT/ CSI, curettage with local adjuvans is 
showing good long term results with <6% local recurrence rate (10) and currently 
has a 5 year survival rate of 83%. In CSII and CSIII, en-bloc resection is required 
and wide resection margins are necessary to prevent local recurrence, as 13% of 
local recurrences show an increase in histological grade. The combined 5 year 
survival rate for CSII/ CSIII is 53% (2;5;10;11).  
 
  
Chapter 1                                                                                                          9 
 
 
II. Secondary chondrosarcoma arising in benign cartilaginous tumors  
 
Enchondroma and secondary central chondrosarcoma 
A conventional chondrosarcoma arising from a pre-existing benign precursor 
lesion is classified as a secondary chondrosarcoma (fig 1). Enchondromas are 
benign cartilaginous lesions arising in the medullary cavity of the bone. 
Enchondromas are most common in the short tubular bones where they can cause 
palpable swellings, and less common in the long tubular bones and flat bones, in 
which case these lesions are mostly asymptomatic and often incidentally detected 
in radiographs. The majority of enchondromas are detected between the second to 
fifth decade of life and are solitary. Occasionally involvement of more than one 
bone or multiple lesions in one bone are observed, indicating enchondromatosis. 
The most common enchondromatosis subtypes are Ollier disease (multiple 
enchondromas often in a unilateral distribution) or Maffucci syndrome (multiple 
enchondromas combined with  (spindle cell) hemangiomas) (12;13).  
Recently, mutations in isocitrate dehydrogenase -1 (IDH1) or -2 (IDH2) were 
identified in 87-93% of enchondromas (14-16). IDH mutations were originally 
discovered in glioblastomas (17), and the molecular mechanism in tumor formation 
is currently being elucidated. Both IDH1 and IDH2 are mitochondrial enzymes in 
the tricarboxylic acid (TCA) cycle and are dependent on NADP+. Under normoxic 
conditions, NADPH and α-ketoglutarate is produced, the latter crucial in 
preventing the stabilization of HIF-1α (18). IDH mutations lead to a shift in the 
TCA cycle favoring the production of the oncometabolite D-2-hydroxyglutarate 
(D2HG) (19-22). The increased D2HG production has been reported to contribute 
to tumor formation through epigenetic mechanisms such as impairment of histone 
and DNA demethylation (23-25). As α-ketoglutarate and D2HG show a high 
degree of structural homology, they share the same substrates. Accumulation of 
D2HG can inhibit the histone demethylases, as well as the TET family of 
methylcytosine hydroxylases, otherwise activated by α-ketoglutarate (26-28). 
Aberrant DNA methylation patterns have been observed in IDH mutant primary 
tumors (23;28-31) including enchondromas (14). Using a knock-in approach, a 
heterozygous IDH1 R132H mutation was introduced into a human colorectal 
cancer cell line, inducing genome-wide histone and CpG methylation, along with a 
change in gene expression, supporting the causative role of IDH mutations in 
tumorigenesis (32). Moreover, IDH induced hypermethylation has been shown to 
block cell differentiation in hematopoetic stem/progenitor cells and adipocytes 
(24;28). 
Prolyl hydroxylases, responsible for the degradation of HIF1/2α proteins and 
maturation of collagen proteins, are also dependent on α-ketoglutarate. The role of 
D2HG in creating a "pseudohypoxic" state by preventing the proteosomal 
degradation of HIF1α is still under debate (27;33), but IDH1 R132H knock-in 
mutant mice were shown to have decreased ROS levels and stabilization of HIF1α 
proteins. Though IDH1 mutations were under a brain-specific promoter, the same 
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study showed collagen maturation to be perturbed after IDH1 R132H knock-in and 
to be attributed to D2HG accumulation (34).  
The role of IDH mutations and the induced epigenetic changes resulting from 
D2HG accumulation in the progression from enchondroma to atypical cartilaginous 
tumor/CSI still remains to be determined (fig 1). Enchondromas were found to be 
mosaic, harboring both wildtype cells and IDH mutant cells (14). Moreover, IDH 
mutations were found in 38-70% of primary and 85-88% of secondary 
chondrosarcomas (14;16;35). In enchondromatosis the risk factors for malignant 
transformation include age and location. Enchondromas located in the long tubular 
bones and flat bones were reported to give rise to chondrosarcomas in 45% and 
50% of Ollier and Maffucci patients, respectively. Although enchondromas are 
most common at the short tubular bones, malignancy at this location occurred in 
only 15% of Ollier patients, and in none of the Maffucci patients. Patients with 
enchondromas in both the long and short tubular bones were most prone to develop 
chondrosarcomas, showing 46% and 62% incidence in Ollier and Maffucci 
patients, respectively (2;36).  
 
Osteochondroma and secondary peripheral chondrosarcoma 
Secondary peripheral chondrosarcomas arise from osteochondromas, benign 
cartilage capped bony projections arising on the surface of the bone. Patients 
usually present in the first three decades of life with a, usually asymptomatic, 
persistent hard mass. In approximately 15% of patients multiple lesions can be 
found, characteristic of multiple osteochondromas (previously called multiple 
hereditary exostoses), a hereditary autosomal dominant syndrome (37) caused by 
germline mutations in exostosin-1 (EXT1) or -2 (EXT2) (fig 1). In sporadic 
osteochondromas, somatic homozygous deletions of EXT1 can be found (37;38).  
EXT is a glucosyltransferase important in the synthesis of heparan sulfate, a 
proteoglycan essential for IHH diffusion in the growth plate (39). 
Chondrocytes mature in a matrix rich environment and are dependent on the 
proteoglycan-mediated diffusion of morphogens through their extracellular matrix. 
The morphogen Indian hedgehog (IHH) and parathyroid hormone-related protein 
(PTHrP) control the cells in the hypertrophic and proliferating zones, through a 
negative feedback loop (40;41). Impaired IHH signaling and retention of PTHrP 
can lead to an increase in proliferating chondrocytes and inhibition of 
differentiation. Recently, osteochondromas were shown to be mosaic, containing 
both wildtype and EXT mutant cells (42;43), and secondary peripheral 
chondrosarcomas have been shown to arise from the wildtype EXT cells as they no 
longer contain EXT mutations (fig 1) (44). The EXT mutations of their neighboring 
cells, however, are thought to create an environment in which the wildtype cells are 
prone to developing yet unknown (epi-)genetic changes (fig 1) (45). Though no 
longer containing EXT mutations, loss of inhibitory feedback of IHH on PTHrP 
and BCL-2 was shown to correlate with progression from osteochondroma to 
peripheral chondrosarcoma (46;47).  




In central chondrosarcoma, EXT and its downstream pathways have been studied 
as well. Despite wildtype EXT, aberrant IHH signaling is found, along with 
retention of PTHrP in high grade central chondrosarcomas (48;49), suggesting an 
EXT independent mechanism towards tumorigenesis. Reports about the suitability 
of the hedgehog pathway as a therapeutic target in central chondrosarcoma are 
conflicting, as targeting the hedgehog pathway with triparanol led to reduction in 
tumor growth in mouse xenografts (48), but cyclopamine was effective in only 1 of 
6 cell lines (50).  
Malignant transformation to secondary peripheral chondrosarcoma is found in ~1% 
of solitary osteochondromas, whereas in patients with multiple osteochondromas 




III Rare chondrosarcoma subtypes  
The rare chondrosarcoma subtypes include dediffferentiated chondrosarcoma 
(10%), mesenchymal chondrosarcoma (3%), and clear cell chondrosarcoma (2%).  
 
Dedifferentiated chondrosarcoma 
A dedifferentiated chondrosarcoma is histologically comprised of two clearly 
defined compartments; a highly cellular high grade anaplastic or undifferentiated 
component juxtaposed to a usually low grade chondrosarcoma. In addition to pain 
and swelling, patients can present with paresthesia and pathological fractures due 
to cortical destruction by the tumor. Upon imaging, an ill-defined lesion can be 
observed, and the irregular calcification showing both ring-like cartilaginous 
components and a high grade lytic permeable component  can indicate the presence 
of a dedifferentiated component (51). Dedifferentiated chondrosarcoma shows a 
relentless clinical course and a large retrospective study revealed that survival is 
highly dependent on presence of metastasis at diagnosis. Patients presenting with 
metastases have a 2 year survival rate of only 10%, compared to a 28% 10 year 
survival in patients presenting without metastasis (52).  
As dedifferentiated chondrosarcoma histologically shows two clearly defined 
regions, genetic markers were investigated to determine whether the two 
compartments are derived from a common origin (53;54). Recently, IDH mutations 
were found in 54% of dedifferentiated chondrosarcomas, and were not mutually 
exclusive with TP53 mutations (14;53). As identical IDH and TP53 mutations as 
well as loss of p16 expression has been found in the two different components this 
is suggestive of a common clonal origin and thought to be early events contributing 
to its histogenesis (fig 1) (53;54). Immunohistochemically, distinct pathway 
activation such as PTHLH expression (55) as well as different loss of 
heterozygosity patterns (54) can be observed, suggesting an early diversion of the 
two components (fig 1). MYC (56) and MDM2 (53) amplification have only been 
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reported in the dedifferentiated component and are therefore likely to be late events 
occurring after the separation of the two components 
As the prognosis is dependent on the dedifferentiated component, research aims at 
identifying pathways distinctly activated in this component for the development of 
therapeutic strategies.  
 
Mesenchymal chondrosarcoma 
Mesenchymal chondrosarcoma shows a mixture of undifferentiated cells with 
islands of well differentiated hyaline cartilage. Mesenchymal chondrosarcoma 
shows a widespread skeletal distribution, including the craniofacial bones, and 
primary soft tissue localization is reported in approximately 20-30%. Patients 
present with pain and swelling, occasionally of sudden onset, but most often 
present for at least one year (57). Due to its aggressive course, long term follow up 
is recommended. Tumor localization in the jaw or metastasis at time of 
presentation is a bad indicator for prognosis, whereas young age appears to be a 
good prognostic factor (58;59). Upon imaging, mesenchymal chondrosarcoma 
presents as an ill-defined, lytic lesion, often with cortical destruction, in most cases 
resembling high grade conventional chondrosarcoma (57).  
Mesenchymal chondrosarcomas were recently shown to carry the HEY1-NCOA2 
fusion gene (60), and a HEY1-NCOA2 negative lesion was found to carry an 
IRF2BP2-CDX1 fusion gene (fig 1) (61). Mesenchymal chondrosarcomas have not 
been found to carry IDH mutations, and mutations in TP53, p16, or MDM2 are 
also found to be rare events (53;62;63). However, Rb pathway dysregulation was 
found in 70% of mesenchymal chondrosarcomas (53).  
 
Clear cell chondrosarcoma 
Clear cell chondrosarcoma represents a low grade chondrosarcoma showing clear 
cells with a distinct membrane surrounded by a hyaline cartilaginous matrix. Clear 
cell chondrosarcoma is most common on the epiphyseal ends of long bones, and 
shows the best prognosis with a mortality of 15%. The most common presenting 
symptom is pain, and upon imaging a well defined lytic lesion in the epiphysis of a 
long bone is observed, occasionally showing a sclerotic rim. The best curative 
option is en-bloc excision with clear margins. Clear cell chondrosarcoma is the 
only subtype reported to have a sex preference as it occurs three times more often 
in men than in women (64).  
Clear cell chondrosarcomas show random chromosome losses or gains, often with 
hemizygous involvement of the CDKN2A/p16 locus (fig 1). No involvement of 
IDH, TP53, or MDM2 has been reported (14;53). 
 
  




Figure 1.1. Progression model 
for conventional 
chondrosarcoma. A: In contrast 
to secondary chondrosarcoma, 
primary chondrosarcoma arises 
from the precursor cell without an 
intermittent benign lesion. EXT 
inactivation is observed in the 
benign osteochondroma. Peripheral 
chondrosarcomas are wildtype for 
EXT, and arise from the EXT 
wildtype cells in the 
osteochondroma. IDH mutations 
are found in enchondromas as well 
as low and high grade central 
chondrosarcomas, but only 
enchondromas were shown to be 
mosaic. Approximately 50% of 
low grade chondrosarcomas were 
shown to harbor IDH mutations. The (epi-)genetic events leading to progression from benign precursor lesion to a low grade tumor are 
unknown, and in progression from low grade to high grade, aneuploidy, loss of heterozygosity, as well as deregulations in the apoptosis, 
survival and growth plate signaling pathways are found. All these factors are likely to contribute to progression in grade and resistance to 
therapy. Both the cartilaginous and dedifferentiated components of dedifferentiated chondrosarcoma have been shown to harbor IDH and 
TP53 mutations, supporting the hypothesis of a common clonal origin. MYC and MDM2 mutations as well as loss of heterozygosity (LOH) 
patterns were found to differ between components, suggesting occurrence after component separation. In mesenchymal chondrosarcoma, the 
HEY1/NCOA2 fusion gene was recently identified, and the IRF2BP2-CDX1 fusion gene in a HEY1/NCOA2 negative lesion, indicating the 
mutual exclusive nature of these fusion genes. In clear cell chondrosarcoma, other than common loss of p16 protein expression, no causative 
mutations have been identified as of yet.  
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III. Chondrosarcoma model systems  
Recurrent and metastatic disease as well as chondrosarcomas located at 
unresectable sites present a major problem, as conventional chemo- and 
radiotherapy have shown to be ineffective (64). In order to improve survival rates 
and quality of life, there is an urgent need for new therapeutic strategies in 
chondrosarcoma. Chemoresistance has long been attributed to the cartilaginous 
matrix surrounding the cells, to the relatively low mitotic rate, as well as to 
possible expression of multi-drug resistance genes. Increasingly, activation of 
various pathways are being recognized in prohibiting apoptosis and promoting cell 
survival in chondrosarcoma (65).  
Ever since the discovery of Imatinib (11), as the prototype of targeted therapy in 
solid tumors, there has been an explosive growth in targeted therapies. In the 
preclinical search for the proper treatment strategy for chondrosarcoma, adequate 
model systems are invaluable. This is especially important in a rare malignancy 
such as chondrosarcoma, in which it is difficult to conduct large randomized 
clinical trials and for which it can be challenging to obtain funding from the 
pharmaceutical industry.  
 
Chondrosarcoma cell lines  
In cancer research, the use of cancer cell lines facilitates the study of the 
characteristics and behavior of cancer cells. Since the publication of the first 
human cell line in 1952, HeLa (66), the changes in the field of tissue culture have 
rapidly advanced cancer research. However, through HeLa, the community also 
learned about the pitfalls of cell lines. The rapid and wide dissemination of HeLa 
shortly after its discovery led to large scale cell line cross contamination. Today, 
most labs have implemented cell line typing in order to closely monitor and 
maintain the unique identity of each cell line (67).  
Cell lines prove an especially useful tool in the search for new treatment strategies. 
A first step is to investigate the effect of any treatment on cell viability using basic 
characteristics of the cells, such as presence of ATP or mitochondrial activity. 
However, a limitation of such viability assays can be the lack of proof of 
occurrence of apoptosis. In a healthy cell, the anionic phosphatidylserines are 
facing the cytoplasmic side of the plasma membrane. During apoptosis, disruption 
of phospholipids in the cellular membrane will cause the phosphatidylserines to 
face outwards. Being a natural binding site for human AnnexinV, recombinant 
AnnexinV can be used in combination with a fluorescent label such as FITC to 
detect apoptosis in cells (68). Combined with live cell imaging, specific apoptosis 
occurrence after drug exposure can be monitored over time (69).  
Real-time monitoring of cell number can also be performed with the xCelligence 
system (ACEA Biosciences). Providing a label-free system, based on cell density, 
this system uses small gold electrodes which cover the bottom of the plate. The 
electrodes are connected to a computer outside the incubator and as cells multiply, 
an increase in resistance over the electrodes can be converted into a cell index (70). 
Moreover, the xCelligence provides a real-time migration assay, with a 16 well-
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plate containing micropores. As cells are plated on the side without electrodes, a 
signal will only arise once cells have started migrating (71).  
Cell lines, however, are so-called 2D cultures. As chondrosarcomas histologically 
show cartilaginous matrix surrounding the cells, a 3D culturing system to 
investigate its role can be used. In 3D culturing, cells can be grown in scaffolds 
made to resemble the natural extracellular matrix (ECM). Correctly mimicking the 
ECM and controlling appropriate stimuli such as growth factors can be challenging 
in a system using scaffolds. A second method, widely used in oncology to examine 
tumor behavior, are multicellular spheroids. In this method, various approaches are 
applied to obtain cell spheroids, which are maintained using appropriate growth 
factors (72). As chondrocytes (73) were shown to create matrix in 3D culture, this 
model can be used to model chondrosarcoma behavior and drug response in vivo.  
 
Chondrosarcoma mouse models  
Ideally, drugs proven effective in cell lines are subsequently proven effective in 
vivo in rodent models before proceeding to the clinic. A stable, reproducible mouse 
model is advantageous for standardizing in vivo research. Current chondrosarcoma 
mouse models either show subcutaneous xenografting of tumor tissue immediately 
after resection from the patient, or subcutaneous injection of cell lines (74). An 
orthotopic model, more closely resembling the patient situation would be 
preferable. The pharmacokinetics of a drug need to be taken into account, as the 
distribution to an intra-osseous and a subcutaneous tumor can differ. In addition, 
subcutaneous injection could alter chondrosarcoma cell behavior through 
communication with surrounding cells. An orthotopic mouse model is therefore 
more likely to correctly predict response of the primary tumor than a subcutaneous 
model.  
In the literature several chondrosarcoma rodent models exist. One such model is 
the orthotopic swarm rat chondrosarcoma model, created using cell lines derived 
from a chondrosarcoma that spontaneously arose in a sprague-dawley rat. 
However, it was recently shown that the cell lines used to create the model consist 
of different cytogenetic properties (75). The literature also describes an orthotopic 
chondrosarcoma mouse model, derived from the JJ012 cell line (76). A limitation 
of these methods is that the role of EXT or IDH mutations in the tumorigenesis of 
osteochondromas and enchondromas, respectively, cannot be investigated. 
Conditional Ext1 knock out mouse models for EXT exist, and also show exostosis 
formation, closely resembling human osteochondromas, however, no malignant 
transformation to chondrosarcoma is observed in these lesions (77-79). So far, two 
IDH conditional knock-in mutant mouse model exist, specific for neural or 
hematopoetic progenitor cells, and in neither model has enchondroma or 
chondrosarcoma formation been found (34;80). As tumor size can only be assessed 
at time of animal sacrifice, when testing drug response, a method enabling live 
monitoring of tumor growth would be ideal. Using luciferase constructs, tumor 
growth can be monitored during the experiment with minimal stress to the animal, 
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as a single intra-peritoneal injection is required to activate the construct and the 
tumor can be visualized using a bio-imager (81).  
 
V. Approaches to identify new treatment strategies  
The hallmarks of cancer as characterized by Weinberg and Hanahan in 2000 (82), 
identified pathways distinctive to cancer cells which can be utilized when 
designing cancer therapeutics. Two of these pathways are recognized to be the 
apoptosis and survival pathways. Apoptosis pathways lead to an acquired capacity 
to evade programmed cell death. Survival pathways including tyrosine kinases can 
lead to a self-sufficiency in growth signals, as well as insensitivity to anti-growth 
signals, limitless replicative potential, sustained angiogenesis, and the acquired 
ability to invade distant tissue and metastasize(83;84).  
 
Apoptotic pathways  
One class of apoptotic proteins is the Bcl-2 family, and a shift favoring anti-
apoptotic Bcl-2 proteins can lead to the acquired capacity to evade programmed 
cell death, even in the presence of death signals (fig 2).  
Besides from its anti-apoptotic properties, Bcl-2 is also a player in the indian 
hedgehog (IHH) pathway during endochondral bone development (85). In both 
central and peripheral chondrosarcoma aberrant IHH signaling is observed along 
with retention of PTHrP. Apart from inhibiting differentiation, PTHrP also inhibits 
apoptosis through stimulating the expression of the anti-apoptotic protein Bcl-2, 
found to be overexpressed in high grade chondrosarcomas (fig 1) (46;48;49;85-89).  
The four Bcl-2 homology (BH) domains are characteristic of the Bcl-2 family, 
enabling oligodimerization. Three classes of proteins control cell survival and 
regulate apoptosis. Anti-apoptotic (Bcl-2, Bcl-xl, Bcl-w) and pro-apoptotic (BAX, 
BAK) family members possess all four BH domains, creating a hydrophobic 
groove able to bind BH3-only proteins (90). Two classes of BH3 proteins exist: i) 
activating BH3 proteins (BID, BIM) promote the oligomerization of BAX/BAK 
dimers, and ii) sensitizing BH3 proteins (BAD) bind the anti-apoptoptic proteins 
(fig 2). Only activating BH3-only proteins have the ability to induce cytochrome C 
release, and can in turn be released from the anti-apoptotic proteins by the 
sensitizing BH3-only proteins. The upregulation of anti-apoptotic proteins as 
reported in cancer, leads to the sequestration of BH3-only proteins, and prohibits 
the formation of BAX/BAK dimers (fig 2). Without the insertion of BAX/BAK 
dimers, the mitochondrial membrane will not be permeabilized, with the 
consequential lack of cytochrome C release and caspase activation (90;91).  
Inhibitors of the Bcl-2 family are based on protein-protein interactions. The first 
inhibitor to be discovered was HA14-1, a nonpeptidic ligand of Bcl-2 (92). The 
new class of inhibitors are called BH3 mimetics, specifically binding the 
hydrophobic BH3 groove of anti-apoptotic Bcl-2 proteins. The BH3 mimetic ABT-
737 (93) has shown promising preclinical results and its orally available 
counterpart, Navitoclax (ABT-263) (94), is currently in clinical trials for various 
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malignancies, including solid tumors (95). Resistance to ABT-737 has been 
attributed to increased Mcl-1 expression (96), and recently, a BH3 alpha-helix 
mimetic was designed, JY-1-106, specifically disrupting the protein-protein 
interactions between Bcl-xl and Mcl-1 with Bak (97).  Finally, the BH3 mimetic 
GX15-070, obatoclax, has been developed to bind Bcl-2, Bcl-xl, Bcl-w, and MCL-




Figure 1.2. Apoptosis pathway. In a healthy cell (left panel), response to death signals 
such as DNA damage can occur through activation of BH3 only proteins. Two types of 
BH3 only proteins will allow for apoptosis to occur: sensitizing BH3 only proteins like 
BAD will release BAX and BAK from the anti-apoptotic Bcl-2 proteins, Bcl-2, Bcl-xl, and 
Bcl-w. The activating BH3 only proteins, such as BID or BIM, will then promote 
BAX/BAK heterodimerization and insertion into the mitochondrial membrane, upon which 
the mitochondrial membrane becomes permeabilized. Consequentially, cytochrome C and 
calcium are released and caspases are activated, leading to apoptosis. In cancer, 
upregulation of anti-apoptotic proteins is often found (right panel), in which case a cell 
becomes desensitized to the activation of BH3 only proteins. BAX and BAK remain 
sequestered to anti-apoptotic proteins and the mitochondrial membrane is not 
permeabilized. The upregulation of anti-apoptotic proteins hereby leads to survival of cells, 
even in the presence of death signals, such as they might occur after chemotherapy.  
  




Survival pathways  
In biochemistry, an enzyme actively transferring phosphate groups from proteins in 
the process of phosphorylation is called a kinase. Tyrosine kinases are kinases 
which become activated once phosphorylated at a specific catalytic tyrosine site 
(99). Of the hallmarks of cancer (82), self sufficiency of growth signals, limitless 
replicative potential and tissue invasion can be traced back to tyrosine kinases 
which play an important role in survival pathways governing cancer cell survival, 
proliferation, and metastasis (83;84). Using kinome profiling, tyrosine kinase 
pathways were found to be active in chondrosarcoma (100).  
Receptor tyrosine kinases (RTK) have a cytoplasmic tyrosine kinase domain, and 
an extracellular ligand binding regulatory domain. As a rule, RTKs require ligand 
binding (typically growth factors) to undergo a conformational change allowing for 
dimerization and autophosphorylation, with resulting downstream signaling (101). 
The increased RTK signaling observed in cancer can occur through gene 
amplification leading to constitutive activation, or through close clustering on the 
membrane leading to homodimerization in absence of ligand (92). The importance 
of tyrosine kinase signaling in cancer has led to the development of a multitude of 
different tyrosine kinase inhibitors, of which 18 have now been approved by the 
FDA for a variety of malignancies (102).  
 
VI. Aim and outline of the thesis 
The aim of this thesis was to unravel mechanisms for chemoresistance and identify 
new therapeutic strategies for targeted treatment in chondrosarcoma. In order to 
rapidly translate results from basic research to clinical practice, pre-clinical models 
including chondrosarcoma cell lines and mouse models were developed.  
Chapter 2 focuses on new therapeutic strategies in chondrosarcoma. As such a 
review of recent preclinical research is linked to ongoing or completed clinical 
trials in chondrosarcoma in an attempt to provide a concise overview of the current 
state of the art of possibilities for targeted therapy in chondrosarcoma. In light of 
the recent discovery of IDH mutations, and advances regarding EXT mutations, 
their respective roles in chondrosarcoma tumorigenesis and chemoresistance is 
discussed, as well as the therapeutic potential of hedgehog signaling.  
In chapters 3 and 4 the development of new chondrosarcoma model systems is 
described. First, the generation and characterization of three new chondrosarcoma 
cell lines (chapter 3), and second, the development of an orthotopic 
chondrosarcoma mouse model (chapter 4).  
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In chapters 5-8, mechanisms of chondrosarcoma chemoresistance are investigated. 
Chapter 5 explores chemoresistance mechanisms in conventional 
chondrosarcoma, focusing on drug inaccessibility due to matrix hindrance, activity 
of multidrug resistance transporters, and overexpression of anti-apoptotic Bcl-2 
proteins (45;94). The role of Bcl-2 proteins in chemoresistance of conventional 
(chapter 5) and dedifferentiated chondrosarcoma (chapter 6) is further examined 
using the BH-3 mimetic ABT-737 in combination with doxorubicin or cisplatin. As 
rare chondrosarcoma subtypes histologically resemble different stages of the 
growth plate, in chapter 6, immunohistochemistry is performed on tissue 
microarrays of rare chondrosarcoma subtypes, to examine expression levels of 
proteins involved in growth plate signaling pathways.  
Finally, tyrosine kinase signaling pathways are investigated. Using kinome 
profiling, the PI3K/AKT and SRC pathway were found to be active (100), and 
were hypothesized to play a role in chondrosarcoma chemoresistance. In chapter 7 
we therefore combine enzastaurin (AKT inhibition) and dasatinib (SRC inhibition) 
with doxorubicin. As Src kinases are reported to play a role in metastasis formation 
(95), migration assays are performed. Hypothesizing that an upregulation in protein 
tyrosine kinases could well be concomitant with an upregulation of receptor 
tyrosine kinases, in chapter 8 a similar approach is used to investigate the 
activities of receptor tyrosine kinases (RTK) in chondrosarcoma cell lines using a 
phospho-receptor tyrosine kinase array. The roles of RTK activation in 
chondrosarcoma proliferation is further examined using kinase inhibitors, with 
analysis of downstream pathway activation. In comparison, mTOR pathway 
activation is studied to investigate downstream activation of RTK signaling.   
Chapter 9 will conclude with a summary of the results and an outlook to the 
future.  
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Primary bone tumors are rare and have a very specific age distribution (fig 2.1). 
Conventional osteosarcoma (OS) is the most frequent primary high-grade bone 
tumor in humans with 4 new cases per 106 population and year with the highest 
incidence in adolescence (1). The second most frequent primary bone malignancy, 
chondrosarcoma, accounts for approximately 3 new cases per 106 population and 
year predominantly affecting adults (2).The clinical management of unresectable 
and metastatic disease as well as therapy resistance  remain a clinical challenge (3). 
This review will discuss the molecular pathways that have been identified as a 
result of intensive genome wide and basic biology analysis and rationale to current 






Chondrosarcomas are hyaline cartilaginous tumors most often arising in bones 
which develop during endochondral ossification. Incidence and location are shown 
in figures 1 and 2. Conventional chondrosarcoma accounts for approximately 85% 
of all primary chondrosarcomas (3) and prognosis is strongly correlated with 
histological grading. Grade I chondrosarcoma, now reclassified as an atypical 
cartilaginous tumor, shows low cellularity and is locally aggressive, but typically 
does not metastasize (2). Grade II and grade III conventional chondrosarcomas 
show increased cellularity with mitoses and reduced cartilaginous matrix, and a 
corresponding increase in metastasizing capacity alongside poor patient survival 
(2;4). Amongst the rare chondrosarcoma subtypes, dedifferentiated 
chondrosarcoma accounts for up to 10% of all chondrosarcomas and shows a 
dismal prognosis. Dedifferentiated chondrosarcoma is comprised of two 
histologically well distinctive components: a high grade dedifferentiated 
component, and a seemingly low grade cartilaginous component (5). Mesenchymal 
chondrosarcoma is considered high grade and accounts for approximately 3% of 
primary chondrosarcoma histologically showing undifferentiated small round cells 
admixed with well differentiated cartilage (6).  Clear cell chondrosarcoma is 
considered low grade and comprises about 2% of all primary chondrosarcomas, 
demonstrating tumor cells with a clear, empty cytoplasm (7).  
  





Figure 2.1. Incidence of chondrosarcoma stratified by age group. Chondrosarcoma 
(CS) is the second most common primary bone malignancy in humans and occurs 
predominantly between the 3rd and 6th decade of life. The increase in incidence observed 
after the 6th decade is attributed to recurrences. Adapted from WHO 2013 
 
Current management of chondrosarcoma and resistance to therapy 
The first line of treatment for chondrosarcoma is surgical resection with local 
adjuvant treatment such as phenol or cryosurgery, followed by filling the cavity 
with bone graft, showing long term local control in atypical cartilaginous tumor / 
grade I chondrosarcoma (8). Due to the necessity of wide resection margins to 
prevent recurrence in grade II and III chondrosarcoma, the patient often needs to 
undergo mutilating surgery. In the event of tumor location at a nonresectable site, 
such as in the skull or pelvis, or metastatic disease, there is still no curative 
treatment (3;9). Chondrosarcoma is notorious for its resistance to conventional 
chemo- and radiotherapy (3). Recently, a phase II study including 25 patients with 
chondrosarcoma using the nucleoside analog gemcitabine (657 mg/m2 on day 1 
and day 8) followed by the anti-mitotic docetaxel (75 mg/m2 on day 8) over a 
course of 21 days, was aborted as only 2 patients showed partial response (10). In a 
recent study including 9 patients with dedifferentiated chondrosarcoma treated 
with surgery and chemotherapy (adriamycin, ifosfamide, cisplatin, and 
methotrexate) all patients died of metastatic disease (11). These results illustrate 
the high need for new targeted treatments in chondrosarcoma, as the conventional 
chemotherapeutics targeting the DNA machinery are not effective.  
Primary chemoresistance of chondrosarcoma has long been ascribed to the 
phenotypic properties, such as hyaline cartilaginous matrix surrounding the cells 
prohibiting access to the cells, poor vascularization, and a slow division rate 
(12;13). As these properties are less prominent in high grade chondrosarcoma, 
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which typically shows less matrix, increased vascularization and increased mitotic 
rate,  the resistance to therapy could also be due to activated anti-apoptosis or pro-
survival pathways (12). Moreover, nuclear accumulation of doxorubicin was 
shown despite the presence of matrix and multidrug resistance pump activity. In 
addition, inhibition of the anti-apoptotic Bcl-2 family members was found to 
overcome resistance to doxorubicin and cisplatin in chondrosarcoma cell lines 
(14).  
 
Targets and novel treatment options in chondrosarcoma 
Over the past years advances have been made identifying multiple active pathways 
in chondrosarcoma, and preclinical work has led to the identification of potential 
targets for clinical trials (table 1). Here the recent identification of IDH mutations 
will be discussed in relation to active survival pathways and HIF1α expression 
found in high grade chondrosarcomas, as well as growth plate signaling pathways 
including anti-apoptotic signaling, and retinoblastoma pathway alterations. 
 
Figure 2.2. Distribution of chondrosarcoma across the skeleton. 
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Survival pathways: IDH mutations 
Mutations in the isocitrate dehydrogenases (IDH) are found in 87% of benign 
enchondromas, 38-70% of primary conventional central chondrosarcoma, and 54% 
of dedifferentiated chondrosarcomas, but not in clear cell or mesenchymal 
chondrosarcomas (15-20). IDH is involved in the tricarboxylic acid cycle (Kreb's 
cycle) (21) and mutations in IHD1/2 lead to a diminished capacity to convert 
isocitrate to α-ketoglutarate (α-KG) and an acquired ability to convert αKG to D-2-
hydroxyglutarate (D2HG), which is considered an oncometabolite (19;21-25).  
The exact mechanism through which D2HG causes tumor formation is unknown 
although increasing evidence points towards epigenetic mechanisms (26-31). 
D2HG impairs the function of the αKG dependent dioxygenase TET2, leading to 
inhibition of DNA demethylation causing CpG island hypermethylation 
(27;32;33). Indeed, enchondromas carrying IDH mutations were hypermethylated 
(17). In addition, D2HG was shown to impair histone demethylation (33). 
Moreover, mutations in IDH are postulated to inhibit the prolyl/lysyl/hydroxylation 
of collagen proteins and thereby their maturation as an IDH1 R132H conditional 
knock-in mouse model showed a reduction in collagen IV maturation (34). Finally, 
D2HG was postulated to induce pseudohypoxia (fig3) by inhibition of the HIF 
proline hydroxylases although this is controversial (22;34;35).  
HIF-1α is upregulated by a multitude of malignancies to cope with reduced 
perfusion, and is associated with increased proliferation, VEGF production, and 
resistance to chemo- and radiotherapy (36-40). High grade conventional 
chondrosarcoma shows activation of the hypoxia pathway through HIF1α (41). 
Most drugs targeting hypoxia, are designed either to target VEGF, the downstream 
target of HIF1α, or to target the PI3K/AKT/mTOR pathway, which can induce 
HIF1α independent of oxygen conditions (fig 3) (36;42). 
 
Survival pathways: PI3K, AKT, mTOR, VEGF 
The PI3K/AKT pathway is often upregulated in cancer and can either inhibit 
apoptosis, or promote cell proliferation (fig 3) (43). Active AKT signaling was 
shown in chondrosarcoma(44) and the PI3K/AKT pathway has been shown to be 
involved in proliferation in mesenchymal chondroprogenitor cells (45). In 
chondrocytes, the PI3K/AKT can be activated by the chondrogenic transcription 
factor SOX9 (46), which is also expressed in chondrosarcoma (47;48). SOX9 
siRNA in a chondrosarcoma cell line (SW1353) induced apoptosis which could be 
rescued by PTEN expression (46). Mutations in the tumor suppressor PTEN are 
rare in chondrosarcoma (49). Perifosine, an AKT inhibitor inhibiting AKT 
membrane recruitment, showed 17% decrease in tumor size in one 
chondrosarcoma patient after two cycles (Steinert, CTOS 2006). A larger phase II 
study was conducted including patients with chemoinsensitive sarcomas but has 
not posted results (NCT00401388).  
Mechanistic TOR (mTOR) is a point of convergence of many pathways involved 
in protein synthesis and cell proliferation, including the PI3K/AKT pathway (fig 
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3). The first suggestion of activation of the mTOR pathway was in mesenchymal 
chondrosarcoma, showing strong cytoplasmic p-AKT, p-mTOR, and PDGFR-
alpha staining (50). In an adjuvant rat orthotopic Swarm Rat chondrosarcoma 
model, everolimus alone or in combination with doxorubicin after curettage 
showed inhibition of mTORC1 and decreased cell proliferation, however, the 
combination with doxorubicin showed an antagonistic effect with activation of the 
mTORC2 pathway (51). Allosteric inhibitors of the mTOR pathway, rapalogs, 
(rapamycin (sirolimus), everolimus, and temsirolimus) have limited efficacy in the 
clinic, but show high synergy with dual PI3K/mTOR inhibitors such as BEZ235 
(52). A clinical trial with temsirolimus and liposomal doxorubicin included 
chondrosarcoma patients (NCT00949325). While awaiting the results of this trial, a 
study including ten patients with unresectable chondrosarcoma who were treated 
with sirolimus and cyclophosphamide showed a disease control rate of 70% (53). 
However, the resistance to rapalogs observed in other malignancies is suggestive 
that in chondrosarcoma a strategy including dual PI3K/mTOR inhibitors such as 
BEZ235 should be considered for future clinical trials.   
Activated Src signaling can also lead to HIF1α expression (fig 3) (12;54;55) and 
promote cell survival. Src signaling was shown to be elevated in chondrosarcoma 
(44), and the tyrosine kinase inhibitor dasatinib showed a decrease in cell 
proliferation in 7 out of 9 cell lines (44). However, in a phase II study no objective 
response was obtained with dasatinib single agent (70mg bid as starting dose) in 
chondrosarcoma patients (Schuetze CTOS 2010).   
Activation of survival pathways can be through stimulation of the receptor tyrosine 
kinases by IGF-1 or PDGF. IGF-1 pathway activation was shown to be involved in 
chondrosarcoma proliferation, migration, apoptosis (56) (57;58), as well as 
progression to malignancy (58). Activation of the PDGF pathway has been shown 
to be related to worse prognosis in chondrosarcoma (59-61). Inhibition with 
imatinib, however, showed no effect in vitro in four chondrosarcoma cell lines 
(44), and in a clinical study including 26 patients no objective response was 
measured (62). HIF1α expression is suggested to result in increased VEGF 
expression in chondrosarcoma (40). Sunitinib and pazopanib are tyrosine kinase 
inhibitors, targeting multiple kinases including both PDGF and VEGF. In 
combination with proton beam radiation, sunitinib was reported to achieve 
complete symptomatic relieve and durable response in a patient with metastatic 
clear cell chondrosarcoma (63). A clinical study with pazopanib is currently 
recruiting chondrosarcoma patients (NCT01330966). 
 
Developmental pathways: Hedgehog  
In osteochondroma, a benign cartilaginous tumor at the surface of bone that can 
give rise to secondary peripheral chondrosarcoma, mutations in the genes encoding 
either exostosin -1 (EXT1) or -2 (EXT2) have been identified (64). EXT1 and EXT2 
are involved in the biosynthesis of heparan sulfate proteoglycans, which are 
necessary for the diffusion of the morphogen Indian Hedgehog (IHH) (65). 
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Recently, osteochondromas were shown to contain a mixture of both EXT mutant 
as well wildtype tumor cells (with functional EXT), and the latter were shown to 
be the precursor cells of peripheral chondrosarcoma (66) since peripheral 
chondrosarcoma have functional EXT, pointing towards a pathogenesis in 
chondrosarcoma independent of EXT.  
 
Figure 2.3. Apoptosis and survival pathways. EXT1/2: exostosin 1/2, IHH: Indian 
hedgehog, PTHrP: parathyroid protein, Bcl-2: B-cell lymphoma 2, BAD: Bcl-2 associated 
protein 2, IDH1/2: isocitrate 1/2, PI3K: phosphoinositide 3-kinase, AKT (PKB: Protein 
kinase B), mTOR: mammalian target of rapamycin, HIF1a: hypoxia inducible factor 1a, 
Src: sarcoma. 
 
IHH is part of a negative feedback loop with parathyroid hormone-related protein 
(PTHrP), creating a tight balance between proliferation and differentiation (fig 3) 
(for review see (67;68)). Aberrant hedgehog signaling is also found in central 
chondrosarcoma (69;70), despite absence of EXT mutations. Blocking of the 
hedgehog pathway with triparanol was shown to be effective (70), but reports on 
the effect of cylopamine are conflicting (69-71).  
A recent randomised phase II clinical trial with IPI-926 (saridegib), a potent 
cyclopamine analogue (72), for patients with metastatic or locally advanced 
conventional chondrosarcoma was terminated as the primary endpoint, 
progression-free survival, was not met (NCT01609179). A second trial is currently 
ongoing with vismodegib, a cyclopamine-competitive SMO-inihibitor 
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(NCT01267955). Preliminary results show stable disease in 4 out of 17 patients 
(Italiano, ASCO 2012). In osteochondroma, primary cilia were found to retain their 
normal length but lose their orientation contributing to loss of chondrocyte 
directionality (73) while 70-100% of human enchondromas and chondrosarcomas 
were found to lack primary cilia (74). In lft88-/- mice lacking primary cilia 
increased hedgehog signaling and enchondroma and chondrosarcoma formation, 
was observed. As cyclopamine depends on the primary cilia for SMO 
accumulation, chondrosarcoma cells lacking primary cilia were unresponsive to 
cyclopamine treatment (74). These results support the role for IHH in initiation of 
chondrosarcoma, and suggest that when inhibiting the hedgehog pathway in 
chondrosarcoma targets should be carefully selected. 
 
Developmental pathways: Anti-apoptosis 
The anti-apoptotic protein Bcl-2 is under direct regulation of PTH1R and is 
upregulated in chondrosarcoma (fig 3) (75). Moreover, Bcl-xl, another anti-
apoptotic protein belonging to the Bcl-2 family was shown to be overexpressed in 
18 chondrosarcoma tissues (76), indicating a specific defense mechanism 
contributing to chemoresistance in chondrosarcoma.  siRNA against Bcl-2, Bcl-xl, 
and XIAP showed an enhanced sensitivity to doxorubicin and radiation (77;78), 
and treatment with the BH-3 mimetic ABT-737, was shown to synergistically 
overcome resistance to doxorubicin and cisplatin (14). Another anti-apoptotic 
protein, not related to the Bcl-2 family, survivin, was also found to be highly 
expressed in chondrosarcoma (79;80) and inhibition experiments in 2 cell lines 
resulted in overcoming resistance to doxorubicin (79). These data point towards an 
effective defense mechanism in which chondrosarcoma cells prevent programmed 
cell death in response to stress signals such as DNA damage.  
Treatment with dulanermin (rhApo2L/TRAIL), a death receptor 4 (DR4) and 5 
(DR5) agonist, showed complete remission in one patient (81), and treatment with 
apomab, a DR5 agonist, showed a 20% reduction in measureable disease in one 
chondrosarcoma patient (82), but showed no efficacy in a follow up phase 2 trial 
with 90 chondrosarcoma patients (NCT00543712). These (pre-) clinical results 
combined with this promising result with dulanermin show that restoring the defect 
in the apoptotic machinery could prove strong therapeutic potential in 
chondrosarcoma. However, since multiple anti-apoptotic proteins are upregulated 
in chondrosarcoma, a multi-targeted approach may be more effective, considering 
that dulanermin, targeting both DR4 and DR5, was more effective than apomab, 
targeting only DR5.   
 
  




Figure 2.4. RB-1 pathway: p16 is a tumor suppressor and inhibits the cyclin dependent 
kinases (CDKs). Upon loss of p16, active CDKs phosphorylate RB-1 and release it from 
the E2F transcription factors, allowing for E2F target gene transcription and uncontrolled 
cell cycle progression.  
 
Retinoblastoma signaling 
The retinoblastoma protein pRb is a tumor suppressor controlling the cell cycle. In 
the absence of p16INK4A, RB-1 is released from E2F transcription factors such as 
histone deacetylases (HDAC) and cell cycle progression and gene transcription can 
occur (fig 4) (83). Recently Rb was shown to be required for hypertrophic 
chondrocyte differentiation, and Rbc/c/p107-/- mice were shown to develop 
enchondromas, indicating an important role for cell cycle regulation during tumor 
development (84).  
Ninety-six percent of conventional central high grade chondrosarcoma show 
alterations in the retinoblastoma pathway (85); not only through loss of the tumor 
suppressor CDKN2A/p16 (86;87) along with elevated CDK4 (88) but also through 
amplifications of CDK6 and E2F3 (89). In dedifferentiated chondrosarcoma p16 
aberrations were found to be common (85%) and associated with loss of 
chromosome 9p (16) or promoter methylation (90).  In mesenchymal and clear cell 
chondrosarcoma p16 alterations are found in 70% and 95% of the cases, 
respectively (16). Inhibition of CDK4 using shRNA against CDK4 was found to 
inhibit cell proliferation in three central chondrosarcoma cell lines (85). In a phase 
I dose defining study of the HSP90 inhibitor alvespimycin, one chondrosarcoma 
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patient showed CR (>6months stable disease) with reduction in CDK4 levels (91), 
supporting further exploration of HSP90 or CDK4 inhibitors in chondrosarcoma.  
On close proximity to the CDKN2 locus on chromosome 9 is the 
methylthioadenosine phosphorylase (MTAP), an enzyme vital for the recycling of 
adenine and methionine synthesis. Deletions involving the MTAP locus (9p21) 
have been reported in 50% of chondrosarcoma cases (89;92-94). In MTAP 
deficient cells, adenine and methionine are not metabolized rendering these cells 
more sensitive to selective inhibition of de novo purine synthesis. Permetrexed 
disodium is a multitargeted anti-folate preventing the formation of precursor purine 
and pyrimidine nucleotides (95).  A phase II trial with permetrexed disodium, has 
been performed in patients with metastatic or locally advanced chondrosarcoma 
(NCT00107419). No results have been posted yet.  
 
Other therapies: COX-2 and aromatase inhibitors 
Estrogen signaling plays a role in skeletal maturation and was found to be active in 
all chondrosarcoma subtypes (96-98). Even though initial results were promising 
(96;99), a recent retrospective series including 6 patients with locally advanced or 
metastatic chondrosarcoma treated with aromatase inhibitors did not show an 
increase in PFS compared to historically untreated patients (98). The prostaglandin 
synthase cyclooxygenase-2 (COX-2) is upregulated during inflammation, but also 
in for example colorectal, breast and prostate cancer (100). COX-2 upregulation 
was shown in chondrosarcoma (101;102) and to be associated with poor survival 
(103). COX-2 inhibition with celecoxib showed decreased cell viability in 4 
chondrosarcoma cell lines, however, in chondrosarcoma xenografts, a relapse was 
observed after 6 weeks (102). The negative results obtained with aromatase 
inhibitors in patients and COX-2 inhibitors in mice do not support clinical 
implementation of these therapeutic strategies.  
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Table 2.1 Overview of Targets and Selected Trials in chondrosarcoma 
Target Drug Mechanism Clinical results 
Clinical trial 






Phase II (n=53) combination with 
docetaxel. Terminated due to lack of 
evidence of efficacy  
(10). 
 permetrexed Prevents 
formation of 
DNA and RNA 
Study completed, no results posted NCT00107419 
AKT/PI3K perifosine Inhibits AKT 
membrane 
recruitment 
Phase I (n=10) combination with 
gemcitabine  
CS patient showed 17% decrease in 




mTOR sirolimus mTOR inhibitor Combination with cyclophosphamide 
in 10 patients 
disease control rate of 70%   
(53) 
SRC dasatinib Small molecule 
kinase inhibitor 













Phase II, completed, no results posted 
Case study: Antitumor activity in 2 
patients with extraskeletal myxoid CS  
Case study: Durable response after 
combination with proton beam 
radiation in 1 patient with metastatic 
clear cell CS 
NCT00474994 
(104) (63) 
 imatinib Competitive 
tyrosine kinase 
inhibitor 
Phase II (n=26), NOR  
 
(62) 
 pazopanib Blocks 
autophosphospho
rylation of PDGF 
receptors, VEGF 
receptors, FGF 
receptors 1 and 







Study terminated due to lack of 



















to DR4 and DR5  
Phase I study n=71  
2 CS patients durable PR  
Case study: near CR over 78 months in 
one patient with metastatic disease  
(81;105) 







Phase I study n=50, terminated due to 
lack of evidence of efficacy 
CS patient 20% reduction in 




alvespimycin HSP90 inhibitor Phase I study n=25 
CS patient CR with reduction in CDK4 
levels  
(9) 
CS: chondrosarcoma, NOR: no objective response, CR: complete response, PR: partial response.  
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Chondrosarcoma is the second most common primary sarcoma of bone. High-
grade conventional chondrosarcoma and dedifferentiated chondrosarcoma have a 
poor outcome. In pre-clinical research aiming at the identification of novel 
treatment targets, the need for representative cell lines and model systems is high, 
but availability is scarce.   
We developed and characterized three cell lines, derived from conventional grade 
III chondrosarcoma (L835), and dedifferentiated chondrosarcoma (L2975 and 
L3252) of bone. Proliferation and migration were studied and we used COBRA-
FISH and array-CGH for karyotyping and genotyping. Immunohistochemistry for 
p16 and p53 was performed as well as TP53 and IDH mutation analysis. Cells were 
injected into nude mice to establish their tumorigenic potential.  
We show that the three cell lines have distinct migrative properties, L2975 had the 
highest migration rate and showed tumorigenic potential in mice. All cell lines 
showed chromosomal rearrangements with complex karyotypes and genotypic 
aberrations were conserved throughout late passaging of the cell lines. All cell lines 
showed loss of CDKN2A, while TP53 was wild type for exons 5-8. L835 has an 
IDH1 R132C mutation, L2975 an IDH2 R172W mutation and L3252 is IDH wild 
type.  
Based on the stable culturing properties of these cell lines and their genotypic 
profile resembling the original tumors, these cell lines should provide useful 





Chondrosarcoma is a malignant bone neoplasm characterized by the deposition of a 
hyaline cartilaginous extracellular matrix. With an incidence of 1:50,000 it 
typically occurs in adults in their 3rd to 6th decade of life. Chondrosarcoma 
represents a heterogeneous group of tumors.  Primary central chondrosarcoma is 
defined by the formation of hyaline cartilage with decreasing matrix production in 
higher grades and constitutes about 80% of all chondrosarcomas (1). 
Dedifferentiated chondrosarcoma is characterized by a low-, or intermediate grade 
chondrosarcoma juxtaposed to a high grade anaplastic sarcoma and constitutes 
about 10% of all chondrosarcomas (2).  
Both high grade conventional and dedifferentiated chondrosarcoma respond poorly 
to conventional chemo- and/or radiotherapy, have a high metastatic rate, and 
consequently have a very poor prognosis (3). It is because of these features that 
there is an urgent need for model systems  in pre-clinical research aimed at 
evaluating  new targeted treatment strategies for chondrosarcoma (4).  
Recently IDH1 and IDH2 mutations were found in conventional central and 
dedifferentiated chondrosarcomas (5). IDH1 and IDH2 mutations are well known 
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in gliomas (6), but are notoriously difficult to grow in culture (7). This is a feature 
shared by, in particular, grade I chondrosarcomas. Recently, a new cell line derived 
from a grade II chondrosarcoma was published, CH-3573 (8). Over the last years, 
cell lines derived from dedifferentiated chondrosarcomas have been developed 
(9;10).  In the pursuit of expanding the panel of cell lines we have succeeded in 
creating three new chondrosarcoma cell lines.  L835 is derived from a grade III 
conventional chondrosarcoma, while L2975 and L3252 originate from 
dedifferentiated chondrosarcomas of bone. These three new cell lines provide a 




Culture of human chondrosarcoma cells 
Tumor-tissue derived from three resected specimens derived from one 
conventional and two dedifferentiated chondrosarcomas were used for culture. 
Samples were coded and all procedures were performed according to the ethical 
guidelines “Code for Proper Secondary Use of Human Tissue in The Netherlands 
2002” (Dutch Federation of Medical Scientific Societies 
http://www.federa.org/sites/default/files/bijlagen/coreon/codepropersecondaryuseof
humantissue1_0.pdf). Specimens were washed 3x with RPMI1640 (Gibco, 
Invitrogen Life-Technologies, Scotland, UK) containing 1% 
penicillin/streptomycin (100U/mL), minced with razor blades and immersed in 
collagenase dispase overnight. After washing, the cells were transferred into small 
collagen-coated culture flasks and cultured in RPMI1640 supplemented with 20% 
heat inactivated Fetal Calf Serum (Gibco, Invitrogen Life-Technologies, Scotland, 
UK), 1% L-glutamax, and 1% penicillin/streptomycin (100U/mL). Cells were 
grown in a humidified incubator with 95% air and 5% CO2 and cultured until 
stably multiplying.  
 
COBRA-Fluoresence in-situ hybridization 
COBRA-FISH on metaphase slides was performed as described previously (11). 
For each cell line several cell culture passages were studied (L835: passage 17 and 
35, L2975 passage 20 and 30, L3252 passage 7, 8, and 20) and karyotypes were 
described for each cell line according to the International System of Human 
Cytogenetic Nomenclature (ISCN) 2009. 
 
Expression of cartilaginous genes 
RNA was isolated from L835 (passage 40), L2975 (passage 58), and L3252 
(passage 21). Chondrogenic phenotype was assessed using RT-PCR for collagen I, 
IIB, III, and X, aggrecan, and SOX9 as described previously (12).  
 
  
 Chapter 3                                                                                                                             56 
 
 
Assessment of cell line identity 
DNA isolation from cell pellets was performed using the wizard genomic DNA 
purification kit (Promega, Madison, WI) according to manufacturer’s instructions. 
DNA concentrations were measured using a Nanodrop ND-1000 
spectrophotometer and quality was checked on a 1% agarose gel stained with 
ethidium bromide. Identity of cell lines was confirmed using the PowerPlex® 1.2 
system (Promega Benelux BV, Leiden, The Netherlands). For L835 passage 36 
was compared to primary tumor tissue, for L2975 passage 37 was used, and for 
L3252 passage 20 was compared to primary tumor tissue.  
 
Doubling time and migration assays  
The RTCA xCelligence system (Roche Applied Sciences, Almere, the 
Netherlands), based on cell-electrode substract impedance detection technology 
(13), was used for doubling time and migration assays. Prior to starting 
experiments cell number curves were run to determine optimal growth curves and 
for doubling time experiments cell lines were plated at a density of 1,000 cells per 
well for L2975 and L3252 and 10,000 cells per well for L835 in growth medium 
(10% FCS in RPMI1640). For migration experiments, 100,000 cells were optimal. 
For doubling time assays, 30 minutes after plating, view-plates were loaded into 
the RTCA station in the cell culture incubator. Cell index (CI) was acquired every 
hour.  
Proliferation was monitored for 400hrs. Every day plates were taken from the 
machine and most representative areas were photographed using a Zeiss axiovert 
40C light microscope (Rijswijk, the Netherlands). 
For migration assays, lower wells of the SIM plates (migration plates) were filled 
with growth medium (20% FCS in RPMI1640) as a chemoattractant, and cells 
were plated in the top wells in empty buffer (RPMI1640 only). CIM plates with 
8µm pores were loaded into the RTCA station in the cell culture incubator 
immediately after plating and cell index (CI) was acquired every 5 minutes. 
Migration was monitored for 24hrs. Experiments were performed in triplicate.  
 
Mutation analysis 
Mutation analysis was performed for TP53 (exons 5-8) (14), and IDH1 and -2 
exons 4 (15) using direct sequencing of DNA as described (14;15). Mutation 
analysis for PIK3CA, KRAS, BRAF, EGFR was performed using hydrolysis 
probes assay (16) at L835 (passage 36), L2975 (passage 37), and L3252 (passage 
20). Mutation analysis for TP53 was performed at those same passage numbers and 
IDH mutation analysis was performed at L835 passage 38 and 47, L2975 passage 
31 and 46, and L3252 passage 20, as well as on DNA obtained from CH-3573 (8). 
To determine expression of the IDH mutated allele cDNA was generated using 1µg 
total RNA as described (12) for L835 (passage 38), L2975 (passage 31), and L3252 
(passage 20). Primers were designed with primer3 software 
(http://frodo.wi.mit.edu/primer3/) and ordered from ISOGEN Bioscience BV 
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(Maarssen, the Netherlands). PCR was done with the quantitative PCR core kit for 
SYBR green I supplemented with fluorescin (Eurogentec, Seraing, Belgium) on 
0.2µL cDNA per reaction in an iCycler iQ Real-time Detection system (Bio-Rad 
Laboratories, Hercules, CA). PCR was done for 40 cycles. PCR products were 
purified using QIAquick PCR purification Kit (Qiagen, Hilden, Germany) 
according to manufacturer’s instructions. Purified products were sequenced by 
Macrogen (Amstelveen, the Netherlands) and resulting sequences were analyzed 
using MutationSurveyor DNA Variant Analysis software (Softgenetics, UK). 
Primer sequences and annealing temperatures are listed in table 3.1. 
 
Table 3.1. IDH primers 
Primer    Tm Product 
Size IDH1 
genomic 
Forward CGGTCTTCAGAGAAGCCATT 59.4 113 
IDH1 
genomic 
Reverse GCCAACATGACTTACTTGATCC 58.6  
IDH2 
genomic 
Forward AACATCCACGCCTAGTCC 56.3 90 
IDH2 
genomic 
Reverse CAGTGGATCCCCTCTCCAC 60.5  
IDH1 
cDNA 
Forward CGGTCTTCAGAGAAGCCATT 59.4 131 
I H1 
cDNA 
Reverse AGGCCCAGGAACAACAAAAT 56.4  
I H2 
cDNA 
Forward AGTGTGGCTGCAAGTGTGC 60.0 365 
I H2 
cDNA 
Reverse GAGATGGACTCGTCGGTGTT 60.1  
 
Table 3.2. Antibodies 
Antibody Clone Dilution Antigen 
Retrieval 
Blocking Source 
p16 g175-405 1:800 Citrate - BD Pharmingen 
(550834) 
p53 DO-7 1:800 Citrate - Dako (M7001) 
Ki67 MIB-1 1:800 Citrate - Dako (M7240) 
  




Array-CGH was performed on DNA derived from the primary tumor as well as 
from  cultured cells of all three cases as described (17). DNA of L835 passage 36, 
L2975 passage 37, and L3252 passage 20 was used. In brief, labeling of 1µg DNA 
was performed using the BioPrime Total Genomic Labeling System (Invitrogen 
Corporation, Carlsbad, CA) following the manufacturer’s protocol. As reference, 
DNA from a commercial source (Promega Corporation, Madison, WI) was used. 
Labeled test and reference samples were mixed and hybridized as a gender 
mismatch. Hybridization was performed on an Agilent 105k oligonucleotide array 
according to manufacturer’s instructions. Slides were scanned using the Agilent 
Scanner with 5μm scan resolution. Scan images were processed with the Feature 
Extraction Software and the generated raw data files were analyzed using Genomic 
Workbench (Agilent Technologies, Santa Clara, CA). In short, the mean of the 
background corrected and Lowess normalized log2 ratios of identical features was 
calculated. Normalization of ratios was done using the overall values as well as the 
values of the control reporter probes on the array. Aberrations were calculated 
using the ADM-2 algorithm with a threshold of 8.6 and displayed with a moving 
average of 1Mb. 
 
Tumorigenicity in mice 
All the experimentation involving laboratory animals was approved by the 
Institutional Animal Care of Valencia University and the Local Government and 
was performed in accordance with the national legislation of Spain. Male nude 
mice were purchased from IFFA-CREDO (Lyon, France), and kept under specific 
pathogen-free conditions throughout the experiments. For each cell line, 2,000,000 
cells were subcutaneously injected in a total of 3 mice (2 months old) under sterile 
conditions. Tumor was removed when size reached 4mm in diameter and a 
fragment of non-necrotic tumor, about 3 to 5 mm3 in size, was used for 
xenografting into two new male nude mice. The second neoplasm was removed 
when the size reached 20mm in diameter. From each tumor a part was snap-frozen 
in liquid nitrogen, a part fixed in formalin and embedded in paraffin, a part was 
used for xenografting into 2 new mice, and a part for further culturing of post-
xenograft cell lines.  
 
  




L835 (passage 35), L2975 (passage 55), and L3252 (passage 17) cells were fixed in 
formalin and prepared using the Shandon Cytoblock cell block preparation system 
(Thermo Scientific, Etten-Leur, the Netherlands). Cells were embedded in paraffin 
according to standard laboratory procedures for tissue fixation. Sections (4-µm 
thick) of these paraffin blocks as well as from formalin fixed paraffin embedded 
original tumor tissue and xenograft passages, were used for H&E, toluidine blue, 
and immunohistochemistry for ki67, p53, and p16 according to standard 
procedures (18). Details of the antibodies can be found in table 3.2.  
 
Results  
Clinicopathological data  
The tissue specimen of L835 was retrieved from the resection specimen of the local 
recurrence of a chondrosarcoma occurring in the left distal radius (figure 3.1A) of a 
54 year-old male. The primary tumor had been resected seven months earlier. 
Histological examination revealed a highly cellular cartilaginous neoplasm, with 
myxoid matrix changes and the presence of mitoses, and spindle cell changes at the 
edge of the lobuli, consistent with a primary central chondrosarcoma of bone, grade 
III according to Evans (19) (figure 3.1D).  
L2975 was derived from the resection of a metastasis of a dedifferentiated 
chondrosarcoma located at the spine of a 57 year-old male. The primary tumor was 
located at the right distal femur, and was originally resected eight months earlier 
(figure 3.1B, 3.B’). The primary tumor was 13.6 cm in size and histological 
examination revealed two components with a sharp interface indicative of 
dedifferentiated chondrosarcoma; a grade II chondrosarcoma was juxtaposed to a 
high grade anaplastic sarcoma (figure 3.1F) with focal deposition of osteoid, 
indicating differentiation towards osteosarcoma (figure 3.1G). Histological 
examination of the spine metastasis revealed exclusively the high-grade anaplastic 
sarcoma, in which osteoid deposition was absent. 
L3252 is derived from the local recurrence of a chondrosarcoma located at the 
chest wall (costa) (Fig 3.1C, D) that had already metastasized to the spine and the 
lung at the time of first presentation. The primary tumor of this 52 year-old female 
demonstrated a cellular, partly myxoid and necrotic cartilaginous tumor, with 
mitoses, indicative of a grade III chondrosarcoma (figure 3.1H). However, at local 
recurrence eight months later, areas of a cartilaginous tumor were intermingled 
with an anaplastic sarcoma lacking differentiation, indicating dedifferentiated 
chondrosarcoma. The tissue used for cell culture was derived from an area in which 
dedifferentiated areas were absent (figure 3.1I). 
  
  





Figure 3.1 - Radiologic and histologic examination of original tumors.  
A: L835 conventional radiography demonstrates a mildly expansile mixed lytic and 
sclerotic lesion in the distal radius with spiculated borders (arrow) and an irregular 
periosteal reaction. Note the presence of an enchondroma in the first metatarsal bone 
(asterisk). B: L2975 conventional radiography shows an ill-defined expansile mixed lytic 
and sclerotic lesion (arrow) originating from the distal femur diaphysis with endosteal 
scalloping of the anterior cortex (asterisk). The sclerotic areas within the lesion suggest 
osteoid matrix formation. B’: L2975 gross specimen shows intramedullar localization of 
dedifferentiated chondrosarcoma with chondrocytic and lobulated dedifferentiated 
compartments. C: L3252 conventional chest radiography shows a large lobulated mass 
originating from the left chest wall with extensive rib destruction. Subtle chondroid 
mineralization can be observed in the lesion. Radiological features are suggestive for a 
chondrosarcoma with a higher grade of malignancy. D: Axial CT image demonstrates 
chondroid mineralization (arrow) within the intra-abdominal component consistent with the 
diagnosis of chondrosarcoma. E: H&E staining of high grade L835 original tumor. H&E 
staining of L2975 original tumor shows anaplastic and cartilaginous component (F) and 
metastasis of the anaplastic component (G). H&E staining of L3252 original tumor shows 
anaplastic and cartilaginous component (H) and recurrence of the cartilaginous component 
(I). J-N: absence of p16 staining is observed in L835 original tumor, L2975 original tumor 
and metastasis, and L3252 original tumor and recurrence, respectively.  
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Establishment of cell lines and transmission light microscopy 
L835 was passaged routinely in vitro for 50 generations, L2975 for 60 generations, 
and L3252 for 30 generations. The cell lines derived from dedifferentiated 
chondrosarcoma (L2975 and L3252) were noticeably easier to culture than the 
L835 cells. This was also reflected by Ki-67 staining on embedded cells, with 
proliferation rates of ~60% (L835) versus ~100% and ~80% for L2975 and L3252, 
respectively. The dedifferentiated chondrosarcoma cells were less susceptible to 
changes in culture conditions reflecting their more aggressive nature. Transmission 
light microscopy revealed L2975 cells to retain their elongated morphology when 
in confluence and L3252 cells to detach when reaching confluence (figure 3.2A). 
Identity of cell lines was confirmed using the PowerPlex® 1.2 system (Promega 
Benelux BV, Leiden, The Netherlands). L835 passage 36, L2975 passage 37, and 
L3252 passage 20 showed identical STR loci when compared to their matching 
original tumors. Data are available on request. qPCR for expression of cartilage 
markers revealed expression of ColI, ColIII, aggrecan, and SOX9 in L835 cell line. 
L2975 cell line expressed ColI, ColIII, ColX, and SOX9. L3252B cell line 
expressed ColI, ColII, ColIII, ColX, aggrecan, and SOX9.  
 




microscopy at 40x 
magnification. 
Top panel shows 
L835 cells with 
round nuclei do 
not fully populate 
the flask; day 13 is 
representative of a 
full flask for this 
cell line. Middle 
panel shows 
L2975 showing a 
full flask at day 6 
already, 
multinucleated 
cells can be 
observed. Bottom panel shows L3252 still actively dividing, and dividing cells tend to 
detach and re-attach to the bottom of the flask. B-D Migration plotted against proliferation 
for the first 10 hours after plating. 1,000 – 10,000 cells were used in the proliferation assay 
and 100,000 cells in the migration assay. Though all cell lines show migrative capacity, 
L2975 cells are most successful and high migrative activity during the first 4 hours after 
which the slope flattens.  
  




All cell lines were able to migrate. Migration for L835 was at the same rate as cell 
attachment in the proliferation assay (figure 3.2B). For L2975, cell migration 
occurred much more rapidly than cell attachment (figure 3.2C). Moreover, due to 
high migration efficiency, and the fact that more cells were applied in the migration 
assay, the cell attachment percentage exceeds that of which is achieved in the 
proliferation assay. For L3252 cells, migration was observed but only for a small 
percentage of cells (figure 3.2D).  
 
Transplantation into nude mice 
L2975 cells were subcutaneously transplanted into nude mice and a tumor of 4mm 
in diameter was observed in 1 out of 3 mice after 3 months. A fragment of the 
resulting tumor was subsequently subcutaneously transplanted into 2 nude mice 
and a tumor of 20mm in diameter was observed in 2 out of 2 mice. 
Morphologically, tumor cells of both the first and second xenograft showed a more 
epithelioid morphology (figure 3.3A, B) while no deposition of cartilaginous 
matrix was observed at H&E or Toluidine Blue staining (results not shown). 
Immunohistochemistry showed that 90% of cells of both xenografts were positive 
for Ki-67 and were thus actively proliferating (results not shown). Cells obtained 
from both xenografts were successfully passaged. Xenografting of L835 and L3252 
did not result in tumors in 8 months. 
 
COBRA-Fluorescence in-situ hybridization   
The cell line L835 showed a stable karyotype (figure 3.4A’). There were many 





 L2975 also revealed a stable karyotype at passage 30 with many numerical 







L3252 was  stable  at passage 20 with many  numerical changes and complex 
rearrangements (figure 3.4C’):  51<2n+>,X,-X,+der(3;11)t(3;11)(p10;q10)t(11;17) 








Figure 3.3 - Histologic examination of xenografted L2975.  
A, B: H&E stainings of first and second passage of L2975 in nude mice showed 
L2975 cells had adapted a more rounded morphology. C: p16 staining of first 
passage confirmed absence of p16 expression; note positive vessel walls (arrow).  
 
Array-CGH and mutation analyses 
In L835 and L2975, all aberrations present in the tumor were retained in the cell 
lines. L835 showed a homozygous CDKN2A deletion in both the original tumor 
and the cell line (figure 3.4A”). L2975 and L3252 both showed a homozygous 
deletion in the cell line (figure 3.4B” and 3.4C”), the deletion status of the primary 
tumor was difficult to assess due to low tumor content and consequently resulting 
suppressed ratio profiles. For both L835 and L2975 clear DNA copy number 
alterations could be observed in the original tumor samples that were enhanced in 
the cell lines. For L3252 tumor DNA this was less pronounced. On close 
examination of the profile, however, one can observe small copy number changes 
consistent with those observed in the cell line. We previously demonstrated L835 
(passage 38) to harbor an IDH1 R132C mutation and L2975 (passage 31) an IDH2 
R172W mutation (15). We here show that L3252 (passage 20) is wild type and that 
also later passages of L835 (passage 47) and L2975 (passage 46) retain the IDH 
mutation. Using cDNA we found the mutated IDH alleles to be expressed (results 
not shown). No hotspot mutations were detected for TP53, PIK3CA, BRAF, 
KRAS, and EGFR in any of the cell lines. 
 
Immunohistochemical characterization 
Since p16 is frequently silenced in human chondrosarcoma (18) we evaluated p16 
in the original tumors, the cell lines and the L2975 xenografts using 
immunohistochemistry. All primary tumors (figure 1J, L, M) and recurrences 
(figure 1L, N) were negative for p16. Consistent with the tumor tissue, all derived 
cell lines lacked p16 protein expression (table 3.3), as did xenografts created from 
L2975 (figure 3.3C). We proceeded to test embedded cells from all cell lines 
shown in table 3.3 for p16 expression and found all to be negative. 
Immunohistochemistry showed nuclear expression of p53 in 10-20% of the tumor 
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cells in L835 and L3252 primary tumor and cell line, while L2975 tumor, cell line, 




Figure 3.4 - COBRA-FISH and Array-CGH.  
A: chromosomal analysis of L835 tumor and cell line showed numerical changes. 
B, C: chromosomal analysis of L2975, L3252 showed complex rearrangements 
consistent with the aggressive nature of dedifferentiated chondrosarcoma. 





Chondrosarcoma is the second most common primary sarcoma of bone and to date 
unresectable chondrosarcomas have a poor outcome (3). Grade III and 
dedifferentiated chondrosarcomas are extremely aggressive in nature and there is 
an urgent need for model systems facilitating research in order to develop novel 
therapeutic strategies. Growing chondrosarcoma cells in culture, however, is a 
challenge and well growing chondrosarcoma cell lines are sparse. We present here 
the establishment and characterization of three new chondrosarcoma cell lines 
originating from grade III and dedifferentiated chondrosarcoma.  
Recently chondrosarcoma has been found to harbor IDH1 and IDH2 mutations 
(5;15) and we published that the mutation is retained in a subset of 
chondrosarcoma cell lines (15). In glioma IDH mutations seem to be the earliest 
event in gliomagenesis even before TP53 mutations occur (20). In conventional 
chondrosarcoma we observe a similar phenomenon, where IDH mutations are 
present already in a high percentage of low-grade tumors and TP53 mutations are 
observed to increase with grade (4;5;15). Cell lines created from IDH mutant 
gliomas have been reported to eliminate their IDH mutation under standard culture 
conditions (7). Recently, however, a glioma cell line carrying an endogenous IDH1 
R132H mutation was published, but this cell line showed a slow growth rate in 
culture (21). We here present three chondrosarcoma cell lines, one carrying an 
IDH1 R132C mutation, one carrying an IDH2 R172W mutation, and one wild type 
for IDH mutations with stable karyotypes and steady growth patterns. These cell 
lines show numerical changes and additional mutations. We speculate that in IDH 
mutant chondrosarcoma the acquisition of additional mutations as we have shown 
here have facilitated their growth in culture.  
The inactivation of tumor suppressor genes is a well-known phenomenon in cancer 
and p16 mutations have been reported in 20-41% of human chondrosarcomas (22-
25). Interestingly, all studies observed loss of p16 to be correlated with increasing 
histological grade in conventional chondrosarcoma. Recently, we showed 
inactivation of p16 in 30/38 (79%) dedifferentiated chondrosarcoma cases (26). We 
previously published three chondrosarcoma cell lines to be negative for p16 using 
western blot (18) and upon overexpression of p16 using lentiviral vectors the 
metabolic activity and cell viability of these cell lines was decreased, indicating 
loss of p16 to play a role in the proliferative capacity of chondrosarcoma cells. 
Introduction of p16 in the endogenously TP53 mutant HT-1080 fibrosarcoma cell 
line, which was recently reported to carry an IDH1 R132C mutation (5), also led to 
cell cycle arrest and growth inhibition (27-29). We report here three new 
chondrosarcoma cell lines lacking p16 expression based on a homozygous deletion 
of the CDKN2A locus as shown by aCGH analysis, and confirmed loss of p16 
expression using immunohistochemistry. Moreover, aCGH analysis showed a copy 
number loss around the 17p13.1 locus in L835, whereas a copy number gain was 
observed in L2975 and L3252. However, mutation analysis for TP53 showed no 
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Table 3.2 - Overview of chondrosarcoma cell lines and their characteristics  
 
1IDH mutations for existing cell lines were described in (15) 
2p53 mutations for existing cell lines were described in (33) 
3p16 mutations for existing cell lines were described in (18) 
na: not available 
Cell line Tumor subtype Histological 
Grade 
Passage IDH11 IDH21 p532 p163 Reference 
Conventional 
Chondrosarcoma 
        
SW1353 Solitary Central II p50 wt R172S V203L - ATCC 
JJ012 Solitary Central II P26 R132G wt G199V - (30) 
CH3573 Solitary Central II P60 wt wt T201- na (8) 
CH2879 Solitary Central III P31 G105G wt wt - (31) 
OUMS27 Solitary Central III P29 wt wt wt - (32) 
L835 Solitary Central III p51 R132C wt wt - Present Study 
Dedifferentiated 
Chondrosarcoma 
        
L2975 Dedifferentiated  p59 wt R172W wt - Present Study 
NDCS1 Dedifferentiated  P22 wt wt C242S - (9) 
L3252 Dedifferentiated  P26 wt wt wt - Present Study 
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activating mutations in exons 5-8, and immunohistochemistry showed no p53 
overexpression. Together, our data suggest that while IDH mutations are important 
as early events in a subset of chondrosarcomas, additional inactivation of p16 may 
be crucial for acquiring a more aggressive phenotype.  
The literature presents us with 5 conventional chondrosarcoma cell lines that have 
been well characterized using pathological, immunohistochemical, and molecular 
genetic methods (8;30-32), and we here present L835 as an additional  cell line. We 
previously published L835 to be able to form 3D pellets (33) and we now show it 
to be highly stable in culture.  L835 cell line showed a slower growth rate 
compared to the dedifferentiated chondrosarcoma cell lines. In all cases complex 
genome alterations were observed. Dedifferentiated chondrosarcoma is comprised 
of two separate components, a high grade anaplastic component and a low to 
intermediate grade cartilaginous component (2). The histogenesis has been under 
debate but evidence points to a single precursor cell with early separation of the 
two components as a small number of genetic changes is identical in both 
components, with additional genetic alterations in the anaplastic component 
(26;34). Indeed, 3 out of 3 dedifferentiated chondrosarcomas with IDH1 mutations 
carried the mutation in both components (26). Moreover, 79% of the anaplastic and 
82% of the cartilaginous components show loss of p16 expression (26).  L2975 and 
L3252 were both derived from the recurrence of a dedifferentiated 
chondrosarcoma; both cell lines exhibited a higher growth rate in vitro, than the 
L835 cell line, but the cells in culture expressed chondrogenic markers. L2975 
proved to be the most aggressive cell line both in culture and in our in vitro 
migration assay, which may explain why this was  the only cell line to be 
successfully xenografted. We show here the use of L2975 dedifferentiated 
chondrosarcoma cells with an IDH2 R172W mutation in mouse models, which can 
be an important asset in the research for new treatment strategies.  
We report the establishment and molecular, genetic and functional characterization 
of one grade III (L835) and two dedifferentiated chondrosarcoma (L2975 and 
L3252) cell lines. This represents a substantial addition to the already existing 
panel of chondrosarcoma cell lines, which together may reflect their heterogeneity. 
In addition to the existing cell lines these cell lines present the field with an 
extensive model system as heterogeneous in IDH1 and IDH2 and TP53 mutations 
as the tumors they are derived from. This panel can be implemented in studies 
ascertaining human chondrosarcoma tumorigenesis, should provide useful tools in 
the ongoing search for new targeted therapies, and aid in expanding our knowledge 








 1. Bertoni F, Bacchini P, Hogendoorn 
PCW. Chondrosarcoma. In World Health 
Organisation classification of tumours. 
Pathology and genetics of tumours of 
soft tissue and bone.Edited by: Fletcher 
CDM, Unni KK, Mertens F. Lyon: IARC 
Press; 2002:247-51. 
 2. Milchgrub S, Hogendoorn PCW. 
Dedifferentiated chondrosarcoma. In: 
World Health Organisation classification 
of tumours. Pathology and genetics of 
tumours of soft tissue and bone.Edited 
by: Fletcher CDM, Unni KK, Mertens F. 
Lyon: IARC Press; 2002:252-4. 
 3. Gelderblom H, Hogendoorn PCW, 
Dijkstra SD, van Rijswijk CS, Krol AD, 
Taminiau AHM, Bovée JVMG: The 
clinical approach towards 
chondrosarcoma. Oncologist 2008, 
13(3):320-9. 
 4. Bovee JVMG, Hogendoorn PCW, 
Wunder JS, Alman BA. Cartilage 
tumours and bone development: 
molecular pathology and possible 
therapeutic targets. Nat Rev Cancer 
2010, 10(7):481-8. 
 5. Amary MF, Bacsi K, Maggiani F, 
Damato S, Halai D, Berisha F, Pollock 
R, O'Donnell P, Grigoriadis A, Diss T, 
Eskandarpour M, Presneau N, 
Hogendoorn PCW, Futreal A, Tirabosco 
R, Flanagan AM. IDH1 and IDH2 
mutations are frequent events in central 
chondrosarcoma and central and 
periosteal chondromas but not in other 
mesenchymal tumours. J Pathol 2011, 
224(3):334-43. 
 6. Yan H, Parsons DW, Jin G, 
McLendon R, Rasheed BA, Yuan W, 
Kos I, Batinic-Haberle I, Jones S, 
Riggins GJ, Friedman H, Friedman A, 
Reardon D, Herndon J, Kinzler KW, 
Velculescu VE, Vogelstein B, Bigner 
DD. IDH1 and IDH2 mutations in 
gliomas. N Engl J Med 2009, 
360(8):765-73. 
 7. Piaskowski S, Bienkowski M, 
Stoczynska-Fidelus E, Stawski R, Sieruta 
M, Szybka M, Papierz W, Wolanczyk M, 
Jaskolski DJ, Liberski PP, Rieske P. 
Glioma cells showing IDH1 mutation 
cannot be propagated in standard cell 
culture conditions. Br J Cancer 2011, 
104(6):968-70. 
 8. Calabuig-Farinas S, Benso RG, Szuhai 
K, Machado I, Lopez-Guerrero JA, de 
JD, Peydro A, Miguel TS, Navarro L, 
Pellin A, Llombart-Bosch A. 
Characterization of a New Human Cell 
Line (CH-3573) Derived from a Grade II 
Chondrosarcoma with Matrix 
Production. Pathol Oncol Res, in press. 
 9. Kudo N, Ogose A, Hotta T, 
Kawashima H, Gu W, Umezu H, 
Toyama T, Endo N. Establishment of 
novel human dedifferentiated 
chondrosarcoma cell line with 
osteoblastic differentiation. Virchows 
Arch 2007 451(3):691-9. 
 10. Yang L, Chen Q, Zhang S, Wang X, 
Li W, Wen J, Huang X, Zheng J, Huang 
G, Huang T, Ju G. A novel mutated cell 
line with characteristics of 
dedifferentiated chondrosarcoma. Int J 
Mol Med 2009, 24(4):427-35. 
 11. Tanke HJ, Wiegant J, Van Gijlswijk 
RPM, Bezrookove V, Pattenier H, 
Heetebrij RJ, Talman EG, Raap AK, 
Vrolijk J. New strategy for multi-colour 
fluorescence in situ hybrydisation: 
COBRA: COmbined Binary RAtio 
labelling. Eur J Hum Genet 1999, 7(1):2-
11. 
 12 Cleton-Jansen AM, van Beerendonk 
HM, Baelde HJ, Bovée JVMG, 
Karperien M, Hogendoorn PCW. 
Estrogen signaling is active in 
cartilaginous tumors: implications for 
antiestrogen therapy as treatment option 
of metastasized or irresectable 
chondrosarcoma. Clin Cancer Res 2005, 
11(22):8028-35. 
 13 Atienzar FA, Tilmant K, Gerets HH, 
Toussaint G, Speeckaert S, Hanon E, 
Chapter 3                                                                                                        69 
 
 
Depelchin O, Dhalluin S. The Use of 
Real-Time Cell Analyzer Technology in 
Drug Discovery: Defining Optimal Cell 
Culture Conditions and Assay 
Reproducibility with Different Adherent 
Cellular Models. J Biomol Screen 2011, 
16(6):575-87.  
 14. Ottaviano L, Schaefer KL, Gajewski 
M, Huckenbeck W, Baldus S, Rogel U, 
Mackintosh C, de AE, Myklebost O, 
Kresse SH, Meza-Zepeda LA, Serra M, 
Cleton-Jansen AM, Hogendoorn PCW, 
Buerger H, Aigner T, Gabbert HE, 
Poremba C. Molecular characterization 
of commonly used cell lines for bone 
tumor research: a trans-European 
EuroBoNet effort. Genes Chromosomes 
Cancer 2010, 49(1):40-51. 
 15. Pansuriya TC, van Eijk, R, d'Adamo 
P, van Ruler MA, Kuijjer ML, Oosting J, 
Cleton-Jansen AM, van Oosterwijk JG, 
Verbeke SL, Meijer D, van WT, Nord 
KH, Sangiorgi L, Toker B, Liegl-
Atzwanger B, San-Julian M, Sciot R, 
Limaye N, Kindblom LG, Daugaard S, 
Godfraind C, Boon LM, Vikkula M, 
Kurek KC, Szuhai K, French, PJ, Bovée, 
JVMG. Somatic mosaic IDH1 and IDH2 
mutations are associated with 
enchondroma and spindle cell 
hemangioma in Ollier disease and 
Maffucci syndrome. Nat Genet 2011, 
43(12):1256-61. 
 16. van Eijk R, Licht J, Schrumpf M, 
Talebian YM, Ruano D, Forte GI, 
Nederlof PM, Veselic M, Rabe KF, 
Annema JT, Smit V, Morreau H, van 
Wezel T. Rapid KRAS, EGFR, BRAF 
and PIK3CA mutation analysis of fine 
needle aspirates from non-small-cell lung 
cancer using allele-specific qPCR. PLoS 
ONE 2011, 6(3):e17791. 
 17. De Jong D, Verbeke SL, Meijer D, 
Hogendoorn PCW, Bovee JVMG, 
Szuhai K. Opening the archives for state 
of the art tumour genetic research: 
sample processing for array-CGH using 
decalcified, formalin-fixed, paraffin-
embedded tissue-derived DNA samples. 
BMC Res Notes 2011, 4:1. 
 18. Schrage YM, Lam S, Jochemsen AG, 
Cleton-Jansen AM, Taminiau AHM, 
Hogendoorn PCW, Bovee JVMG. 
Central chondrosarcoma progression is 
associated with pRb pathway alterations; 
CDK4 downregulation and p16 
overexpression inhibit cell growth in 
vitro. J Cell Mol Med 2008, 
13(9A):2843-52. 
 19. Evans HL, Ayala AG, Romsdahl 
MM. Prognostic factors in 
chondrosarcoma of bone. A 
clinicopathologic analysis with emphasis 
on histologic grading. Cancer 1977, 
40:818-31. 
 20. Watanabe T, Nobusawa S, Kleihues 
P, Ohgaki H. IDH1 mutations are early 
events in the development of 
astrocytomas and oligodendrogliomas. 
Am J Pathol 2009, 174(4):1149-53. 
 21. Luchman HA, Stechishin OD, Dang 
NH, Blough MD, Chesnelong C, Kelly 
JJ, Nguyen SA, Chan JA, Weljie AM, 
Cairncross JG, Weiss S. An in vivo 
patient-derived model of endogenous 
IDH1-mutant glioma. Neuro Oncol 2012, 
14(2):184-91. 
 22. Asp J, Sangiorgi L, Inerot SE, 
Lindahl A, Molendini L, Benassi MS, 
Picci P. Changes of the p16 gene but not 
the p53 gene in human chondrosarcoma 
tissues. Int J Cancer 2000, 85(6):782-6. 
 23. Asp J, Brantsing C, Lovstedt K, 
Benassi MS, Inerot S, Gamberi G, Picci 
P, Lindahl A. Evaluation of p16 and Id1 
status and endogenous reference genes in 
human chondrosarcoma by real-time 
PCR. Int J Oncol 2005, 27(6):1577-82. 
 24. Ropke M, Boltze C, Neumann HW, 
Roessner A, Schneider-Stock R. Genetic 
and epigenetic alterations in tumor 
progression in a dedifferentiated 
chondrosarcoma. Pathol Res Pract 2003, 
199(6):437-44. 
Chapter 3                                                                                                        70 
 
 
 25. van Beerendonk HM, Rozeman LB, 
Taminiau AHM, Sciot R, Bovée JVMG, 
Cleton-Jansen AM, Hogendoorn PCW. 
Molecular analysis of the 
INK4A/INK4A-ARF gene locus in 
conventional (central) chondrosarcomas 
and enchondromas: indication of an 
important gene for tumour progression. J 
Pathol 2004, 202(3):359-66. 
 26. Meijer D, de Jong D, Pansuriya TC, 
van den Akker BE, Picci P, Szuhai K, 
Bovee JVMG. Genetic characterization 
of mesenchymal, clear cell, and 
dedifferentiated chondrosarcoma. Genes 
Chromosomes Cancer, in press. 
 27. Fahham N, Sardari S, Ostad SN, 
Vaziri B, Ghahremani MH. C-terminal 
domain of p16(INK4a) is adequate in 
inducing cell cycle arrest, growth 
inhibition and CDK4/6 interaction 
similar to the full length protein in HT-
1080 fibrosarcoma cells. J Cell Biochem 
2010, 111(6):1598-606. 
 28. Li WW, Takahashi N, Jhanwar S, 
Cordon-Cardo C, Elisseyeff Y, Jimeno J, 
Faircloth G, Bertino JR. Sensitivity of 
soft tissue sarcoma cell lines to 
chemotherapeutic agents: identification 
of ecteinascidin-743 as a potent 
cytotoxic agent. Clin Cancer Res 2001, 
7(9):2908-11. 
 29. Rasheed S, Nelson-Rees WA, Toth 
EM, Arnstein P, Gardner MB. 
Characterization of a newly derived 
human sarcoma cell line (HT-1080). 
Cancer 1974, 33(4):1027-33. 
 30. Scully SP, Berend KR, Toth A, Qi 
WN, Qi Z, Block JA. Marshall Urist 
Award. Interstitial collagenase gene 
expression correlates with in vitro 
invasion in human chondrosarcoma. Clin 
Orthop Relat Res 2000, 376:291-303. 
 31. Gil-Benso R, Lopez-Gines C, Lopez-
Guerrero JA, Carda C, Callaghan RC, 
Navarro S, Ferrer J, Pellin A, Llombart-
Bosch A. Establishment and 
characterization of a continuous human 
chondrosarcoma cell line, ch-2879: 
comparative histologic and genetic 
studies with its tumor of origin. Lab 
Invest 2003, 83(6):877-87. 
 32. Kunisada T, Miyazaki M, Mihara K, 
Gao C, Kawai A, Inoue H, Namba M. A 
new human chondrosarcoma cell line 
(OUMS-27) that maintains chondrocytic 
differentiation. Int J Cancer 1998, 
77(6):854-9. 
 33. van Oosterwijk JG, Herpers B, 
Meijer D, Briaire-de Bruijn IH, Cleton-
Jansen AM, Gelderblom H, van de Water 
B, Bovée JVMG. Restoration of 
chemosensitivity for doxorubicin and 
cisplatin in chondrosarcoma in vitro: 
BCL-2 family members cause 
chemoresistance. Ann Oncol in press. 
 34. Bovée JVMG, Cleton-Jansen AM, 
Rosenberg C, Taminiau AHM, 
Cornelisse CJ, Hogendoorn PCW. 
Molecular genetic characterization of 
both components of a dedifferentiated 
chondrosarcoma, with implications for 









Orthotopic mouse model for chondrosarcoma of 



































This chapter is based on the manuscript: van Oosterwijk JG, Plass JRM, Meijer D, Que I, 
Karperien M, Bovée JVMG. Orthotopic mouse model for chondrosarcoma of bone: an in 
vivo tool for drug testing. Submitted 
 




Chondrosarcoma is a malignant cartilaginous tumor of bone. Recently, mutations 
in isocitrate dehydrogenase-1 (IDH1) and -2 (IDH2) were identified in central 
chondrosarcomas. Notoriously resistant to conventional treatment modalities the 
need for model systems to screen new treatment options is high.  
We used two cell lines, CH2879 (wildtype for IDH and TP53 mutations) and 
SW1353 (harboring IDH2 R172S and TP53 V203L mutations) to generate new 
chondrosarcoma mouse models. Cell lines were stably transduced with a lentiviral 
luciferase expression vector and after clonal selection luciferase expressing clones 
were subcutaneously and orthotopically implanted in nude mice. Mice injected 
with CH2879 cells were treated with doxorubicin over a period of 6 weeks. 
Both cell lines resulted in tumor growth. CH2879 tumors were consistently larger 
than SW1353 tumors. No difference in size could be observed between 
subcutaneous and orthotopic tumors. Tumor growth could be monitored over time 
through assessment of luciferase activity, without harming the mice. Using this 
model we show that doxorubicin does not have a significant effect on in vivo tumor 
growth.  
We here show an orthotopic chondrosarcoma mouse model that can be used to test 





Chondrosarcoma is a malignant cartilaginous tumor, predominantly affecting 
adults.  Several subtypes with different clinicopathological features are recognized, 
of which conventional central chondrosarcoma is most common (~90%). 
Chondrosarcoma is characterized by the deposition of cartilaginous matrix, which 
is abundant in low grade tumors, and becomes more myxoid in high grade 
chondrosarcomas. Grade I  chondrosarcoma has recently been reclassified as 
atypical cartilaginous tumor, due to its locally aggressive, but non-metastatic 
behavior (1). Grade II and grade III chondrosarcomas, showing a decrease in 
deposition of hyaline cartilaginous matrix along with increased cellularity, show an 
increased metastatic behavior (2). The current therapeutic strategy for 
chondrosarcoma is surgical resection, however due to the intrinsic resistance to 
conventional chemo- and radiotherapy there is nothing to offer patients with 
inoperable tumors and metastatic disease (3). The past decade has brought major 
advances in the field of chondrosarcoma genetics and therapeutic targets. Early on, 
EXT mutations have been identified in osteochondromas (4;5), and recently IDH 
mutations were identified in enchondroma, conventional central chondrosarcoma 
as well as dedifferentiated chondrosarcoma (6-8). The advances in the field also 
include an expansion in the number of cell lines. At the moment of writing there is 
a total of 7 conventional chondrosarcoma cell lines (9-13), and 3 dedifferentiated 
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chondrosarcoma cell lines (9;14). 5 of these cell lines show mutations in IDH1 
(n=3) or IDH2 (n=2) (8;9). However, for advancing chondrosarcoma research and 
to rapidly translate results from basic research to clinical practice, reliable and 
representative animal models are necessary.  
Most current models are based on the subcutaneous xenografting of 
chondrosarcoma cell lines or human tumor tissue, misrepresenting the natural niche 
of the tumor in the bone (15). Currently, a swarm rat chondrosarcoma model exists, 
derived from a tumor tissue line originally isolated from a spontaneously arising 
tumor in a Sprague-Dawley rat. Though a working model, the original tissue has 
given rise to several different lines of differentiation, each showing unique 
cytogenetic profiles and tumorigenic properties in vivo (16). In 2010, an orthotopic 
chondrosarcoma mouse model derived from the grade II cell line JJ012 was 
published. Cells were injected in matrigel, and 2/4 intratibial tumors showed 
spontaneous metastasis formation (17). Transgenic models for chondrosarcoma 
have not been developed yet. Mouse models with EXT mutations show formation 
of exostoses, but no progression to chondrosarcoma (18-20). Similarly, transgenic 
mice carrying IDH mutations in neural progenitor cells show a defect in collagen 
maturation, but no chondrosarcoma formation (21).  
We here present 2 models, derived from the grade II SW1353 (IDH2 R172S p53 
V203L) cell line and from the grade III CH2879 (IDH wt p53 wt) cell line. Using 
CH2879 we were able to confirm the resistance to doxorubicin, and show that this 





The chondrosarcoma cell lines CH2879 and SW1353 were cultured in RPMI 1640 
medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum 
(Lonza, Breda, the Netherlands), 1% glutaMAX (Invitrogen, Bleiswijk, the 
Netherlands), and 50 U/mL penicillin with 50 μg/mL streptomycin (MP 
Biomedicals, Eindhoven, the Netherlands). Hek293t cells were cultured in DMEM 
(Invitrogen, Bleiswijk, the Netherlands) supplemented with 10% heat-inactivated 
fetal bovine serum (Lonza) and 100 U/mL penicillin with 100 μg/mL streptomycin. 
 
Production of lentiviral particles in Hek293t cells 
The self-inactivating lentiviral vector, pLV.CMV.luc.bc.PURO, and “helper” 
vectors, pMD 2\VSV-G, pMD L\pRRE, and pRSV-rev, were kindly provided by 
dr. Eric Kaijzel (LUMC). Briefly, the lentiviral vector together with the three 
“helper” vectors were cotransfected overnight into Hek293t cells using 
Lipofectamine 2000 (Invitrogen, Bleiswijk, the Netherlands) in OptiMem 
(Invitrogen, Bleiswijk, the Netherlands) after which medium was replaced by fresh 
culture medium. Viral supernatants were harvested 48hrs after transfection, filtered 
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through a 0.45 μm filter, and stored at -80°C until transduction in chondrosarcoma 
cell lines. 
 
Generation of clonal luciferase expressing chondrosarcoma cell lines 
The chondrosarcoma cells were transduced with the lentiviral supernatant in the 
presence of 1 μg/mL dextran (Sigma-Aldrich, Zwijndrecht, the Netherlands) for 4 
hours. After transduction, cells were selected using 2 μg/mL puromycin (Sigma-
Aldrich, Zwijndrecht, the Netherlands). Following antibiotic selection, single cell-
derived cultures were obtained using limited dilution and screened for luciferase 
activity. As estrogen signaling was shown to be active in cartilaginous tumors (22), 
clones were selected using TaqMan gene expression arrays for ESR1, CYP19A1, 
and AR according to manufacturer’s protocol (Applied Biosystems, Bleiswijk, the 
Netherlands). All cultures selected for in vivo implantation were tested for the 
presence of HIV p24.  
 
Animals  
All procedures were approved by the Leiden University animal experimental 
committee and Local Government (Animal protocols 08158 and 10019), performed 
in accordance with the national legislation of the Netherlands and in compliance 
with the ‘Code of Practice Use of Laboratory Animals in Cancer Research’ 
(Inspectie W&V, July 1999).  Athymic mice (BALB/c nu/nu 6 weeks old) were 
acquired from Charles River (Charles River, L’Arbresle, France), housed in 
individually ventilated cages, and food and water was provided ad libitum. For all 
in vivo experiments, a total of 46 mice were used.  
 
CH2879 and SW1353 tumor cell injection in mice  
For both CH2879 and SW1353 cell lines, three single-cell derived luciferase 
expressing clones were used for both subcutaneous and orthotopic implantation 
into mice. 12 mice were subcutaneously injected. A total of 4 mice were injected 
with the different CH2879 clones, 4 mice with the different SW1353 clones and 4 
with non-transduced cell lines to control for interference with tumorigenicity by 
luciferase construct.  
Orthotopic injection was performed using two separate methods. In total 33 mice 
were orthotopically injected with either SW1353 or CH2879. Mice were 
anesthetized by isoflurane prior to subcutaneous or orthotopic injection in the tibia 
with luciferase expressing cells (1*106 cells in 40 μL PBS or 2.5*105 cells in 10 μL 
PBS respectively). Eighteen mice were injected using the first method; 9 with 
SW1353 LUC clones and 9 with CH2879 clones; 3 mice per clone. Orthotopical 
injection was performed with an injection of a single-cell suspension of luc+ cells 
into the right tibiae as described previously (23). In brief, two small holes 
(~0.35mm each) 4-5 mm apart were created in the bone cortex of the upper right 
tibiae using a dental drill, and reservoir for the cells was created by flushing out the 
bone marrow from the proximal end of the shaft. After inoculation with a 30-gauge 
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needle through the lower hole, the cutaneous wound was sutured. In the second 
method, 15 mice were injected with CH2879 LUC 10. Orthotopical injection was 
performed with an injection of a single cell suspension directly into the tibia 
without the prior creation of a reservoir.  
The progression of cancer cell growth was monitored weekly by optical imaging. 
After the experimental period, or 7 weeks after start of signal detection for mice 
not on treatment regime, the animals were sacrificed and tumors were collected for 
histological assessment.  
 
In vivo treatment of CH2879 orthotopic tumors 
The 15 mice injected using the second method (immediate injection without prior 
creation of a reservoir), were divided into two groups after signal detection for 
investigating the effect of doxorubicin on tumor growth. Seven mice were treated 
with 12 mg/kg doxorubicin over a course of 6 weeks in which they were 
administered a single dose once every 2 weeks through i.p. injection. Control group 
consisted of eight mice monitored over 6 weeks. Doxorubicin was obtained from 
the in-house hospital pharmacy in a 0.9% NaCl solution. Treatment was started 
when tumors could be detected using the IVIS 100 (Caliper LifeSciences, 
Hopkinton, MA), ie bioluminescent (BLI) signals of 105 P/s/cm2 (~0.6cm3). In case 
mice would show a bioluminescent signal ≥109 P/s/cm2 (~1cm3) they were to be 
considered to have too severe a tumor burden and were sacrificed. After treatment 
course was completed, or mice showed severe clinical signs as a result of tumor 
burden or treatment, mice were sacrificed and tibiae were collected for histological 
assessment. Lungs were harvested to investigate possible metastases. 
 
In vivo imaging 
To monitor luciferase activity, mice were anesthetized using isoflurane. Images 
were acquired 5 minutes after i.p. injection of D-luciferin (150 mg/kg) using 30 sec 
exposure time. Tumor take was monitored using the IVIS 100 (Caliper 
LifeSciences, Hopkinton, MA) and bioluminescent signals were quantified using 
Living Image 3.0 (Caliper LifeSciences, Hopkinton, MA).  
 
Tissue embedding and staining 
Lungs were fixed in 4% paraformaldehyde and embedded in paraffin. Tibiae were 
decalcified in 0.4M EDTA/PBS after fixing in 4% paraformaldehyde. After 
decalcification with EDTA, tibiae were embedded in paraffin and 5µm sections 
were stained with hematoxylin and eosin (H&E) for morphology or 0.08% 
toluidine blue (Brocacef Holding, Maarssen, The Netherlands) to assess matrix 
formation.   
 




Figure 4.1: Generation of chondrosarcoma mouse model. A: Subcutaneous injection of 
SW1353 and CH2879 cells led to tumor growth in 4/4 mice. Standard deviation indicates 
variation in measurements between the 4 injected mice. B: Orthotopic injection of SW1353 
and CH2879 cells led to tumor growth in 3/3 mice, CH2879 clone luc 10 resulted in larger 
tumors than other clones. Standard deviation indicates variation in measurements between 
the 4 injected mice. C: Each SW1353 clone was injected orthotopically in the left tibia of 3 
mice. SW1353 clone 8 is shown with BLI signals at week 2 (left panel) and week 7 (central 
panel) with luminescence scale (right panel). Luciferase signals for this clone did not show 
an increase during the 7 week observation time. Standard deviation indicates variation in 
measurements between the 9 injected mice. D: Each CH2879 clone was injected 
orthotopically in the left tibia of 3 mice. CH2879 clone LUC 10 is shown with BLI signals 
at week 2 (left panel) and week 7 (central panel) with luminescence scale (right panel). This 
clone showed the strongest increase in luciferase signals during the 7 week observation 
time, as evidenced by the strong red signal.  Standard deviation indicates variation in 
measurements between the 9 injected mice. 
  





Transduction of CH2879 and SW1353 cell lines 
Based upon expression of estrogen signaling markers (results not shown), three 
representative clones were selected for each cell line. For SW1353, clones 1, 4, and 
8 most closely resembled the nontransduced cell line, for CH2879, clones 4, 7, and 
10 were most similar. All clones showed luciferase expression and were negative 
for HIV p24.  
 
Tumor growth after injection of luciferase transduced SW1353 and CH2879 
chondrosarcoma cell lines 
Six week old Balb/C nude mice were injected with either SW1353 or CH2879. 
Tumor growth was observed within 1 week, evidenced by emission of 
bioluminescent signal at the first measurement (week 1) after both subcutaneous 
(fig 4.1A) and orthotopic (fig 4.1B, C, D) injection. Subcutaneous injection of 
SW1353 clone 1 and 4 led to tumors in 4/4 mice, whereas clone 8 led to tumors in 
1/4 mice, orthotopic injection of SW1353 clones led to tumor growth in all cases 
(9/9 mice). CH2879 clone 4 and 7 led to tumor growth in 3/4 mice, clone 4 led to 
tumor growth in 4/4 mice, orthotopic injection of CH2879 clones led to tumor 
growth in all 9 mice. No bioluminescent signals were observed in the lungs and 
histological examination also indicated no evidence of metastases. 
Luciferase activity of CH2879 tumors continued to increase during the course of 7 
weeks, indicative of progressive tumor growth, whereas SW1353 derived tumors 
showed a stagnated signal strength, suggestive of halted growth. The size of the 
CH2879 derived tumors were consistently larger than the SW1353 derived tumor, 
as evidenced by stronger BLI signals (fig 4.1A, B). In both SW1353 and CH2879, 
orthotopic and subcutaneous injection resulted in comparable BLI signal. The 
clone showing the strongest luciferase signal, CH2879 LUC 10, (fig 4.1B, D), was 
selected for further experiments. Orthotopic injection of luciferase transfected cells 
using prior creation of a reservoir for the cells led to tumor growth within one to 
two weeks. Using the second method using immediate injection of the cells, it took 
up to 4 weeks until tumors were detectable by bioluminescent imaging. However, 
as immediate orthotopic injection was considered less painful for the mice and did 
result in successful tumor growth, in subsequent experiments mice were directly 
injected with tumor cells.  
 
  





Figure 4.2: Orthotopic CH2879 tumor resemble chondrosarcoma morphology with 
matrix deposition. Control mouse (Mock A-D) and mouse treated with doxorubicin (DXR, 
E-H) using H&E staining (A,B; E,F) and toluidine blue staining (C,D; G,H) showing purple 
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CH2879 tumors resemble high grade chondrosarcoma 
Orthotopic injection of CH2879 LUC 10 cells shows diaphyseal localization of 
tumor cells, with tumor cells growing circumferentially and expanding through the 
cortex (fig 4.2 A, E). The histological analysis of the tumor cells shows that they 
strongly resemble that of a high grade chondrosarcoma (fig 4.2 B, D, F, H). The 
tumor is located close to the growth plate, but does not infiltrate the growth plate 
(fig 4.2 A, C, E, G). Toluidine blue staining shows matrix formation (fig 4.2 C, D, 
G, H).   
 
Doxorubicin treatment does not influence chondrosarcoma tumor growth 
Mice orthotopically injected with CH2879 LUC 10 cells were treated with 
doxorubicin 12mg/kg for 6 weeks. Treatment started when luciferase 
measurements were at BLI 105. Mean BLI starting values for mice on doxorubicin 
(n=7) were 8.4x106 P/s/cm2 (±3.5 x106) with end BLI values 1.9x108 P/s/cm2 (±1.5 
x108). For the control group (n=8) starting BLI values were 4.1x106 P/s/cm2 (±5.3 
x106) with end BLI values 5.9x107 P/s/cm2 (±2.1 x107). Fold change of tumor 
growth at the start of treatment was set at 1 to allow for comparison of the different 
groups. After start of treatment, mice receiving doxorubicin showed a delay in 
tumor progression when compared to control mice (fig 4.3A). However, during the 
last cycle of doxorubicin, a strong increase in tumor growth was observed (fig 
4.3A), suggesting resistance to doxorubicin. Figure 4.3 B-E shows bioluminescent 
imaging of 3 control mice at start of treatment (fig 4.3B) and end of treatment (fig 
3C) as well as 3 mice treated with doxorubicin at start of treatment (fig 4.3D) and 
end of treatment cycle (fig 3E) along with the luminescence scale (fig 4.3F). As 
tumors in the doxorubicin treated group show stronger BLI signals both at start and 
end of treatment, the total tumor growth over the course of 6 weeks, as calculated 
by fold change (fig 4.3A), amounts to a similar signal increase. Statistical analysis 
of both the BLI signals and the fold change showed that doxorubicin treatment was 
not found to significantly influence the tumor growth (two tailed independent t-test 
for fold change p=0.143; for BLI signals p=0.2). Mouse weight was stable during 
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showed a short 
lapse in tumor 
growth but start 
to catch up with 
untreated 
(MOCK) mice 













signals for 3 
untreated mice 
at start of signal detection (B) and after 6 weeks (C). D, E: Bioluminescent signals for 3 
mice treated with doxorubicin at start of signal detection and doxorubicin treatment (D) and 
after 6 weeks at completion of treatment cycle (E). F: Luminescence scale indicating the 
strength of BLI signals in p/sec/cm2/sr, based on the premise that a larger tumor will emit 
more luciferase and therefore a stronger signal will be detected, represented in the red 
spectrum on the scale. The increase is tumor size from B-C and D-E in control and 
doxorubicin treated mice is observed by the increase in red signal. 
  





Chondrosarcoma is notoriously resistant to conventional chemotherapy. The mouse 
model developed here supports this resistance as it is observed in the clinic. Indeed, 
no significant difference between untreated tumors and tumors treated with 
doxorubicin is observed. In this era of targeted therapeutics, identification of 
targets is crucial, and over the past years new therapeutic targets have been 
identified using the growing number of chondrosarcoma cell lines. Apoptotic 
pathways have been shown to be upregulated in chondrosarcoma, and inhibition of 
survivin (24) and the anti-apoptotic Bcl-2 family members (25-27) were shown to 
result in increased sensitivity to chemotherapeutics and radiotherapy (28). 
Moreover, survival pathways involving HIF1α (29-31), Src (32;33), PI3K (32;34), 
and the mTOR (35;36) pathways have been shown to play crucial roles in 
chondrosarcoma survival. The development of new targeted therapeutics targeting 
the apoptosis and survival pathways provides unlimited opportunities for 
combination treatments. Recently, synergy between PI3K and Bcl-2/Bcl-xl 
inhibition was shown in renal cell carcinoma cell lines (37), and both were shown 
to potentiate MEK inhibition in lung and pancreatic tumor models (38). Preclinical 
results in chondrosarcoma strongly advocate similar combinations in 
chondrosarcoma. However, due to the rarity of chondrosarcoma, the execution of 
large clinical trials is a major hurdle. The presence of good animal models, such as 
the one presented here, to test therapeutic candidates before proceeding to the 
clinic is therefore invaluable.  
Most existing chondrosarcoma mouse models are subcutaneous (15), whereas 
human chondrosarcoma typically occurs either in the medulla of the bone or on the 
surface of the bone (1). A mouse model mimicking the human situation is 
preferable when studying chondrosarcoma characteristics and new therapeutic 
strategies, especially since matrix deposition around the tumor cells and tumor 
blood supply have been hypothesized to play a role in chemoresistance (33). The 
models presented here utilize a luciferase construct enabling the live imaging of 
tumor growth, an especially useful tool when studying drug response. Interestingly, 
during the development of our model, we observed that direct deposition of tumor 
cells in the bone resulted in better grafting than subcutaneous injection. Possibly 
through creating a niche which better resembles the natural environment of the 
tumor. We compared two injection methods, in the first method cells were injected 
after drilling a hole in the tibia, and in the second method cells were immediately 
injected in the tibia. Even though a short delay in tumor onset was observed, 
tumors succeeded to grow without prior creation of a reservoir, a method also 
considered to be less painful for the mice.  
However, subcutaneous xenograft chondrosarcoma mouse models have advanced 
our understanding of EXT mutations and the hedgehog signaling in cartilage 
tumors (39). Recently, an orthotopic xenograft mouse model with spontaneous 
metastases, derived from the chondrosarcoma cell line JJ012, was developed. We 
Chapter 4                                                                                                        82 
 
 
were unable to grow tumors using the JJ012 cell line (results not shown). This 
discrepancy could be explained by the fact that we did not use matrigel to facilitate 
injection and homing of the chondrosarcoma cells. However, the CH2879 and 
SW1353 cell lines did not need matrigel to form tumors.  
We here show the development of orthotopic chondrosarcoma mouse models, 
using a luciferase construct for live imaging of tumor growth. Strongly resembling 
human chondrosarcoma, these models provide a new tool for in vivo studying of 
targeted therapeutics. Especially in chondrosarcoma, a rare malignancy making 
large randomized trials difficult to conduct, the development of such a mouse 
model can aid in bridging the gap between pre-clinical research and clinical 
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Chondrosarcomas are malignant cartilage forming tumors notorious for their 
resistance to conventional chemo- and radiotherapy. Postulated explanations 
describe the inaccessibility due to abundant hyaline cartilaginous matrix, presence 
of multi-drug resistance (MDR) pumps, and expression of anti-apoptotic BCL-2 
family members.  
We studied the sensitivity of chondrosarcoma cell lines (SW1353, CH2879, JJ012, 
OUMS27) and 2 primary cultures for doxorubicin and cisplatin. We examined the 
role of extracellular matrix using 3D pellet models and MDR pump activity using 
FACS analysis. The role of BCL2 family members was investigated using the BH3 
mimetic ABT-737.  
Chondrosarcoma cells showed highest resistance to cisplatin. 3D cell pellets, 
morphologically strongly resembling chondrosarcoma in vivo, confirmed nuclear 
incorporation of doxorubicin. MDR pump activity was heterogeneous among 
cultures. Chondrosarcoma cells responded to ABT-737 and combination with 
doxorubicin led to complete loss of cell viability and apoptosis with cytochrome C 
release.  
Despite MDR pump activity and abundance of hyaline cartilaginous matrix, 
doxorubicin is able to accumulate in the cell nuclei. By repairing the apoptotic 
machinery we were able to sensitize chondrosarcoma cells to doxorubicin and 
cisplatin, indicating an important role for BCL-2 family members in 




Chondrosarcoma is a malignant hyaline cartilaginous tumor of the bone, and is the 
second most common primary bone malignancy in humans. Several subtypes of 
chondrosarcoma exist, with conventional chondrosarcoma being the most common 
(~80%) (1). Conventional chondrosarcomas (CS) can occur either in the medulla of 
the bone (central chondrosarcoma) or at the surface (peripheral chondrosarcoma). 
As chondrosarcomas have clinically proven to be resistant to conventional chemo- 
and radiotherapy, no (systemic) treatment can be offered for high grade, 
irresectable, or metastatic tumors (2;3). Recent literature focuses on investigating 
activated pathways and assessing their validity as novel targeted treatment 
strategies for these inoperable tumors (4). 
Several hypotheses explaining primary resistance in conventional 
chondrosarcoma have been postulated. It is suggested that chemoresistance is 
caused by a possible impediment of chemotherapeutic agents to penetrate the 
extracellular matrix (5). In grade I chondrosarcomas, there is a vast amount of 
hyaline extracellular matrix (3;6-8). Low grade chondrosarcomas are composed of 
slowly dividing cells while conventional chemo- and radiotherapy target rapidly 
dividing cells (9). In higher grade chondrosarcomas, the extracellular matrix 
appears more myxoid and cells divide more rapidly but especially in these tumors 
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chemoresistance confers an important clinical problem. Alternatively, the activity 
of multi-drug resistance (MDR) pumps may cause chemoresistance in 
chondrosarcoma, as has been described in various cancer types. The role of P-
glycoprotein in resistance to doxorubicin has been shown in two chondrosarcoma 
cell lines (10) and retrospective studies (11). Finally, the parathyroid hormone 
related peptide (PTHrP) pathway was found to be activated in chondrosarcoma 
with high BCL-2 expression, correlating with increasing histological grade (6;8). 
Since BCL-2 is an anti-apoptotic protein, its aberrant expression may contribute to 
chondrosarcoma resistance (12).  
In order to determine the cause of chemoresistance in conventional central 
chondrosarcoma, we tested the different hypotheses described above: 3D pellet 
models were used to investigate the role of matrix surrounding the tumor cells. We 
assessed the activity of the multidrug resistance pumps and established the role of 
BCL-2 family members. Our data indicate that tumor matrix and MDR pumps are 
not critical to chemoresistance of chondrosarcoma whereas the activity of anti-
apoptotic BCL-2 family members controls the onset of cell killing caused by 





Doxorubicin and cisplatin were obtained from the in-house hospital pharmacy in a 
0.9% NaCl solution. Therapeutic concentrations of doxorubicin in patients are 5-
100µM with an in vitro range of 1-10 µM, for cisplatin these are 3-13µM with an 
in vitro range of 1-50µM (13). ABT-737 (Abbott Laboratories Inc, IL, USA) and 
R-roscovitine (R7772, Sigma Aldrich, Zwijndrecht, The Netherlands) were 
dissolved in DMSO.   
 
Cell culture 
Acute Lymphatic Leukemia cell line HL-60, chondrocyte cell line LBPVA (14), 
osteosarcoma cell line MNNG, as well as chondrosarcoma cell lines and primary 
cultures (table 5.1), were cultured in RPMI1640 (Gibco, Invitrogen Life-
Technologies, Scotland, UK) supplemented with 1% L-glutamax, 1% 
penicillin/streptomycin (100U/mL), and 10% (cell lines) or 20% (primary 
cultures), heat-inactivated Fetal Calf Serum (Gibco, Invitrogen Life-Technologies, 
Scotland, UK). Normal human mesenchymal stem cells (MSC) L2069 (15) were 
grown in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Breda, The 
Netherlands) supplemented with 1 mg/ml glucose, 2% penicillin/streptomycin 
(P/S), and 10% Fetal Bovine Serum acetyl salicyclic acid (ASA) (FBS ASA; 
Hyclone, Logan, UT). Cells were grown at 37°C in a humidified incubator with 
95% air and 5% CO2. All primary chondrosarcoma cultures were generated from 
chondrosarcomas surgically resected in our institute. All samples were coded and 
all procedures were performed according to the ethical guidelines “Code for Proper 
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Secondary Use of Human Tissue in The Netherlands” (Dutch Federation of 
Medical Scientific Societies). Cells were cultured until stably multiplying and 
chondrogenic phenotype was confirmed using RT-PCR for collagen I, IIB, III, and 
X, aggrecan, and SOX9 (16). DNA was isolated from the cells for subsequent 
TP53 mutation analysis (17).  Identity of cell lines was confirmed using the 
PowerPlex® 1.2 system after completion of experiments (Promega Benelux BV, 
Leiden, The Netherlands). 
Cell counting and viability assay 
Cell counting for proliferation assay was performed with a Casey ® cell counter 
(Roche Applied Sciences, Almere, the Netherlands). Chondrosarcoma cell lines 
and primary cultures were plated in 96 well plates for viability assessment (2-5x104 
cells/well for cell lines and 2x105 for primary cultures) and allowed to adhere 
overnight. Cells were incubated with the drugs for 24, 48, or 72 hours, after which 
a WST-1 assay was performed according to manufacturer’s instruction (Cat. No. 
11 644 807 001; Roche Diagnostics GmbH, Penzberg, Germany) and analyzed 
with a light spectrometer (Victor3V, 1420 Multilabel counter, Perkin Elmer, NL). 
All experiments were performed in triplicate at least three times. Graphs show data 
from one representative experiment. Error bars indicate standard deviation. 
Synergy was calculated using the Chou & Talalay method for Combination Index 
calculations (18).  
 
3D Pellet model 
3D cell pellets were generated from cultures CH2879, OUMS27, L835, and MSCs 
L2069 as described (15).  Cell pellets were allowed to differentiate for 4 weeks 
after which they were treated with either 1µM or 10µM doxorubicin 2x week. 
After a total of 6 weeks, pellets were harvested, washed in PBS 3x, fixed in 
formalin, embedded in paraffin. Pellet slides were mounted using 4'-6-diamidino-
2phenylindole (DAPI) -containing VECTASHIELD (Vector Laboratories, 
Burlingame, CA) and examined under a Leica DM500B fluorescent microscope. 
Doxorubicin incorporation was recorded at 480nm. Pellet morphology and matrix 
formation were examined using H&E staining and 1% toluidine blue staining 
(Brocacef Holding, Maarssen, The Netherlands). Immunohistochemistry for Ki-67 
(DAKO, Heverlee, Belgium) and cleaved caspase 3 (Cell Signaling, Leiden, The 
Netherlands) were performed as described (19). Percentage of positive cells was 
calculated using NuclearQuant software (3DHISTECH, Budapest, Hungary).   
 
Multidrug resistance pump assay 
Activities of three multidrug resistance pumps Multidrug Resistance Protein 
1 (MDR1), Multidrug Resistance-Associated Protein 1 (MRP1), and Breast 
Cancer Resistance Protein (BCRP) were measured using the MDQ assay 
(SOLVO Biotechnology, Budapest, Hungary) according to manufacturer’s 
instructions in all cell lines. Ligand incorporation was analyzed using FACS  
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Table 5.1. Description of chondrosarcoma cell lines and primary cultures  
Cell Line Bone of 
origin 
Grade Gender Age Passage Expression cartilage 
markers (Real-Time PCR) 




SW1353 Humerus II F 72 21 Col 1, 2B, 3,10,aggr, sox9a V203L MDR1 ATCC 















L835b Humerus III M 55 15 Col 1, 2A, 3, 10, aggr a wildtype MDR1/ 
BCRP 
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analysis on a BDTM LSR II flow cytometer. Calcein incorporation was 
recorded at 488nm, and mitoxantrone at 633nm. Dead cells were labeled 
with Propidium Iodide (Sigma Aldrich, Zwijndrecht, The Netherlands) (20) 
and gating was set at 10.000 live cells. Means of Geometric counts were 
calculated from all events. Experiments were performed in triplicate on one 
day using the same instrument settings. 
 
BCL-2 and MCL1 expression analysis 
A standard quantitative reverse transcriptase PCR (qRT-PCR) with SYBR green 
(16) was performed for MCL1 and BCL-2. Primers were designed using primer3 
software (http://frodo.wi.mit.edu/primer3/) (Table 5.2) and ordered from ISOGEN 
Bioscience BV (Maarssen, The Netherlands). Relative gene expression levels were 
normalized for the amount of cDNA input using the genes CYPa, CPSF, and 
GPR108, based on their constant expression in chondrosarcoma (21). For 
immunoblotting, 20µg of each sample was run on SDS-PAGE and proteins were 
transferred onto polyvinylidene difluoride membranes (Immobilon-P, Millipore, 
UK) using electrophoresis. Membranes were preincubated with skinned milk in 
phophate buffered saline-Tween 0.05%. Rabbit monoclonal antibodies against 
BCLXL (54H6), BCL-2 (50E3), and MCL1 (4572) were obtained from Cell 
Signaling Technology (Leiden, the Netherlands). Mouse monoclonal antibody 
against alpha-tubulin (DM1A) was obtained from Sigma-Aldrich (Zwijndrecht, the 
Netherlands). 
 
Table 5.2: Primers used in qRT-PCR 
Primer   Sequence 
MCL1  forward 5’ GGT GGC ATC AGG AAT GT 3’ 
  reverse 5’ ATC AAT GGG GAG CAC T 3’ 
BCL-2  forward 5’ ACA TCG CCC TGT GGA TGA CT 3’ 
  reverse 5’ GGG CCG TAC AGT TCC ACA AA 3’ 
 
Apoptosis assay 
20.000 cells were grown in black 96-well microclear plates (Greiner®, Sigma-
Aldrich, Zwijndrecht, The Netherlands) to perform a live cell apoptosis assay 
based on the binding of AnnexinV-Alexa633 conjugate (prepared as in (22)) to 
phosphatidyl-serine on the outer membrane of apoptotic cells. Increase of 
fluorescent apoptotic cells after drug exposure was followed by time-lapse imaging 
with 30 minute intervals using the BD Pathway® 855 (Becton Dickinson, Breda, 
The Netherlands) for 24 hours. Time series were quantified using in house 
developed macros for Image-Pro Plus (Media Cybernetics, Bethesda, USA). 
Apoptotic cells were expressed as the total pixel area of fluorescent objects in each 
frame. Drugs were added 0, 0 and 24, or 0, 24 and 48 hours before imaging; last 24 
hours of treatment of each culture was measured using AnnexinV labeling 
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immediately prior to imaging. To establish apoptosis specificity of the assay, all 
caspase activity was blocked using the pan-caspase inhibitor, z-VAD-fmk 
(Bachem-Holding AG, Weil am Rhein, Germany) at 50µM, 30 minutes before and 
continued during treatment and imaging. All experiments were performed in 




Cells were fixed in 4% buffered formaldehyde (Added Pharma, Oss, The 
Netherlands). Washing steps were performed with 1x PBS and blocking with 0.5% 
BSA + 0.1% Triton X100 in 1x PBS (TBP) at room temperature. 
Immunofluorescent staining was performed for cytochrome C (556432, BD 
PharMingen, CA, USA) and cleaved caspase 3 (9664, Cell Signaling, Leiden, The 
Netherlands) overnight after which washing steps were performed with TBP. Cells 
were post-fixed in 4% formaldehyde for 5 minutes. Imaging was performed at a 
Nikon TiE2000 confocal laser scanning microscope (Nikon, Amstelveen, The 




Chondrosarcoma cultures are sensitive to doxorubicin while resistant to cisplatin 
For doxorubicin an IC50 of 6µM was observed in the most responsive cell line 
(OUMS27) and an IC50 of >100µM in the least responsive cell line (SW1353) 
(figure 5.1A, table 5.3). Cell cultures showed a poor response to cisplatin 
treatment; total resistance even at 80µM was observed for L869 and SW1353 
(figure 5.1B, table 5.3). Live cell imaging with AnnexinV labeling, performed with 
10µM doxorubicin and 50µM cisplatin, showed a significant induction of apoptosis 
(p<0.05 one-way ANOVA) for cell lines responsive to doxorubicin, such as 
OUMS27, but not after cisplatin treatment (figure 5.1C). For non responsive 
cultures, such as L835, no significant induction of apoptosis could be achieved 
after either treatment (figure 5.1D). All apoptosis could be inhibited using a general 
caspase inhibitor zVAD-fmk (p<0.05 one-way ANOVA) (figure 5.1C, D). p53 
analysis showed three cultures to be negative for p53 mutations with no correlation 
of mutation status with drug response (table 5.1). 
 
3D pellets show chondrosarcoma morphology and doxorubicin incorporation 
3D pellet cultures were created from OUMS27, CH2879, and L835 and 1 MSC 
culture. Cell pellets had a maximal diameter of about 1mm. 3D pellets made from 
the MSC culture showed ample matrix surrounding the cells, resembling the 
cellular make-up of a low grade chondrosarcoma (figure 5.2A, Ai). 3D cell pellets 
from high grade chondrosarcoma cell lines (grade II, III) morphologically 
resembled high grade chondrosarcoma (figure 5.2B, Bi) showing high cellularity.  
Chapter 5                                                                                                        94 
 
 
Doxorubicin incorporation showed nuclear accumulation at both 1µM and 10µM, 
even in L835 which shows resistance to doxorubicin at 10µM (figure 5.2D-Dii), 
and in MSC cell pellets with ample matrix formation (results not shown). Ki-67 
staining showed decreased proliferation in all pellets after treatment although this 
was not significant (figure 5.2Ci, E-Eii). Cleaved caspase 3 staining on pellets 
showed 10% of cells had undergone apoptosis in non-treated pellets, whereas 
pellets treated with doxorubicin  showed caspase activation in almost all cells 
(p<0.05, one-way ANOVA, figure 5.2C, F-Fii). Activation of caspase in cell 
pellets as opposed to the resistance we showed in figure 5.1 in the 2D cultures is 
due to differences in exposure to doxorubicin: 3D pellets were treated 4x and 2D 
cultures only once.  
 
 
Figure 5.1. Cell viability of chondrosarcoma cells is inhibited and apoptosis induced 
by high dose doxorubicin but not cisplatin. Dose response curves for chondrosarcoma 
cell lines show sensitivity to doxorubicin at high concentrations (A) and resistance to 
cisplatin (B) after 72 hours incubation. OUMS27 cells show a significant increase of 
apoptosis (AnnexinV) after addition of doxorubicin 1µM (DXR), but not after addition of 
cisplatin 5µM (CDDP) (C). Addition of zVAD-fmk (zVAD) before doxorubicin allowed 
for significant inhibition of apoptosis (fluorescence intensity shown by AnnexinV binding, 
measured over 24hrs). L835 shows no significant induction of apoptosis after either 
treatment (D). Error bars in graphs show standard deviations from 3 measurements. 
*significant increase of apoptosis compared to mock (medium only treatment) and DMSO 
treatment (one-way ANOVA, p<0.05) ** significant decrease of apoptosis compared to 
treatment without zVAD (one-way ANOVA, p<0.05)   
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DXR (µM) b 
Combination 
ABT-737 (µM)  b 
Combination 
index (CI) d e 
Combination 
CDDP (µM)  c 
Combination 
ABT-737 (µM)  c 
Combination 
index (CI) d f 
OUMS27 6 50 25 0,1 5 0,22 0,1 5 0,20 
CH2879 60 40 20 0,1 0,25 0,01 1 0,1 0,03 
JJ012 25 35 100 g 0,1 0,5 0,01 0,1 5 0,05 
SW1353 150g 400 g 135 g 1 1 0,01 0,5 5 0,04 
L835 70 200 g 60 g 0,25 0,5 0,01 5 5 0,11 
 
a Concentrations needed to achieve 50% reduction in cell viability 
b Concentrations needed to achieve 50% reduction in cell viability during combination assay with Doxorubicin and ABT-737 
c Concentrations needed to achieve 50% reduction in cell viability during combination assay with Cisplatin and ABT-737 
d Combination index as calculated according to the Chou & Talalay method for synergistic relationships. A combination index <1 indicates 
synergy between drugs.  
e Combination index for the combination Doxorubicin and ABT-737  
f Combination index for the combination Cisplatin and ABT-737 
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Figure 5.2. 3D pellet models show similar cellular organization as chondrosarcoma 
tissues and doxorubicin incorporation. Low grade chondrosarcoma (A) strongly 
resembles 3D 
pellet created 
from MSC cell 
culture (L2069) 






from L835, a 
grade III 
chondrosarcoma 


















data of pellets 
(L2069, 
OUMS27, 
CH2879, and L835) with error bars indicating lowest and highest counts, shows that 
cleaved caspase 3 staining is present in 100% of cells after 10µM doxorubicin (C) and Ki67 
staining in about 5% of cells (C’). Staining for Ki67 (E-E”) and cleaved caspase 3 (F-F”) in 
L835 pellets treated with 0, 1, and 10 µM doxorubicin show decrease in number of cells 
proliferating and an increase in apoptosis. After treatment with 10µM, cellularity decreases, 
pictures were obtained at 40x magnification 
* Significant difference between treated and untreated (one-way ANOVA p< 0.05) 
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MDR pump activity is found in chondrosarcoma cultures 
We determined MDR pump activity in chondrosarcoma cell lines and primary 
cultures, and in a chondrocyte cell line LBPVA (14). Pump activity was compared 
to HL-60, described to have high MDR1 activity, and to osteosarcoma cell line 
MNNG which has been described to express MDR1 and MRP1, with higher 
MDR1 activity (23). This was confirmed using our MDQ assay. Considerable 
heterogeneity was observed in the activity of MDR pumps throughout the cell 
lines, with MDR1 (p-glycoprotein) demonstrating activity in all cell lines except 
OUMS27 and LBPVA. MRP1 activity was observed in LBPVA, 2 cell lines 
(JJ012, CH2879) and primary cultures. L869, JJ012, and CH2879 showed activity 
of all three pumps, with highest activity observed in L869 (figure 5.3, table 5.1).  
 
Inhibition of BCL-2 family members but not MCL-1 reduces cell viability and 
increases apoptosis  
RT-PCR confirmed mRNA expression of BCL-2 and BCL-XL, with expression 
levels similar to that of HL-60 (figure 5.4A) in which these expression levels have 
been linked to chemoresistance (24). Western blot analysis showed high expression 
of BCL-XL in all cell lines (figure 5.4B) while BCL-2 expression was less uniform. 
Using ABT-737, HL-60 showed complete loss in cell viability at 0.5μM, as 
reported (25). In chondrosarcoma cell lines, CH2879 and OUMS27 showed the 
best response, with IC50s of 20µM and 25µM, respectively. Cell counting showed 
cell proliferation at 10µM to correspond with cell viability (figure 5.5). L835 
showed intermediate response to ABT-737 (IC50 60µM), for other cell lines, the 
IC50 values exceeded 100µM (figure 5.4C, table 5.3). Live cell imaging during 24 
hours of ABT-737 (25µM) treatment showed a significant increase of apoptotic 
cells compared to DMSO treatment, all of which could be inhibited using the 
caspase inhibitor zVAD-fmk (figure 5.4E,F). It has been described that in tumors 
resistant to BCL-2 inhibition, MCL1 upregulation might play a role (26). Indeed 
RT-PCR demonstrated 2-fold increases of MCL1 mRNA expression in 
chondrosarcoma cell lines compared to household genes (fig 5.4A). Also, MCL1 
expression was confirmed at the protein level using western blot (fig 5.4B) 
although lower than BCL-2 or BCL-XL. We used R-roscovitine, a non-specific 
CDK inhibitor described to downregulate MCL-1 (27) to assess the role of MCL-1 
in the response to ABT-737. High concentrations of R-roscovitine (5µM and 
10µM) failed to induce reduction in cell viability (figure 5.4D) or apoptosis on its 
own or in combination with ABT-737 (results not shown).  
 





Figure 5.3. Activity of Multi-Drug-Resistance pumps in chondrosarcoma cultures.  
Ligand incorporation with and without the presence of pump inhibitors was measured using 
FACS analysis. A, B:FACS analysis of L835; insets show mean GEO counts with the 
standard deviation. C: graphical representation of pump activity per cell line. Ligand 
incorporation (Δ%) represents the difference of total GEO counts with inhibitor to total 
GEO counts without inhibitor. Activity was compared to HL-60 cell line and to an 
osteosarcoma cell line (MNNG). MRP1 activity was higher than in HL-60 in the 
chondrocytic cell line and in L869, but equal in JJ012 and CH2879. Activity of the MDR1 
pump (p-glycoprotein) was observed in nearly all cultures. BCRP activity varied highly 
among cultures.  
  




BCL-2 inhibition can reverse chemoresistance of chondrosarcoma  
Simultaneous addition of ABT-737 and doxorubicin or cisplatin to cell cultures did 
not show additive effects. Combination treatments proved most effective with 
respect to cell viability when at least 24 hours were left in between drug 
administration, with ABT-737 treatment before and after doxorubicin or cisplatin 
addition (results not shown). The combination of doxorubicin or cisplatin with 
ABT-737 allowed for the reduction of both treatments to sublethal concentrations 
(table 5.3). Combination Index (CI) calculations for synergy analysis revealed high 
synergy between ABT-737 and both doxorubicin and cisplatin; a mean CI of 0.05 
for the combination with doxorubicin and a mean CI of 0.09 for the combination 
with Cisplatin (table 5.3). The combination of doxorubicin with ABT-737 was 
most effective also with respect to apoptosis (figure 5.6). Live cell imaging to 
evaluate apoptosis was performed using 5µM ABT-737 and 1µM doxorubicin or 
5µM cisplatin. For most cell lines a clear advantage was observed when ABT-737 
treatment was performed 24 hours before doxorubicin or cisplatin treatment; with 
doxorubicin being the most effective combination (figure 5.6A, C; OUMS27 and 
CH2879 shown as representatives for these four cell lines). For L835, ABT-737 
treatment showed the largest increase in apoptosis when administered after 
doxorubicin or cisplatin (figure 5.6B). Immunofluorescence for cytochrome C 
combined with Hoechst staining 24hrs after addition of each drug showed increase 
in cytochrome C release after addition of each drug; after the third cycle of drug 
addition almost all cells had undergone apoptosis and few nuclei could be 
identified (figure 5.6D).  
 





Figure 5.4. BCL-2 but not MCL1 overexpression protects chondrosarcoma cell lines 
from apoptosis. A: normalized mRNA expression levels of BCL-2 and MCL1 in 
chondrosarcoma cell lines showing constant expression in chondrosarcoma. B: Western 
Blot analysis of MCL1, BCL-XL, and BCL-2 expression in chondrosarcoma cell lines. 
BCL-2 and BCL-XL are present in all cell lines, and markedly higher than MCL1. C,D: 
Cell lines were treated with ABT-737 (C) or R-roscovitine (D) for 72 hrs. Dose response 
curves show sensitivity to ABT-737 at high concentrations and resistance to R-roscovitine 
for mitochondrial activity. E,F: OUMS27 and L835 cells show apoptosis (fluorescencence 
intensity shown by AnnexinV binding) after 72hrs of 25µM ABT-737 treatment. Addition 
of zVAD before ABT-737 allowed for significant inhibition of apoptosis (AnnexinV 
binding). Error bars in graphs show standard deviations from 3 measurements. 
*significant increase of apoptosis compared to mock (medium only treatment) and DMSO 
treatment (one-way ANOVA, p<0.05) ** significant decrease of apoptosis compared to 
treatment without zVAD (one-way ANOVA, p<0.05) 
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 Figure 5.5 ABT-737 successfully 
inhibits cell proliferation of 
chondrosarcoma cells. 
Chondrosarcoma and HL-60 cells 
were treated with medium (mock), 
DMSO, or ABT-737 for 72hrs. Cell 
count for mock treatment was put at 
100% proliferation. HL-60 cells 
showed some sensitivity to DMSO 
treatment. For all cell lines, 
sensitivities reduction in cell 
proliferation (cell number) were 
comparable to those observed in cell viability.  
 
 Figure 5.6. Combination therapy of ABT-737 with doxorubicin and cisplatin induces 
apoptosis in chondrosarcoma cells. Cells were treated with respective drugs for 24hrs 
time periods, apoptosis was monitored with AnnexinV staining. Y axes show total pixel 
area of AnnexinV positive cells. Combination therapy of ABT-737 with doxorubicin was 
most effective in inducing apoptosis in all cell lines. OUMS27 and CH2879 (A,C) were 
most responsive to treatment with ABT-737 before and after doxorubicin (DXR) treatment, 
whereas L835 (B) seemed slightly more sensitive to doxorubicin treatment before and after 
ABT-737. Error bars show standard deviation from 3 measurements. D: Increase in 
cytochrome C release (green) is observed during treatment, with loss of cells at the end of 
treatment (Hoechst, blue), caspase 3 release (red) could be observed after ABT-737 
addition (20x magnification). 
  





Chondrosarcomas are resistant to conventional chemotherapy and radiotherapy. In 
the ongoing pursuit to find new, targeted, treatment strategies we set out to define 
the reasons for chemoresistance. Postulated hypotheses regarding the mechanisms 
underlying chemoresistance include the high abundance of cartilaginous matrix, the 
expression of MDR pumps, and the expression of anti-apoptotic proteins (5). 
We first assessed the sensitivity of our cell lines and primary cultures to 
single treatments of doxorubicin and cisplatin, the most commonly used 
chemotherapeutic agents in sarcomas, using 2D cell culture. All cultures responded 
poorly, especially to cisplatin. As 2D cultures lack matrix formation, we used 3D 
pellet cultures, shown to be good models for cartilage formation (28;29), to study 
the effect of the chondroid matrix on diffusion of therapeutic agents in vitro. We 
here demonstrate 3D pellets of MSC and chondrosarcoma cell lines to strongly 
resemble low grade and high grade chondrosarcoma, respectively. Previously, 
doxorubicin was reported to remain in chondrosarcoma cells during washout 
experiments in 2D cell cultures (30;30;31). Using 3D pellets we now show that the 
chondroid matrix does not hinder doxorubicin from entering the nuclei of the cells.  
Numerous reports on the role of MDR pumps in chemoresistance exist. 
MRP1 (encoded by ABCC1) expression has been described to play a role in 
resistance to cisplatin (32). P-glycoprotein (ABCB1) activity (33) and BCRP 
(ABCG2) activity are described to play a role in doxorubicin efflux (34). P-
glycoprotein expression has previously been found on the surface of the 
chondrosarcoma cell lines JJ012 and SW1353 (30;31;35) and endogenous P-
glycoprotein expression has been described in human growth plate, suggesting a 
physiological role (10). Recently, ABT-737 has been shown to be a substrate for P-
glycoprotein (36). We show strong variation in the activity of MDR pumps over a 
wide panel of cell cultures and pump activity could not be correlated with the in 
vitro response to doxorubicin, cisplatin or ABT-737. 
Thus, we demonstrate that despite high matrix production (MSCs) and P-
glycoprotein activity (CH2879, L835), doxorubicin is able to enter the nuclei of the 
cells. This suggests a different, more specific mechanism possibly including a 
defective apoptotic pathway. It has been described that mutations in p53 can 
influence the response to DNA damaging agents such as doxorubicin (37). 
However, we found no correlation between p53 status and response.  
We previously demonstrated BCL-2 expression in 63-71% of high grade 
conventional chondrosarcoma (6;8). We investigated the role of anti-apoptotic 
BCL-2 family members using the BH3 mimetic ABT-737. ABT-737 is a small-
molecule inhibitor of the BCL-2 family and has been reported to be effective in, 
among others, myeloma and ovarian cancer cell lines (38-40). The apoptotic 
machinery in chondrosarcoma cultures was activated through inhibition of BCL-2 
family members with ABT-737 and cells were sensitized to doxorubicin and 
cisplatin. Using the BH3 mimetic ABT-737 proved more effective than the 
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previously reported use of small interfering RNA (siRNA) against BCL-2 which 
was unable to induce apoptosis on its own (30), supporting a role for other BCL-2 
family members. Moreover, recently, a small IAP (inhibitor of apoptosis) member, 
survivin was shown to be highly expressed in chondrosarcoma, indicating that also 
other factors contribute to a defective apoptotic machinery in chondrosarcoma (41). 
We show high synergy between ABT-737 and doxorubicin or cisplatin with 
combination indices for both combinations far below 1. Synergistic effects were 
observed only when combination treatments were administered with a 24 hour time 
gap and not when administered simultaneously, this is in concordance with the 
findings published on ABT-263 which accelerates apoptosis during drug-induced 
mitotic arrest (42). These data support that aberrant expression of BCL-2 family 
members, but not MCL-1, in chondrosarcoma debilitates the apoptotic pathway as 
it should be activated in response to conventional chemotherapy, and that 
combination strategies are successful in overcoming this resistance mechanism.  
In conclusion, using a 3D pellet model we have shown that doxorubicin is 
able to diffuse across at least 1mm chondroid matrix surrounding chondrosarcoma 
cells and that it is able to enter and accumulate in the nuclei despite MDR pump 
activity. We showed in vitro that complete apoptosis can be achieved in 
chondrosarcoma cells at low concentrations of doxorubicin and cisplatin if 
combined with ABT-737, pointing towards an important role for BCL-2 and BCL-
XL in chemoresistance. The orally available homologue of ABT-737; ABT-263, is 
used in clinical trials with low side effects (43). Our results strongly support the 
combination treatment of chondrosarcoma patients with ABT-263, with our data 
supporting a stronger synergistic effect in combination with doxorubicin.  
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Mesenchymal - , clear cell - , and dedifferentiated chondrosarcoma are extremely 
rare and together constitute 10-15% of all chondrosarcomas. Their poor prognosis 
and lack of efficacious treatment emphasizes the need to elucidate the pathways 
playing a pivotal role in these tumors.  
We constructed tissue microarrays containing 42 dedifferentiated - , 23 clear cell - , 
and 23 mesenchymal chondrosarcomas and performed immunohistochemistry to 
study the expression of growth plate-signaling molecules, and molecules shown to 
be involved in conventional chondrosarcoma. We observed high expression of 
SOX9 and FGFR3, as well as aberrant cellular localization of heparan sulfate 
proteoglycans, in all subtypes. We found TGFbeta signaling through pSMAD2 and 
PAI1 to be highly active in all chondrosarcoma subtypes suggesting TGFbeta 
inhibitors to be a possible therapeutic strategy in rare chondrosarcoma subtypes. 
Like in conventional chondrosarcoma, antiapoptotic proteins (Bcl-2, and / or Bcl-
xl) were highly expressed in all subtypes. Inhibition with the BH-3 mimetic ABT-
737 rendered dedifferentiated chondrosarcoma cell lines sensitive to doxorubicin or 
cisplatin. We here show that antiapoptotic proteins may play an important role in 
chemoresistance, suggesting a promising role for targeting Bcl-2 family members 
in chondrosarcoma treatment irrespective of subtype. 
 
Introduction 
Chondrosarcoma of bone is a malignant tumor characterized by the 
formation of cartilage. It mainly affects adults in the third to sixth decades of life. 
In addition to conventional chondrosarcoma, several rare subtypes are recognized 
with distinct histological and clinical features. These subtypes include clear cell 
chondrosarcoma, mesenchymal chondrosarcoma, and dedifferentiated 
chondrosarcoma. Together they constitute 10-15% of all chondrosarcomas. 
Previously, it was suggested that the distinct chondrosarcoma subtypes show 
striking histological similarities with cartilaginous cells of the growth plate in 
various states of differentiation (1). This model is supported by results from 
expression analysis of extracellular matrix genes (2). 
Clear cell chondrosarcoma (2%) is a low-grade malignant tumor, which 
rarely metastasizes, but commonly recurs after curettage. About 15% of the 
patients die as a result of the disease. The disease is characterized by tumor cells 
with clear, empty cytoplasm, resembling the hypertrophic cells of the growth plate 
(1). In addition, expression of collagen type X and osteonectin further supports the 
resemblance to chondrocytes in the hypertrophic state (3). 
Mesenchymal chondrosarcoma (2% of all CS) is a highly malignant lesion 
which occurs in bone as well as in soft tissue of relatively young patients. The 
tumor consists of differentiated cartilage mixed with undifferentiated small round 
cells and usually follows an aggressive course with a high rate of distant metastases 
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and a 5-year overall survival of 55% (4). Histologically the undifferentiated cells 
resemble the resting cells of the growth plate (1) and Aigner et al confirmed the 
premesenchymal chondroprogenitor origin of these cells by studying cell 
differentiation and matrix gene expression (2;5).  
Dedifferentiated chondrosarcoma (10%) is a tumor containing two clearly 
defined components: a high-grade non-cartilaginous anaplastic sarcoma juxtaposed 
to a usually low-grade well-differentiated cartilage tumor, with a sharply defined 
junction between the two components (6). It has a poor prognosis and no targets for 
therapy have been reported to date (7).  
Nearly all chondrosarcomas arise in bones formed by endochondral 
ossification. Endochondral ossification occurs in the growth plate, in which four 
zones can be distinguished: the resting zone, the proliferating zone, the transition 
zone, and the hypertrophic zone (8). With the elucidation of the EXT genes being 
involved in the development of multiple as well as solitary osteochondromas 
(benign cartilaginous tumors at the surface of the bone), parallels between the 
normal growth plate and cartilage tumors became obvious since they shared a 
strong morphological resemblance (for review see: (9)). The exostosins are 
involved in heparan sulfate chain elongation on heparan sulfate proteoglycans 
(HSPGs). HSPGs include syndecan, perlecan and the splice variant of CD44 
including variable exon 3 (CD44v3) and are crucial for facilitating signaling of 
FGF, Wnt, BMP, TGFbeta and indian hedgehog (IHH), all of which are important 
for chondrocyte proliferation and differentiation in the normal growth plate 
(reviewed in 10). The process of chondrocyte proliferation and differentiation is 
tightly regulated by a paracrine feedback loop involving both IHH/ parathyroid 
hormone like hormone (PTHLH) and fibroblast growth factor (FGF) signaling (11). 
Wnt signaling promotes chondrocyte differentiation in a SOX9 dependent manner 
(12). TGFbeta signaling can regulate PTHLH expression independently of IHH 
(13). Multiple studies have confirmed the importance of these pathways in 
conventional central and peripheral chondrosarcoma (14;15). In contrast, because 
of the rarity of clear cell, dedifferentiated and mesenchymal CS, little information 
is available on the role of these pathways in rare chondrosarcoma subtypes. 
In this study, we therefore investigated the expression of the master 
transcription regulator for chondrogenic differentiation (SOX9), HS and HSPGs 
(10E4, syndecan 2, 3 and 4, CD44 variable exon 3 and NDST2), and proteins 
involved in PTHLH (PTHLH, PTHR1 and BCL-2), FGF (FGF18 and FGFR3), 
WNT (beta catenin), BMP (pSMAD1) and TGFbeta (pSMAD2 and PAI1) 
pathways as well as the expression of COX2 and KIT based on possible therapeutic 
consequences, in 42 dedifferentiated chondrosarcomas, 23 clear cell 
chondrosarcomas, and 23 mesenchymal chondrosarcomas. Based on the results we 
further investigated the role of Bcl-2 in chemoresistance of two dedifferentiated 
chondrosarcoma cell lines. 
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Materials and Methods 
Tumor tissue 
For this study, 42 dedifferentiated chondrosarcomas, 23 mesenchymal 
chondrosarcomas, and 23 clear cell chondrosarcomas were collected within the 
EuroBoNeT consortium, a European Commission granted Network of Excellence 
for studying the pathology and genetics of bone tumors. In total, formalin-fixed 
paraffin-embedded (FFPE) specimens from 88 patients were collected from the 
archives of the Department of Pathology, LUMC, The Netherlands (n=13), 
Nuffield Department of Orthopaedic Surgery, University of Oxford, UK (n= 6), 
The Royal National Orthopaedic Hospital, Middlesex, UK (n=22), Laboratory of 
Oncologic Research, ROI, Italy (n=30), Department of Pathology, RH, Denmark 
(n=10), and Department of Pathology, Medizinische Universität Graz, Austria 
(n=7). All specimens in this study were handled according to the ethical guidelines 
described in "Code for Proper Secondary Use of Human Tissue in The 
Netherlands" of the Dutch Federation of Medical Scientific Societies. Tumors were 
selected based on accepted clinicopathological and radiological criteria (16). All 
were primary tumors except for three clear cell chondrosarcomas and six 
mesenchymal chondrosarcomas, from which only material derived from the 
recurrent tumor was available. Histology was reviewed by two experienced bone 
tumor pathologists (JVMGB and PCWH). Clinicopathological data are shown in 
Table 6.1. Histological grading of the cartilaginous component of dedifferentiated 
CS was performed according to Evans (17).  
 
Tissue microarray (TMA) construction 
TMAs containing 2mm cores of all samples in triplicate were prepared using a 
TMA Master (3DHISTECH Ltd, Budapest, Hungary). From the dedifferentiated 
chondrosarcomas we included both the cartilaginous and the anaplastic 
components. From the mesenchymal chondrosarcomas we selected areas with the 
undifferentiated small cells as well as areas with cartilaginous differentiation. 
Normal non-decalcified liver, kidney, and tonsil samples were included on the 
TMAs for orientation purposes and as internal positive controls. 
 
Immunohistochemistry (IHC) 
Immunohistochemical reactions were performed according to standard laboratory 
methods (18) and visualized using DAB+ Substrate Chromogen System (Dako, 
Heverlee, Belgium). Details of the primary antibodies used for 
immunohistochemistry are described in Table 6.2. The negative controls were 
tissue sections incubated in PBS/BSA 1% without primary specific antibodies. All 
TMAs were scored by two observers independently (DM and JVMGB) both of 
whom were unaware of the clinicopathological data. Discrepancies were discussed 
to reach consensus. Staining intensity (0 = absent, 1 = weak, 2 = moderate, 3 = 
strong) and extent of the staining (0 = 0%, 1 = 1-24%, 2 = 25-49%, 3 = 50-74% 
and 4 = 75%-100%) were assessed. These two measures were added to the sum 
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score, which was used in all the analyses. For dedifferentiated chondrosarcoma, the 
well-differentiated and the dedifferentiated component were scored separately. 
Likewise, for mesenchymal chondrosarcoma both the cartilaginous areas and the 
small cell component were evaluated separately. Tumors were divided into two 
groups, having low (mean sum score of <2.5) or high (mean sum score of ≥2.5) 




Table 6.1 Clinicopathological data of 88 formalin-fixed paraffin-embedded 
rare chondrosarcomas 
   DDCS MCS CCS 
Total number of tumors 42 23 23 
Male 21 8 17 
Female 21 15 6 
Median age yrs (range) 66 (26-85) 29.5 (15-70) 43 (20-79) 
Median follow up (range)* 11 (1-216) 40 (7-204) 57 (1-408) 
*follow-up available for 34 dedifferentiated chondrosarcoma, 18 mesenchymal, and 20 
clear cell, chondrosarcoma patients  






Kaplan Meyer analyses were performed using Breslow Generalized Wilcoxon for 
statistical significance. Survival analyses were performed for metastasis-free 
survival per subtype. Cox regression analysis was carried out with clinical outcome 
(metastasis-free survival) as the independent variable. Correlation between 
expression and grade and individual stainings were evaluated using Pearson chi-
squared test for independent variables. Values of p ≤ 0.05 for asymptomatic 2 sided 
testing were considered significant. Spearman rank correlation coefficients were 
calculated for correlations between protein expression patterns. Due to low patient 
number, loss of cores, and incomplete information on some cases, it was not 
possible to calculate Kaplan Meyer curves for each staining. The data was analyzed 
using SPSS version 17.0 software (Chicago, IL, USA).  
  




Dedifferentiated chondrosarcoma cell lines L2975 (19) en NDCS-1 (20) were 
cultured in RPMI1640 (Gibco, Invitrogen Life-Technologies, Scotland, UK) 
supplemented with 1% penicillin/streptomycin (100U/mL) and 10% heat-
inactivated Fetal Calf Serum (Gibco, Invitrogen Life-Technologies, Scotland, UK). 
Cells were grown at 37°C in a humidified incubator with 95% air and 5% CO2. 
Identity of cell lines was confirmed using the PowerPlex® 1.2 system after 
completion of experiments (Promega Benelux BV, Leiden, The Netherlands). 
ABT-737 (Abbott Laboratories Inc, IL, USA) was dissolved in DMSO, and 
doxorubicin and cisplatin were obtained from the in-house hospital pharmacy in a 
0.9% NaCl solution. For inhibition assays, the cell lines were plated in 96 well 
plates for viability assessment (2x105 cells/well) and allowed to grow and adhere 
overnight after which the respective drugs were added in their corresponding 
concentrations. Combination assays were performed as described (21). In short, 
over the course of 96hrs, cells were treated twice with ABT-737 with an 
intermittent treatment of cisplatin or doxorubicin. Dose response curves were 
established for each cell line using dosages ranging from 100nM to 1µM for 
doxorubicin and cisplatin and 100nM to 5µM for ABT-737, after which 
combination assays were performed using combinations of all dosages. 
Combination indices could not be calculated as IC50s were not reached for single 
treatments. All experiments were performed in triplicate and at least three times. 
Graphs show data from one representative experiment. Error bars indicate the 
standard deviation.   
 
Immunoblotting 
Immunoblotting using Bcl-2 (clone C 21 Santa Cruz, Heerhugowaard, the 
Netherlands) and Bcl-xl (clone 54H6, cell signaling, Leiden, the Netherlands) 
antibodies was performed as previously described (22), using 20µg of each sample.   
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Table 6.2. Procedures and details of the primary antibodies used for immunohistochemistry 
antibody Manufacturer dilution antigen retrieval Blocking localisation pos. control 
PTHLH Oncogene 1:200 trypsin 30 min - cytoplasmic skin 
PTHR1 Upstate  1:400 citrate - cytoplasmic skin 
Bcl-2 Dako 1:1000 citrate - cytoplasmic Tonsil 
Bcl-xl Cell Signaling 1:400 citrate - cytoplasmic Prostate 
FGFR3  Sigma 1:4000 citrate - cytoplasmic umbilical cord 
FGF18 Sigma (Atlas) 1:4000 citrate - cytoplasmic tonsil 
SOX9  Atlas 1:100 citrate Milk nuclear testis 
pSMAD1 Cell signaling 1:100 citrate Milk nuclear colon 
pSMAD2 Cell signaling 1:50 citrate NGS nuclear Kidney 
CTNB1 Transduction Biosciences 1:2000 citrate - cytoplasmic Skin 
SDC2 Lifespan biosciences 1:200 - - cytoplasmic growth plate 
SDC3  Proteintech.Group Inc. 1:200 citrate NGS cytoplasmic colon carcinoma 
SDC4 Atlas 1:1000 citrate - cytoplasmic placenta 
NDST1 Abcam 1:800 Tris-EDTA - cytoplasmic Ileum 
PAI-1 American Diagnostics 1:200 - - cytoplasmic cervix carcinoma 
CD44v3  Novocastra 1:200 citrate - cytoplasmic tonsil 
10 E4 Seikagaku corporation 1:400 Heparitinase 
buffer 
NGS cytoplasmic skin 
PTGS2 Nuclilab 1:100 citrate NGS cytoplasmic colon carcinoma 
KIT Dako 1:2000 - - cytoplasmic GIST 
 
  





Histological analysis of dedifferentiated chondrosarcoma 
For the 42 dedifferentiated chondrosarcomas, the anaplastic component 
demonstrated an undifferentiated sarcoma in 30 cases, of which 23 showed spindle-
cell morphology. Nine cases showed osteosarcomatous differentiation in the 
dedifferentiated component. From three tumors the dedifferentiated part was not 
available. The cartilaginous component demonstrated grade I morphology in 19 
cases, grade II in eight and grade III in four cases. From 11 tumors no cartilaginous 
component was available. 
 
Wnt and SOX9 
Nuclear CTNB1 expression as a read-out for canonical Wnt-signaling was absent 
in all tumors.  Variable intensity of cytoplasmic staining was, however, observed in 
all tumor subtypes (table 6.3). The master transcriptional regulator for 
chondrogenic differentiation SOX9 (23) was expressed in a large portion of all 
three subtypes. A trend of slightly higher expression in the cartilaginous parts of 
the tumors was observed (fig 6.1A, B, table 6.3). In the cartilaginous cells of 
dedifferentiated chondrosarcoma Spearman’s rank correlation revealed an 
association (p < 0.05) between protein expression of SOX9 and SDC2 (rs = 0.70), 
SDC3 (rs = 0.71), and SDC4 (rs = 0.44). 
 
Heparan sulfate proteoglycan expression 
Heparan sulfate as demonstrated by immunoreactivity for 10E4 was variable. The 
anaplastic component of dedifferentiated chondrosarcoma as well as the small cell 
component of mesenchymal chondrosarcoma demonstrated more extensive and 
more intense expression as compared to their cartilaginous components. The 
expression in clear cell chondrosarcoma was limited (fig 6.1C). NDST1 (N-
deacetylase/N-sulfotransferase), an enzyme that can interact with EXT1 and EXT2 
during heparan sulfate chain formation (24), was highly expressed in 
dedifferentiated chondrosarcoma, and in the small cell component of mesenchymal 
chondrosarcoma. In the cartilaginous components of mesenchymal 
chondrosarcoma and in clear cell chondrosarcomas high NDST1 expression was 
observed in approximately half of the tumors (fig 6.1D, table 6.3). The expression 
of the heparan sulfate proteoglycans syndecan 2, -3, and -4 and of CD44 variable 
exon 3 was also variable in all 3 tumor subtypes (fig 6.1E, F, G, H). Expression of 
syndecans 2, -3, and -4 was higher in the dedifferentiated parts of dedifferentiated 
chondrosarcomas than in the cartilaginous parts and the other tumor types.  
 
FGF signaling 
The expression of FGFR3 was strong and extensive in most tumors of all three 
subtypes (fig 6.2A, B). The expression of FGF18, the ligand for FGFR3 in the 
normal growth plate, was more variable (fig 6.1I).  





Figure 6.1: Dot plots representing sum scores for all immuno stainings in all tumor 
tissues included on the TMA, grouped by tumor type.  
A: CTNB1. B: SOX9. C: 10e4. D: NDST-1. E: Syndecan 2 (SDC2). F: Syndecan 3 
(SDC3). G: Syndecan 4 (SDC4). H: CD44v3. I: FGF-18. J: p-SMAD1. K: PTHR1. L: 
COX-2. and M: KIT. DDCS, anaplastic component of dedifferentiated chondrosarcoma; 
DDCS cart, the cartilaginous component of dedifferentiated chondrosarcoma; MCS, the 
small cell component of mesenchymal chondrosarcoma, MCS cart, the cartilaginous 
component of mesenchymal chondrosarcoma; CCS, clear cell chondrosarcoma. 
 




Nuclear pSMAD1 expression, which indicates active BMP signaling, was moderate 
in all three subtypes (fig 6.1J). TGFbeta signaling, as evidenced by PAI-1 and 
nuclear pSMAD2 staining, was rather high in all three subtypes (fig 6.2C-E, table 
6.3). Expression of pSMAD2 showed some variation, ranging from high expression 
in half of the mesenchymal chondrosarcomas in the small-cell component, to 
almost all clear cell chondrosarcomas. In clear cell chondrosarcoma, PAI-1 
expression was positively correlated with both pSMAD2 (rs = 0.71; p < 0.001) and 
pSMAD1 (rs = 0.60; p = 0.009). We also demonstrated a positive correlation 
between PAI-1 and pSMAD2 expression in dedifferentiated chondrosarcoma (rs = 
0.45; p = 0.01), and high pSMAD2 protein expression was significantly associated 
with longer metastasis-free survival (HR = 0.38, p=0.048) (fig 6.2F). 
 
PTHLH signaling 
Parathyroid-hormone signaling was assessed using PTHLH and PTHR1 (25). 
PTHLH was high in dedifferentiated chondrosarcoma and clear cell 
chondrosarcoma (fig 6.3A, B), whereas, PTHR1 expression was found to be low in 
most of the clear cell chondrosarcomas and mesenchymal chondrosarcomas. In 
dedifferentiated chondrosarcoma PTHR1 expression was low in the cartilaginous 
component with higher expression in the anaplastic component (fig 6.1K).  
 
Bcl-2 and Bcl-xl signaling and chemoresistance  
Bcl-2 was assessed as the downstream signaling molecule of PTHLH in the growth 
plate (26). A positive correlation between PTHR1 expression and Bcl-2 was 
observed in clear cell chondrosarcoma (rs = 0.47; p = 0.04). Since anti-apoptotic 
proteins were shown to play an important role in chemoresistance of conventional 
chondrosarcoma (21), we additionally evaluated the expression of the Bcl-2 family 
member Bcl-xl. Both clear cell and mesenchymal chondrosarcoma showed high 
expression of both Bcl-2 (fig 6.4C, D) and Bcl-xl (fig 6.4F). In contrast, in 
dedifferentiated chondrosarcoma, high expression of mainly Bcl-xl was found (fig 
6.3E, F). L2975 and NDCS-1 are dedifferentiated chondrosarcoma cell lines 
showing strong expression of Bcl-xl and Bcl-2 (fig 6.4G). As L2975 showed only 
40% reduction in cell viability after 1µM doxorubicin and 10% reduction in cell 
viability after 1µM cisplatin and no reduction in cell viability could be achieved in 
NDCS-1 after treatment with either doxorubicin or cisplatin (fig 6.3A, B), we 
continued to investigate the effect of inhibition of Bcl-2 family members using the 
BH-3 mimetic ABT-737. Cells were treated with ABT-737 prior to and after 
doxorubicin or cisplatin addition as we previously showed that this was the most 
effective course of combination treatment (21). Interestingly, even though single 
treatment with 5µM ABT-737 did not result in a reduction of cell viability in either 
cell line (fig 6.3C), at concentrations as low as 100nM, inhibition of Bcl-2 family 
members was sensitizing the cells to both doxorubicin and cisplatin (fig 6.4H).  
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Table 6.3 Percentage of tumors showing high expression (mean sum score of ≥2.5) of proteins per subtype as determined by 
immunohistochemistry  
   Dedifferentiated CS Clear cell CS Mesenchymal CS 
  dedifferentiated areas cartilaginous areas  Small cells Cartilaginous areas 
Bcl-2 10/38 (26%) 1/25 (4%) 19/22 (86%) 22/23 (96%) 10/17 (59%) 
Bcl-xl 36/39 (92%) 10/32 (31%) 13/17 (76%) 8/12 (67%) 3/8 (38%) 
PTHLH 30/37 (81%) 25/27 (93%) 11/12 (92%) 4/7 (57%) 1/5 (20%) 
PTHR1 28/38 (74%) 8/25 (32%) 4/22 (18%) 9/23 (39%) 3/17 (18%) 
SOX9 31/39 (79%) 26/30 (87%) 16/17 (94%) 19/23 (83%) 18/18 (100%) 
NDST1 38/38 (100%) 22/31 (71%) 9/21 (43%) 21/22 (95%) 8/14 (57%) 
10 E 4  32/38 (84%) 7/32 (22%) 3/22 (14%) 1/17 (6%) 13/23 (58%) 
CD44V3 14/36 (39%) 6/23 (26%) 4/21 (19%) 7/23 30%) 4/18 (22%) 
SDC2 36/37 (97%) 18/31 (58%) 19/22 (86%) 13/22 (59%) 4/14 (29%) 
SDC3 31/36 (86%) 19/28 (68%) 14/22 (64%) 15/23 (65%) 2/9 (22%) 
SDC4 35/38 (92%) 10/23 (43%) 21/22 (95%) 18/23 (78%) 6/17 (35%) 
pSMAD1 19/39 (49%) 8/31 (26%) 10/21 (48%) 13/23 (57%) 7/20 (35%) 
pSMAD2 29/39 (74%) 22/33 (67%) 21/22 (95%) 9/17 (53%)  15/23 (65%) 
PAI1 38/38 (100%) 26/28 (93%) 20/21 (95%) 21/21 (100%) 13/14 (93%) 
CTNB1 31/37 (84%) 9/30 (30%) 7/21 (33%) 22/23 (96%) 6/15 (40%) 
FGF18 34/38 (89%) 18/30 (60%) 20/22 (91%) 12/23 (52%) 3/16 (19%) 
FGFR3 40/40 (100%) 26/31 (84%) 21/21 (100%) 21/23 (91%) 17/18 (94%) 
PTGS2 2/39 (5%) 17/32 (53%) 4/22 (18%) 1/23 (4%) 0/17 (0%) 
KIT 2/37 (5%) 0/26 (0%) 0/21 (0%) 2/23 (9%) 0/19 (0%) 






Figure 6.2: Active FGF signaling and TGFbeta signaling through pSMAD2 and PAI1 
in all rare subtypes of chondrosarcoma.  
A: High FGFR3 expression in CCS. B: Sum scores of FGFR3 in all tumor tissues included 
on TMA, by tumor type.  C: High level of PAI1 expression in cartiilaginous component 
(left panel) and anaplastic component (right panel) of dedifferentiated chondrosarcoma. 
D,E: Sum scores of PAI1 (D) and pSMAD2 (E) in all tumor tissues included on TMA, by 
tumor type.  F: Kaplan Meier of pSMAD2 staining in dedifferentiated chondrosarcoma 
(DDCS) shows positive association between pSMAD2 expression and metastasis free 
survival (p=0.01).  




Possible therapeutic targets PTGS2 and KIT 
In contrast to central chondrosarcomas (27), PTGS2 (COX-2) expression was 
rather low in the rare chondrosarcoma subtypes. Only in the dedifferentiated 
component of dedifferentiated chondrosarcoma was high expression observed in 
approximately half of the tumors. Expression of the tyrosine kinase receptor KIT 
was low to absent in all tumor subtypes (fig 6.1L, M, table 6.3). 
 
Discussion 
To identify possible therapeutic targets in rare chondrosarcoma subtypes, we 
investigated expression of signaling pathways that play pivotal roles in the normal 
growth plate and in conventional chondrosarcoma. The chondrosarcoma subtypes 
that are the subject of our study are rare and an extensive study of possible 
therapeutic targets in these tumors has not previously been carried out. Through the 
EuroBoNeT consortium we were able to collect paraffin blocks of a relatively large 
series enabling us to systematically analyze the activity of growth plate signaling 
pathways. Not only did we observe differences between the subtypes, but also 
between the cartilaginous cells and anaplastic or small cells in dedifferentiated and 
mesenchymal chondrosarcoma, respectively. Heparan sulfate proteoglycan and 
PTHLH expression were noted to vary between tumor types and cell types (fig 
6.1). All heparan sulfate proteoglycans studied, including SDC2-4 and CD44v3, as 
well as 10E4 and NDST1, were expressed in the cytoplasm of the cells and 
sometimes to a lesser extent on the membrane. Aberrant cellular localization of 
these proteins is a known phenomenon in osteochondromas and chondrosarcomas 
(15;28;29). 
SOX9, TGFbeta, and FGFR3 signaling was highly active in all chondrosarcoma 
subtypes. Whereas activating FGFR3 mutations stimulate proliferation in certain 
types of cancer, they cause several forms of dwarfism-associated 
chondrodysplasias in humans and mice, demonstrating an inhibitory effect in bone 
(30). In this study, we demonstrated high FGFR3 expression in central 
dedifferentiated -, mesenchymal - , and clear cell chondrosarcoma. Previously, we 
demonstrated high FGFR3 in peripheral dedifferentiated chondrosarcomas, but 
rather low expression in secondary peripheral chondrosarcomas (31). In 2007, Oji 
et al demonstrated high FGFR3 mRNA and protein in rat chondrosarcoma cells in 
vitro. Stimulation of the FGFR3 receptor with an FGFR3 agonist reduced the 
proliferative rate of the cells. However, the addition of a polyclonal antibody for 
FGFR3 did not reverse this effect, suggesting a deregulation in the FGFR3 
signaling pathway (32). Based on the literature, overexpression of FGFR3 in 
chondrosarcoma would be expected to inhibit IHH and thereby PTHLH (25). 
However, our study showed PTHLH to be highly expressed in most of the tumors, 
indicating pathway activity independent of FGFR3, as was also found for 
conventional chondrosarcoma (14;18).  
 




 Figure 6.3: Dose response curves for doxorubicin (A) cisplatin (B) and ABT-737 (C).  
A, B: L2975 shows 40% reduction in cell viability after 1µM doxorubicin (DXR) and 10% 
reduction in cell viability after 1µM cisplatin (CDDP), whereas NDCS-1 shows no 
reduction in cell viability after either doxorubicin or cisplatin. C: Neither cell line shows a 
response to ABT-737 treatment alone.  
 
In accordance with previous findings in central chondrosarcoma (18) we found 
PTHR1 expression to be higher in the anaplastic cells of dedifferentiated and 
mesenchymal chondrosarcomas as compared to the cartilaginous cells in these 
tumors and in clear cell chondrosarcomas, suggesting a role for PTHLH signaling 
in the fast proliferation of these tumors. Despite the low PTHR1 expression in clear 
cell and mesenchymal chondrosarcoma, we observed high expression of Bcl-2, 
indicating that this might be induced via a different signaling pathway, such as an 
apoptosis directed pathway. We previously found absence of Bcl-2 in peripheral 
dedifferentiated chondrosarcomas (31). We here show that Bcl-2 expression was 
generally high in mesenchymal and clear cell chondrosarcoma, whereas 
dedifferentiated chondrosarcoma rather shows high expression of Bcl-xl. In 
conventional central chondrosarcoma, we previously showed high Bcl-2 expression 
(18) and recently showed that conventional central chondrosarcoma cells with high 
expression of Bcl-2 family members could be sensitized to doxorubicin and 
cisplatin by inhibition of Bcl-2 family members using the BH-3 mimetic ABT-737 
indicating an important role for Bcl-2 family members in chemoresistance of 
conventional chondrosarcoma (21). We now also show high Bcl-2 and Bcl-xl 
expression in the two dedifferentiated chondrosarcoma cell lines and a reversal of 
chemoresistance during combination treatment with ABT-737 and conventional 
chemotherapeutics. As a BH-3 mimetic ABT-737 has also been shown to inhibit 
Bcl-xl (33). Our results indicate an important role for Bcl-2 and Bcl-xl in the 
chemoresistance of dedifferentiated chondrosarcoma cells. The high Bcl-2 and Bcl-
xl expression in mesenchymal and clear cell chondrosarcoma suggests that also in 
these subtypes Bcl-2 family members contribute to chemoresistance and that 
patients might benefit from a treatment combining Bcl-2 family inhibitors and 
chemotherapy. At the time of preparing this manuscript, no cell lines of these 
subtypes are available to further test this.  
 
  




Figure 6.4: Bcl-2 as a possible target in rare chondrosarcoma subtypes. A: PTHLH 
expression in dedifferentiated chondrosarcoma. C: High Bcl-2 expression in mesenchymal 
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and were not responsive to ABT-737 as a single agent. Combination of ABT-737 with 
doxorubicin or cisplatin, however, showed strong inhibition of cell viability suggesting a 
role for Bcl-2 family members in chemoresistance of dedifferentiated chondrosarcoma 
(concentrations are in µM).  
  




To investigate BMP and TGFbeta signaling, we evaluated the expression of 
pSMAD1, and pSMAD2 and PAI-1, respectively. BMP signaling, as indicated by 
pSMAD1 expression, was variable in all three subtypes. pSMAD1 expression was 
slightly higher in the dedifferentiated and small cell components of dedifferentiated 
and mesenchymal chondrosarcoma, respectively. In the growth plate, pSMAD1 
plays a role in early condensation, correlating with the phenotypic characteristics of 
these components. TGFbeta signaling, as indicated by expression of pSMAD2 and 
PAI-1, was highly active in all chondrosarcoma subtypes investigated. High 
expression of PAI-1 was observed previously in the anaplastic components of 
conventional and peripheral dedifferentiated chondrosarcomas (31;34). In the 
cartilaginous components of peripheral dedifferentiated chondrosarcomas a 
prognostic value has been described for PAI-1 expression (31). In our study, high 
pSMAD2 in the anaplastic component of dedifferentiated chondrosarcoma was 
related to longer metastasis-free survival.  
TGFbeta is known to have a dual role in cancer. Not only does it  promote tumor 
growth, invasion and metastasis, it is also described to prevent malignant 
progression in the surrounding environment of an oncogenic process (35). Since 
TGFbeta signaling was active in a subset of dedifferentiated - and mesenchymal 
chondrosarcomas, and in almost all clear cell chondrosarcomas, TGFbeta might be 
a promising therapeutic target. The most useful agents in blocking TGFbeta 
signaling are likely TGFbeta-targeting monoclonal antibodies like fresolimumab 
and tyrosine kinase inhibitors (36). In dedifferentiated and mesenchymal 
chondrosarcomas, PAI-1 expression was higher than pSMAD2 expression 
indicating that PAI-1 may also be under the influence of other signaling pathways, 
like the EGFR signaling pathway (37). Further studies will be needed to determine 
the involvement of the EGFR pathway and the value of EGFR-targeting treatment 
in these subtypes. 
As in conventional chondrosarcoma (38), KIT expression was absent in rare 
chondrosarcoma subtypes. In addition, the absence of nuclear CTNB1 indicated 
that canonical Wnt signaling is not important in these tumor types. Recently our 
group demonstrated beneficial effects of celecoxib treatment in central 
chondrosarcomas (27). However, whereas 65% of the conventional 
chondrosarcomas express PTGS2, expression was absent in most of the rare 
chondrosarcoma subtypes making beneficial effects of celecoxib unlikely.  
In summary, we observed both common and distinct protein expression patterns in 
three rare chondrosarcoma subtypes. High pSMAD2 and PAI-1 expression 
emphasize the importance of TGFbeta signaling and suggest that TGFbeta 
inhibitors might be a promising therapeutic option for patients with rare 
chondrosarcoma subtypes. In addition, our results suggest an important role for the 
Bcl-2 family members Bcl-2 and Bcl-xl in chemoresistance of the rare 
chondrosarcoma subtypes. Similar to conventional chondrosarcoma, the 
chemoresistance of dedifferentiated chondrosarcoma in vitro could be overcome 




using inhibition of Bcl-2 family members, repairing the apoptotic machinery 
rendering the cells sensitive to chemotherapy. This suggests that the combination 
of BH-3 mimetics with conventional chemotherapeutic agents is a promising 
therapeutic strategy for metastatic or inoperable chondrosarcoma, irrespective of 
the histological subtype.   
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Chondrosarcomas are malignant cartilage-forming tumors of bone. Due to their 
resistance to conventional chemotherapy and radiotherapy currently no treatment 
strategies exist for unresectable and metastatic chondrosarcoma. Previously, 
PI3K/AKT/GSK3β and Src kinase pathways were shown to be activated in 
chondrosarcoma cell lines. Our aim was to investigate the role of these kinases in 
chemoresistance and migration in chondrosarcoma in relation to TP53 mutation 
status. 
We used 5 conventional and 3 dedifferentiated chondrosarcoma cell lines and 
investigated the effect of PI3K/AKT/GSK3β pathway inhibition (enzastaurin) and 
Src pathway inhibition (dasatinib) in chemoresistance using WST assay and Live 
cell imaging with AnnexinV staining. Immunohistochemistry on tissue microarrays 
(TMAs) containing 157 cartilaginous tumors was performed for Src family 
members. Migration assays were performed with the RTCA xCelligence System. 
Src inhibition was found to overcome chemoresistance, to induce apoptosisand to 
inhibit migration. Cell lines with TP53 mutations responded better to combination 
therapy than wildtype cell lines (p=0.002). TMA immunohistochemistry confirmed 
active Src (pSrc) signaling, with Fyn being most abundantly expressed (76.1%).  
These results strongly indicate Src family kinases, in particular Fyn, as a potential 
target for the treatment of inoperable and metastatic chondrosarcomas, and to 




Chondrosarcoma is a malignant cartilage-forming neoplasm of bone and the second 
most common bone sarcoma in humans (1). Conventional chondrosarcoma does 
not respond to existing chemo- and radiotherapy modalities (2). Metastasis 
formation eventually occurs in 71% of grade III chondrosarcoma cases, andwith a 
10 year survival rate of 29% this poses a serious treatment problem (3).  
Chemoresistance in chondrosarcoma has long been ascribed to poor 
vascularization, hyaline extracellular matrix production and slowly dividing cells 
(4;5). Though this is true for low grade chondrosarcomas, high grade 
chondrosarcomas typically are composed of rapidly dividing cells with more 
myxoid matrix production (2;6). In the search for molecular targets, negative 
regulators of the apoptotic pathway, such as BCL-2 (7-10), and survivin (11), were 
identified to be upregulated in chondrosarcoma, and shown to play a role in 
chemoresistance (11;12). 
Apart from defective apoptotic pathways, deregulated kinase pathways are of 
growing interest in the field of cancer and have been suggested to play a role in 
chondrosarcoma (6). We have previously shown activating hyperphosphorylation 




of AKT, and Src family kinases and inactivating hyperphosphorylation of GSK3β 
using kinome profiling of chondrosarcoma cell lines and primary cultures (13).  
Both PI3K/AKT/GSK3β and Src signaling pathways are described in a variety of 
different cancer types as well as in progression to malignancy (14-17) and can be 
activated by receptor tyrosine kinases (RTKs) (18-20). Activation of the Src 
pathway promotes cell survival, proliferation, and migration, but can also activate 
the PI3K/AKT/GSK3β pathway through phosphorylation of PI3K, thereby leading 
to increased AKT phosphorylation (21). Activation of Protein Kinase C (PKC) by 
RTKs can also activate the PI3K/AKT pathway, either through phosphorylation of 
PI3K or through direct phosphorylation of AKT (22;23) (figure 7.1A). Moreover, 
PKC and AKT can both phosphorylate GSK3β at Ser9 (19;24). 
Due to the intricate interplay of PI3K/AKT/GSK3β and Src signaling pathways in 
cancer and the observation that both pathways are activated in chondrosarcoma we 
hypothesized that the activation of these pathways in chondrosarcoma contributes 
to chemoresistance   
We therefore investigated the role of both pathways in cell proliferation and 
chemoresistance. Our data indicate that Src family kinases, Fyn in particular, play a 
role in chemoresistance and cell migration, and that TP53 mutated cells are 






Doxorubicin and cisplatin were obtained from the in-house hospital pharmacy in a 
0.9% NaCl solution. Therapeutic concentrations of doxorubicin in patients are 5-
50µM with an in vitro range of 1-10 µM, for cisplatin these are 3-13µM with an in 
vitro range of 1-50µM (25). The PKC inhibitor enzastaurin (26) (Eli Lilly, IN, 
USA) and the Src inhibitordasatinib (27) (Bristol-Meyers Squibb, Princeton, NJ, 
USA) were dissolved in DMSO.   
 
Cell culture 
Chondrosarcoma cell lines (table 7.1), as well as MCF-7 and HeLa cell lines were 
cultured in RPMI1640 (Gibco, Invitrogen Life-Technologies, Scotland, UK) 
supplemented with 1% L-glutamax, 1% penicillin/streptomycin (100U/mL), and 
10% heat-inactivated Fetal Calf Serum (Gibco, Invitrogen Life-Technologies, 
Scotland, UK). Cells were grown at 37°C in a humidified incubator with 95% air 
and 5% CO2. Cells were cultured until stably multiplying.Chondrogenic phenotype 
was confirmed using RT-PCR for collagen I, IIB, III, and X, aggrecan, and 
SOX9(28). Identity of cell lines was confirmed using the Cell IDTM System after 
completion of experiments (Promega Benelux BV, Leiden, The Netherlands). 
 





















1IDH mutations for used cell lines were described in (12;30) 
2TP53 mutations for used cell lines were described in (12;29) 
  
Cell Line Tumor Type Grad
e 
Gender Age Passage TP531 IDH12 IDH22 Reference 
 
SW1353 Solitary Central II F 72 21 V203L wt R172S ATCC 
OUMS27 Solitary Central III M 65 27 wt wt wt (58) 
CH2879 
 
Solitary Central III F 35 >80 wt wt wt (59) 
JJ012 Solitary Central II M 39 9 G199V R132G wt (60) 
L835 Solitary Central III M 55 50 wt R132C wt (12) 
          
L2975 Dedifferentiated 
CS 
 M 57 60 wt R172W wt (12) 
NDCS1 Dedifferentiated 
CS 
 M 38 60 C242S wt wt (61) 
L3252 Dedifferentiated 
CS 
 F 52 30 wt wt wt (12) 




Cell viability assay 
Chondrosarcoma cell lines were plated in 96 well plates for viability assessment 
(2x104-2x105 cells/well depending on growth rate) and allowed to grow and adhere 
overnight after which the respective drugs were added in their corresponding 
concentrations. Combination assays were performed as described (29) with 
alternating treatments combining enzastaurin, dasatinib, and/ or doxorubicin. All 
experiments were performed in triplicate and at least three times. Graphs show data 
from one representative experiment. Error bars indicate the standard deviation.  
 
Immunoblotting 
Immunoblotting using  AKT, pAKT, Fyn (Cell Signaling, Leiden, the Netherlands) 
and pSrc  antibody (pSrc pY418, Invitrogen Life Technologies, Bleiswijk, the 
Netherlands) to investigate the Src and PI3K/AKT signaling pathway and p53 
(Do7, Dako, Heverlee, Belgium), MDM2 (IF2, Zymed, Bleiswijk, the Netherlands) 
and p21 (Santa Cruz, Heidelberg, Germany) was performed as previously 
described (13), using 20µg of each sample.  
 
Mutation analysis 
To identify mutations in AKT1, direct sequencing was performed as described 
(30), using DNA derived from 57 tumors, 8 cell lines, and 1 primary culture 
(L3310) using forward primer 3'-TAGAGTGTGCGTGGCCTCTCA-5' and reverse 
primer 3'-CTGAATCCCGAGAGGCCAA-5' to screen for hotspot mutations in the  
AKT1-E17K pleckstrin homology domain.   
 
Apoptosis assay and Immunofluorescence 
Apoptosis assay and immunofluorescence for caspase 3 and cytochrome C were 
performed as described (29;31). In short, 20.000 chondrosarcoma cells were grown 
in black 96-well microclear plates (Greiner®, Sigma-Aldrich, Zwijndrecht, The 
Netherlands) to perform a live cell apoptosis assay (31), with AnnexinV-Alexa633 
conjugate using the BD Pathway® 855 (Becton Dickinson, Breda, The 
Netherlands). Time series were quantified using in house developed macros for 
Image-Pro Plus (Media Cybernetics, Bethesda, USA). Drugs were added 0, 24, and 
48 hours before imaging and Annexin V-Alexa633 conjugate was added 
immediately prior to imaging. For all treatments, a pan-caspase inhibitor, z-VAD-
fmk (Bachem-Holding AG, Weil am Rhein, Germany), was added 30 minutes 
before drug addition and imaging in order to establish apoptosis specificity of the 
assay. Prior to imaging, live nuclei were stained with HOECHST-33342 at 
100ng/ml. All experiments were performed in triplicate and at least three times. 
Error bars show standard deviation from one representative experiment. 
 
  





The RTCA xCelligence system (Roche Applied Sciences, Almere, the 
Netherlands), based on cell-electrode substract impedance detection technology, 
was used for migration assays. For migration assays, lower wells of the SIM plates 
(migration plates) were filled with growth medium (20% FCS in RPMI).Cell lines 
were plated at a density of 80.000 cells per well in the top wells in empty buffer 
(RPMI only) containing0, 0.2, 0.4, 0.6, 0.8, or 1.0 µM dasatinib.SIM plates were 
loaded into the RTCA station in the cell culture incubator immediately after plating 
and cell index was acquired every 5 minutes. Cell index as acquired by the 
software was set to 100% migration after flattening of the slope. Experiments were 
performed in triplicate. 
 
TMA construction and clinicopathological data 
Tissue microarrays (TMAs) were constructed from formalin-fixed, paraffin-
embedded tissue using standard procedures (32) using a 2.0 mm diameter punch 
automated tissue arrayer (3DHistech Ltd, Budapest, Hungary). Each array 
contained three cores per tumor wherever possible including 7 control tissues (skin, 
colon, tonsil, prostate, mamma carcinoma, spleen and liver). Using a tape-transfer 
system (Instrumedics, Hackensack, NJ, USA), 4-μm sections were transferred to 
glass slides.All specimens in this study were handled according to the ethical 
guidelines described in "Code for Proper Secondary Use of Human Tissue in The 
Netherlands" of the Dutch Federation of Medical Scientific Societies. 157 patients 
with cartilaginous tumors were selected from the archives of the Leiden University 
Medical Centre. Selected cases included 137 conventional chondrosarcomas 
(central chondrosarcoma, n=92; peripheral chondrosarcoma, n=45) and 20 benign 
cartilage tumors (osteochondroma, n=9; enchondroma, n=11). Only primary 
tumors were selected. Histology was reviewed by an experienced bone tumor 
pathologist (J.V.M.G.B.). Clinicopathological data are shown in table 7.2.Total 
follow up was available for 136 of 157 patients, with 14 patients showing 
metastasis at completion of this study.  Histological grading of chondrosarcoma 












Immunohistochemistry was performed on the TMAs. Slides were incubated with 
antibodies against Src, Lck, Fyn, Yes, and phosphorylated Src (pSrc, recognizes 
active Src family members phosphorylated at Y419). Details of antibodies and 
procedures are provided in table 7.3. Immunohistochemical reactions were 
performed according to standard laboratory methods (7) and visualized using 
DAB+ Substrate Chromogen System (Dako, Heverlee, Belgium). TMA slides were 
scanned using a high resolution Mirax Desk Intrument (Zeiss, Mirax 3D Histech, 
Hungary) and scored independently by two observers (JVMGB and JGvO) and 
discrepancies were discussed. Staining intensity (0 = absent, 1 = weak, 2 = 
moderate, 3 = strong) and extent of the staining (0 = 0%, 1 = 1-24%, 2 = 25-49%, 3 
= 50-74% and 4 = 75%-100%) were assessed. Staining was considered high (score 
≥4) or low (score <4). As external positive and negative control for all the 
antibodies specimens of normal tonsil were used. Cores with a negative internal 




  Peripheral (n =45) Central (n =92)  
Male vs female 27 vs 18 39 vs. 53 
Median age at diagnosis 37 (14-82) 50 (20-84) 
Histology   
Grade I 31 42 
Grade II 11 36 
Grade III 3 14 
Metastasis 4/45 10/92 
Median follow-up (months) 121 (15-299) 103 (7-292) 





Survival was evaluated by Kaplan–Meier analysis and the log-rank test. Values of 
p ≤ 0.05 were considered statistically significant. Variables that achieved 
significance (p ≤ 0.05) were entered subsequently into a multivariate analysis using 
the Cox regression model. Cox regression analysis was carried out with clinical 
outcome (overall survival) as the independent variable. Correlation between 
expression and grade and individual stainings were evaluated using Pearson chi-
squared test for independent variables. Values of p ≤ 0.05 for asymptomatic 2 sided 
testing were considered significant. The data were analyzed using SPSS version 
17.0 software (Chicago, IL, USA). 
For combination assays the combination index according to the method of Chou 
and Talalay (33) was calculated. A combination index (CI) of below 1 indicates 
synergy, and CI of above 1 indicates additive effect. Correlation between 
combination indices was evaluated using independent 2 sided t-test using Graphpad 
Prism 5 software (La Jolla, CA, USA). Values of p ≤ 0.05 were considered 
significant.  
 




PI3K/AKT/GSK3β pathway is not involved in chemoresistance of chondrosarcoma 
cell lines   
To investigate the PI3K/AKT/GSK3β pathway, chondrosarcoma cells were treated 
with 1µM and 10µM enzastaurin (26), a PKCβ inhibitor shown to inhibit AKT 
signaling and GSK3β phosphorylation (34). Whereas the cervical cancer cell line 
HeLa shows 70% reduction in cell viability after treatment with 10µM enzastaurin 
(fig 7.1B), chondrosarcoma cell lines were less sensitive to enzastaurin treatment. 
Two chondrosarcoma cell lines showed complete resistance (NDCS-1 and L2975) 
while in the two most responsive cell lines (SW1353 and L3252) a maximum 
reduction in cell viability of ~40% was achieved (fig 7.1B). As the PI3K/AKT/ 
GSK3β pathway is involved in cell survival, we set out to examine its role in 
chemoresistance. Enzastaurin was combined with doxorubicin over the course of 
72hrs, alternating treatments every 24hrs, as we previously showed that drug 
Antibody Clone Dilution Antigen 
Retrieval 
Blocking Source 
Src 327554 1:200 Citrate NGS R&D Systems Europe Ltd, Oxon, UK 
Yes 339827 1:4000 Citrate Milk R&D Systems Europe Ltd, Oxon, UK 
Lck Y123 1:250 Citrate - Abcam, Cambridge, UK 
Fyn Y303 1:30000 Citrate Milk Abcam, Cambridge, UK 
pSrc AF2685 1:200 Citrate Milk R&D Systems Europe Ltd, Oxon, UK 




administration on separate days was most effective (29). While there was no 
difference in response between IDH mutated and IDH wildtype cell lines, cell lines 
with TP53 mutations responded better to combination treatment than TP53 
wildtype cell lines (p=0.002) (fig 7.1B) . However, a lack of synergy between the 
two drugs was observed (combination indices >2), as reduction in cell viability was 
attributed to the effect of doxorubicin alone (NDCS-1) or the additive effect of 
enzastaurin and doxorubicin. Activation of AKT1 can be through mutations in the 
pleckstrin homology domain, found mostly in solid tumors (35), leading to 
activated downstream signaling and decreased sensitivity to kinase inhibitors (36). 
Hotspot mutations in the pleckstrin homology domain of AKT1 were absent in the 
primary chondrosarcoma tumor tissues or cell lines.  
 
Inhibition of Src family kinases with dasatinib does not potentiate the effect of 
enzastaurin in chondrosarcoma cell lines 
To exclude active Src signaling causing the limited response we observed to 
enzastaurin we combined enzastaurin with the Src inhibitor dasatinib. In five cell 
lines (CH2879, OUMS27, SW1353, NDCS-1, and L3252) cell viability after 
combination treatment dropped below 50% (fig 7.1C). However, the reduction in 
cell viability could not be ascribed to a synergistic effect in any of the cell lines. 
Rather it was found to be due to the effect of dasatinib (L835, NDCS-1 and L3252) 
or the additive effect of dasatinib and enzastaurin (combination indices >2, fig 
7.1C). TP53 mutation status was not correlated to response (p=0.38, fig 7.1C). 
Interestingly, treatment with 1µM dasatinib for 24hrs was found to decrease 









Figure 7.1. Chondrosarcoma cell lines are not sensitive to PKC inhibition. A: 
Schematic representation of activation of PI3K and Src pathway by receptor tyrosine 
kinases (RTKs). RTKs can activate protein kinase C (PKC), phosphatidylinositol 3-kinase 
(PI3K), and Src. PKC and Src can also activate the PI3K/AKT/GSK3β pathway, promoting 
survival, proliferation, and migration. The Src pathway activates the Ras/Raf pathway. 
Enzastaurin is a selective PKC inhibitor also reported to inhibitinactivating phosphorylation 
of GSK3β. Dasatinib is a Src inhibitor. Adapted from Fizazi (62).B: HeLa cell line showing 
70% decrease in cell viability after treatment with enzastaurin. Chondrosarcoma cell lines 
poorly respond to enzastaurin alone, and an additive effect is observed when alternating 
10µM doxorubicin (DXR) and 10µM enzastaurin (Enz) for 24hrs each for 72hrs in total. 
No difference is observed when order of administration is reversed. Significant difference 
between TP53 mutant and wildtype cell lines (p=0.002).C: Combination of enzastaurin 
with Src inhibitor dasatinib (Das) showing additive effect in chondrosarcoma cell lines. No 
significant difference is observed between TP53 mutant and wildtype cell lines (p=0.38). 




Src signaling contributes to chemoresistance of chondrosarcoma cells 
We have previously shown Src signaling to be involved in chondrosarcoma cell 
proliferation (13). Immunoblotting confirmed the presence of phosphorylated Src 
(Y418) in the chondrosarcoma cell lines, with lowest expression in L835 cells, and 
24hrs with 1µM dasatinib resulted in decreased pSrc levels (Fig 7.2A).  To 
examine the role of Src signaling in chemoresistance, dasatinib was combined with 
doxorubicin. A synergistic effect was observed in cell lines CH2879, OUMS27, 
SW1353, JJ012, NDCS-1, and L2975 (combination indices ranging from 0.09 to 
0.88 fig 7.2C), and the order of drug administration did not influence efficacy. 
Interestingly, a significant difference between both the cell viability (p=0.002) and 
the combination indices (p=0.043) was observed between cell lines with and 
without TP53 mutations, and both cell lines that were resistant to combination 
treatment (L835 and L3252) were wildtype for TP53 mutations. We continued to 
investigate p53 accumulation as well as MDM2 and p21 expression in cells treated 
with and without treatment with dasatinib (fig 7.2B). As expected, high p53 protein 
expression with low to absent p21was seen in the three TP53 mutant cell lines. All 
TP53 wildtype cell lines demonstrated low p53 and p21 protein expression with the 
exception of CH2879, demonstrating high levels of p53 and p21. Protein levels 
were not affected by dasatinib treatment. All cell lines showed low MDM2 protein 
expression. No correlation with IDH mutations was found.   
 
Src inhibition combined with doxorubicin induces apoptosis 
Using annexinV binding live cell imaging we confirmed our previous findings (13) 
that dasatinib monotreatment does not induce apoptosis (fig 7.2D first 24 hours). 
However, when combined with doxorubicin, up to 50% of cells had entered 
apoptosis after completion of the third cycle of combination treatment; (JJ012 cell 
line shown as representative cell line, fig 7.2D). Due to the effect of doxorubicin 
during the first 24 hours, 10% more cells had entered apoptosis during combination 
treatment starting doxorubicin, than during combination treatment starting with 
dasatinib. Apoptosis could be inhibited using the pan-caspase inhibitor zVADfmk 
(results not shown).  
 
Dasatinib inhibits migration of chondrosarcoma cell lines 
As Src family members also play a role in motility and adhesion (37), we 
continued to investigate the migratory capacity of the chondrosarcoma cell lines. 
Using a transwell system, all chondrosarcoma cell lines showed migratory 
properties, and started migrating approximately 30 minutes after plating, except for 
JJ012 cells, which started migrating only 4 hours after plating (results not shown). 
In the presence of dasatinib, however, a complete inhibition of cell migration was 
achieved for all cell lines at concentrations as low as 200nM (fig 7.2E, F). No 
difference between cell lines harboring TP53 mutations and wildtype cell lines was 
observed.   






Figure 7.2. The Src pathway is involved in chondrosarcoma chemoresistance.  
A: Immunoblotting showing AKT, pAKT, Fyn, pSrc and loading control α-tubulin (a tub) 
for untreated chondrosarcoma cell lines and after 24 hrs 1µM dasatinib (Das). MCF-7: 
breast cancer cell line, shown as positive control. Presence of all kinases in all cell lines. 
phophorylated Src  in all cell lines, although levels are very low in L835. After 24hrs 1µM 




dasatinib treatment, levels of pSrc (at Y418) are decreased in all cell lines, and of pAKT in 
OUMS27, L835, L3252, JJ012, and NDCS-1. B: Immunoblotting showing p53, MDM2, 
and p21 in untreated chondrosarcoma cell lines (Mock) and after 24hrs 1µM dasatinib 
(Das). U2OS (osteosarcoma) cell line is shown as positive control. MDM2 expression is 
low in all cell lines. TP53 wildtype cell lines are negative for p53 protein expression, with 
low p21 protein expression, except for CH2879. TP53 mutant cell lines show high TP53 
protein expression with low p21 protein expression. No change in protein levels is observed 
after 24hrs 1µM dasatinib treatment. C: Combination of dasatinib (Das) with doxorubicin 
(DXR) leads to synergistic loss of cell viability at concentrations which are ineffective on 
their own in most cell lines. Combination treatment was more effective in TP53 mutant cell 
lines than in TP53 wildtype cell lines (p=0.002 for cell viability, p=0.043 for combination 
indices). D: Apoptosis assay in JJ012 cell line alternating 1µM dasatinib (Das)and 1µM 
doxorubicin (DXR)demonstrates the occurrence of apoptosis during combination. 
Apoptosis is calculated as percentage of AnnexinV-Alexxa633 stained cells per total 
number of HOECHST stained cells. D, E: Dasatinib successfully inhibits migration in 
chondrosarcoma cell lines in concentrations as low as 200nM. E: SW1353 cell line shown 
as representative over the course of 4 hrs, F: bar chart showing migration for all cell lines.  
 
 
Figure 7.3. Immunohistochemistry demonstrating expression of Src family members 
in conventional chondrosarcoma tissue. 
A: High pSrc expression in grade I chondrosarcoma. B: High intensity nuclear FYN 
expression in grade I chondrosarcoma. C: High intensity cytoplasmic and nuclear 
Srcexpression in grade I chondrosarcoma. D: Absence of Yes expression in grade II 
chondrosarcoma. E: Absence of Lck in grade II chondrosarcoma. Scale bars: 50µm. F: 
Scatterplot showing distribution of staining scores among chondrosarcoma tissue samples.  




Fyn is the most important Src family member in chondrosarcoma tissues 
To identify the most important Src family member in chondrosarcoma, we 
evaluated the expression of the 4 family members Src, Yes, Fyn and Lck, as well as 
pSrc in primary tumor samples. Active Src signaling as evidenced by positive 
staining for pSrc was found in 88-100% of the tumors (table 7.4, fig 7.3A, F).Of 
the 4 Src family members we found Fyn (76.1% high expression (89/117)) and Src 
(46.6% high expression (48/103)) to be most abundantly expressed in 
chondrosarcoma (table 7.4, figure 7.3B, C, F). In contrast, high expression of Yes 
and Lck was observed in only 5% of all chondrosarcoma cases (6/116 and 6/120 
respectively) (table 7.4, figure 7.3D, E, F). During the staining procedures some 
cores were lost due to inherent structural instability of the tissue. A significant 
increase in Src expression was seen between grade I and grade II peripheral CS 
(p=0.005 Pearson chi squared test). Though not significant, Src expression in 
tumors was found to be inversely correlated with overall survival (p=0.3 log rank). 
Fyn expression was found to significantly increase with increasing histological 
grade in both peripheral chondrosarcoma (p= 0.05 Pearson chi squared test) and 
central chondrosarcoma (p= 0.000 Pearson chi squared test). No significant 
correlations to metastasis were found. Using western blot we confirmed expression 




Chondrosarcomas are resistant to conventional chemotherapy. Despite ongoing 
research, there is still nothing to offer patients with unresectable or metastatic 
disease and the need for new, targeted therapies is high. We here explored the 
effects of increased PI3K/AKT/GSK3β and Src signaling on chondrosarcoma 
chemoresistance and cell migration using enzastaurin and dasatinib, respectively. 
We show that dasatinib is more effective in overcoming chondrosarcoma 
chemoresistance than enzastaurin, and acts synergistically with doxorubicin to 
inhibit cell viability and induce apoptosis. Most importantly, we show that in cell 
lines with TP53 mutations, the combination of tyrosine kinase inhibitors with 
doxorubicin is more beneficial than in wildtype TP53 cell lines.  
Chondrosarcoma is a heterogeneous disease, and this heterogeneity is represented 
in the cell lines. Recently, IDH1 and IDH2 mutations were found in 
chondrosarcoma (38), and we published that these mutations are retained in 
chondrosarcoma cell lines (12;30). Of the two cell lines that were nonresponsive to 
combination treatment of doxorubicin with dasatinib, one central chondrosarcoma 
cell line (L835) carried an IDH1 mutation, whereas the other (dedifferentiated 
chondrosarcoma cell line (L3252)) was wildtype for IDH. Thus, no correlation 
between IDH mutation status and response to dasatinib monotreatment or 
combination treatment with doxorubicin was observed. More likely, the lack of 




sensitivity to dasatinib in the L835 cell line is caused by the low pSrc activity in 
this cell line.  
Src inhibition with dasatinib resulted in successful sensitization for doxorubicin 
treatment, especially in TP53 mutant chondrosarcoma cell lines. Approximately 
30% of chondrosarcomas carry TP53 mutations, and these mutations are found 
especially in high grade chondrosarcomas (39;40). Three of the eight cell lines 
carry a TP53 mutation (SW1353, JJ012, and NDCS-1), and these cell lines also 
showed a better response to combination treatment with low combination indices 
when compared to TP53 wildtype cell lines. This is an interesting result as mutant 
TP53 is described to actively inhibit apoptosis through activation of p21 (41) or to 
confer chemoresistance through engaging in oncogenic transcription complexes 
(42). Previously, dasatinib was found to interfere with the p53 transcriptional 
activity induced by the MDM2 inhibitor nutlin-3(43). We show that dasatinib does 
not affect p53 nor p21 protein expression in chondrosarcoma cells. Dasatinib as a 
single agent proved ineffective in chondrosarcoma patients (Schuetze, CTOS 
2010). However, recent clinical studies with dasatinib in other malignancies have 
shown its efficacy not only irrespective of TP53 status as a single agent (44), but 
also to overcome TP53 mutation status related chemoresistance (45). The results of 
these clinical studies in combination with the data we show here strongly suggest 
clinical evaluation of the efficacy of dasatinib in combination with doxorubicin in 
chondrosarcoma patients harboring TP53 mutations.  
Since we demonstrate Src signaling to play a role in chemoresistance, we further 
explored the expression of the different Src family kinases (SFKs) in human 
chondrosarcoma tissues. Fyn was most widely expressed (89/117) and was found 
to increase with increasing histological grade, suggesting a role in chondrosarcoma 
progression. Fyn is reported to be upregulated in multiple cancers, and to be 
associated with malignant progression and metastasis formation (37;46;47). We 
confirmed that indeed the Src pathway is important in chondrosarcoma cell 
motility, since dasatinib completely inhibited migratory capacity of all 
chondrosarcoma cell lines even at low dose.  
Clinical trials with dasatinib have shown the efficacy and low toxicity of dasatinib 
in combination with conventional chemotherapeutic agents in solid tumors (48). In 
a phase II study of dasatinib with hyper-CVAD in patients with Philadelphia 
chromosome positive lymphoblastic leukemia, long term remission was achieved 
in newly diagnosed patients (49), and in a phase I-II study of dasatinib with 
doxetaxel in castration resistant prostate cancer, disappearance of bone lesions was 
obtained (50). The results obtained with dasatinib in combination with 
chemotherapy strongly encourage the exploration of dasatinib in combination with 
doxorubicin in patients with chondrosarcoma. 





Table 7.4 Protein expression in tumors using immunohistochemistry 
 Osteochondroma Peripheral Chondrosarcoma  Enchondroma Central Chondrosarcoma 
  Grade I Grade II Grade III   Grade I Grade II Grade III 
pSrc 3/3 (100%) 12/13 (92%) 6/6 (100%) 3/3 (100%)  4/5 (80%) 21/24 (88%) 21/22 (96%) 10/10 (100%) 
Src 1/7 (14%) 7/17 (41%) 8/8 (100%) 2/3 (67%)  4/7 (57%) 12/31 (39%) 12/31 (39%) 7/13 (54%) 
Yes 0/7 (0%) 3/23 (13%) 0/10 (0%) 0/3 (0%)  0/7 (0%) 0/36 (0%) 3/30 (10%) 0/14 (0%) 
Fyn 7/8 (88%) 16/20 (80%) 9/10 (90%) 3/3 (100%)  5/5 (100%) 17/35 (49%) 31/35 (89%) 13/14 (93%) 
Lck 0/3 (0%) 1/23 (4%) 2/10 (20%) 0/3 (0%)  0/7 (0%) 1/38 (3%) 0/33 (0%) 2/13 (15%) 
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Both the PI3K/AKT/GSK3β and Src kinase pathways are activated by receptor 
tyrosine kinases (RTKs) (18;19), and play diverse roles in promoting growth, 
survival, and metastasis (16-18;20;51). We show here that constitutive activation of 
AKT due to mutations does not play a role in chondrosarcoma, and further research 
should elucidate which RTK is responsible for the high AKT, GSK3β, and Src 
phosphorylation (13). A possible candidate is IGF-1, which can activate the 
PI3K/AKT and Src pathway through the RTK IGF-1R (52), and has been shown to 
induce PI3K/AKT signaling and migration in chondrosarcoma cell lines (53). Src 
family kinases can induce phosphorylation of the RTK domains of IGF-1 as well as 
the PDGF receptors through SHP-2 leading to receptor internalization. This 
increases binding efficacy with PI3K, leading to increased proliferative capacity of 
cancer cells (54;55). Moreover, AKT functions as a gatekeeper of apoptosis 
through phosphorylation of BAD. AKT mediated phosphorylation of BAD inhibits 
its binding capacity to antiapoptotic BCL-2 family members, which will prevent a 
cell from entering apoptosis (56;57). We recently published that the antiapoptotic 
BCL-2 family members also play a role in chondrosarcoma chemoresistance (29). 
Combined with the results of the present study, this is suggestive of a common 
mechanism. However, more studies are needed to explore whether the activation of 
the IGF pathway by Src leading to the inhibition of BH3 proteins and apoptosis 
through AKT may be involved in chondrosarcoma chemoresistance. 
In conclusion, we found that inhibition of the Src pathway was successful in 
overcoming chemoresistance and inhibited migration.  A synergistic response to 
combination treatment was observed which was significantly stronger (p=0.002) in 
cell lines harboring TP53 mutations. Moreover, as we observed the Src family 
member Fyn to be the most prevalent in chondrosarcoma tissues, we hypothesize 
Fyn to play a major role in the chemoresistance and malignant progression of 
chondrosarcoma. These results aid in the understanding of signaling pathways in 
chondrosarcoma and may lead to the development of effective therapeutic 
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Chondrosarcomas are notoriously resistant to conventional chemotherapy. There is 
an urgent need to identify therapeutic targets and to develop novel treatment 
strategies for this disease. 
We found multiple RTKs to be activated in chondrosarcoma cells and to have 
critical roles in mediating cell growth. Strong phosphorylation of S6 was detected 
in 69% of conventional chondrosarcoma and 44% of dedifferentiated 
chondrosarcoma clinical samples and is likely due to RTK activation. Inhibition of 
PI3K and mTOR, signaling proteins downstream of RTKs and upstream of S6, 
potently blocked the growth of chondrosarcoma cells in vitro and in vivo.  
NRAS mutations were identified in 12% of conventional central chondrosarcoma 
tumor tissues. An NRAS mutation-harboring chondrosarcoma cell line was 
sensitive to treatment with a MEK inhibitor. 
Our findings provide new insights into the genetics and the heterogeneity of 
chondrosarcomas, and have implications for the clinical development of 




Chondrosarcomas are notoriously resistant to cytotoxic chemotherapeutic agents. 
We sought to identify critical signaling pathways that contribute to their survival 
and proliferation, and which may provide potential targets for rational therapeutic 
interventions.  
Activation of receptor tyrosine kinases (RTKs) was surveyed using phospho-RTK 
arrays. S6 phosphorylation and NRAS mutational status were examined in 
chondrosarcoma primary tumor tissues. Small interfering RNA or small molecule 
inhibitors against RTKs or downstream signaling proteins were applied to 
chondrosarcoma cells and changes in biochemical signaling, cell cycle, and cell 
viability were determined. In vivo anti-tumor activity of BEZ235, a 
phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) 
inhibitor, was evaluated in a chondrosarcoma xenograft model.  
Several RTKs were identified as critical mediators of cell growth, but the RTK 
dependencies varied among cell lines. In exploration of downstream signaling 
pathways, strong S6 phosphorylation was found in 69% of conventional 
chondrosarcomas and 44% of dedifferentiated chondrosarcomas. Treatment with 
BEZ235 resulted in dramatic reduction in the growth of all chondrosarcoma cell 
lines. Tumor growth was similarly inhibited in a xenograft model of 
chondrosarcoma. In addition, chondrosarcoma cells with an NRAS mutation were 
sensitive to treatment with a MEK inhibitor. Functional NRAS mutations were 
found in 12% of conventional central chondrosarcomas. 
RTKs are commonly activated in chondrosarcoma, but because of their 
considerable heterogeneity, targeted inhibition of the PI3K/mTOR pathway 
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represents a rational therapeutic strategy. Chondrosarcomas with NRAS mutations 




Chondrosarcomas, mesenchymal tumors with cartilaginous differentiation, are 
biologically and clinically heterogeneous. Complete surgical resection of localized 
disease remains the only known curative treatment. No systemic treatments have 
been proven to be effective in the metastatic or unresectable setting. Therefore, 
there is an urgent need to identify therapeutic targets and to develop novel 
treatment strategies for patients with this disease (1-4). 
Deregulated expression and/or function of receptor tyrosine kinases (RTKs) by 
gene amplification, mutation, or translocation has been found to be important for 
cancer cell proliferation, survival, motility and invasion, as well as tumor 
angiogenesis and resistance to chemotherapy (5, 6). Given their pivotal role in 
tumor initiation and progression, RTKs have become one of the most prominent 
target families for drug development, and more than ten inhibitors or antagonistic 
antibodies have been approved for the treatment of cancer (7, 8). 
In this study, we used phospho-RTK arrays to simultaneously assess the 
phosphorylation status of 40+ RTKs in chondrosarcoma cells under conditions of 
serum depletion. We found that although several RTKs are constitutively activated, 
this occurs in differing patterns among different human tumor-derived cell lines. 
Several RTKs were identified as critical mediators of cell growth through the use 
of small interfering RNAs (siRNAs) and small molecular inhibitors. To seek a 
therapeutic strategy for chondrosarcoma, we explored the effects of targeting a 
common downstream signaling pathway of RTKs on cell growth, and found that 
the dual pan-class I phosphoinositide-3-kinase (PI3K)/mammalian target of 
rapamycin (mTOR) inhibitor BEZ235 significantly inhibited growth of 
chondrosarcomas both in vitro and in vivo. A chondrosarcoma cell line with an 
NRAS mutation was exclusively sensitive to MEK inhibition. 
 
Materials and Methods 
 
Cell lines and Culture Conditions 
Human chondrosarcoma cell lines included SW1353 (American Type Culture 
Collection), CS-1 (gift of Dr. Francis J. Hornicek, Massachusetts General Hospital, 
Boston, MA), JJ012 (gift of Dr. Joel A. Block, Rush University, Chicago, IL), CH-
2879 (kindly provided by Prof. Antonio Llombart-Bosch, Valencia University, 
Spain) and OUMS-27 (kindly provided by Dr. M. Namba, Okayama University 
Medical School, Japan) (9-12). Cells were cultured in RPMI 1640 supplemented 
with 10% fetal bovine serum and 1x Penicillin-Streptomycin-Glutamine (10378-
016, Invitrogen, Carlsbad, CA) at 37ºC in a humidified incubator with 95% air and 
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5% CO2. Cell line identity was verified by high-resolution short tandem repeat 
(STR) profiling with Promega PowerPlex ®1.2 system.  
 
Phospho-RTK Array 
First-generation phospho-RTK arrays (#ARY001, R&D Systems, Minneapolis, 
MN) were used for assessing the phosphorylation status of 42 RTKs in 
chondrosarcoma cells under serum-depleted condition. Phospho-RTK analyses 
were performed as recommended by the manufacturer. Subconfluent cells were 
washed once with serum-free media, and incubated in serum-depleted medium for 
24 hr before harvest. A total of 450 g of protein was used for the assay.  
For qualitative assessment of signal, pixel densities on developed X-ray film were 
analyzed using a transmission mode scanner and the Adobe Photoshop software. 
The pixel densities of the areas (49 x 26 pixels, width x height) surrounding the 
pair of duplicate dots were determined. The pixel density of the PBS negative 
control was used as a background value and subtracted from each read. RTKs with 
a signal greater than the positive controls were scored as “+++”; RTKs with a 
signal level similar to positive controls were scored as “++”; and RTKs with a 
signal less than positive controls, but 5-fold higher than antibody isotype negative 
controls were scored as “+”. RTKs with signal less than 5-fold higher than the 
antibody isotype negative control were labeled as “-”. 
We used second-generation phospho-RTK arrays (#ARY001B, R&D Systems, 
Minneapolis, MN) to analyze the effects of long-term treatment of BEZ235 on the 
phosphorylation of RTKs because the first-generation RTK arrays were no longer 
available. The new arrays include 49 RTK capture antibodies but no longer contain 
antibody isotype negative controls. The pixel density was measured as described 
above. The changes in the phosphorylation level of RTKs were determined by 
comparing the intensity of RTK signals in BEZ235-treated samples to the 0.1% 
DMSO-treated control samples. 
 
Immunoprecipitation and Immunoblots  
Cells were lysed on ice in buffer containing 50 mM HEPES (pH 7.5), 150 mM 
NaCl, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 100 mM NaF, 10 mM 
Na4P2O710 H2O, 1 mM Na3VO4, and 1x Protease Inhibitor Cocktail (Roche 
Diagnostics, Germany). The following antibodies were used for 
immunoprecipitation from clarified cell lysates: EGFR (Calbiochem #GR01, San 
Diego, CA), ERBB2 (Calbiochem #OP15), Insulin R (Santa Cruz #sc-711, Santa 
Cruz, CA), IGF1R (Santa Cruz #sc-713), EphA2 (Upstate, #05-480), AXL (Santa 
Cruz #SC-1096), and PDGFR (Santa Cruz #SC-338). The immunoprecipitants 
were separated by SDS/PAGE and transferred to nitrocellulose membranes (Bio-
Rad, Hercules, CA). Antibodies for immunoblotting were purchased from 
Calbiochem (ERBB2 #OP15), Lab Vision, Fremont, CA (ERBB3 #MS-201-P), 
Upstate Biotechnology, Lake Placid, NY (anti-phosphotyrosine antibody 4G10 
#05-1050), Sigma, St. Louis, MO (-tubulin T9026), Santa Cruz (AXL #SC-1096, 
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PDGFR #SC-338) and Cell Signaling, Danvers, MA (EGFR #2232, p-EGFR 
#2234, p-ERBB2 #2243, p-ERBB3 #4791, MET #3127, p-MET #3129, p-
PDGFR #2992, Insulin R #3025, IGF1R #3027, AKT #9272, p-AKT (Ser473) 
#9271, p-AKT (Thr308) #9275, MAPK #9107, p-MAPK #9101, S6 #2217 and p-S6 
(Ser235/236) #2211, 4EBP1 #9644, p-4EBP1(Thr37/46) #2855, p-4EBP1(Ser65) #9451, 
p-4EBP1 (Thr70) #9455).  
 
Inhibitors 
MET inhibitor PHA665752 was purchased from Tocris Biosciences (Ellisville, 
MO). EGFR/ERBB2 inhibitor BIBW-2992 and MEK inhibitor ARRY-142886 
(AZD6244) were purchased from Medicilon (Shanghai, China) and OTAVA 
(Toronto, Canada), respectively. Insulin-like Growth Factor 1 Receptor 
(IGF1R)/Insulin Receptor (INSR) inhibitor PQIP was a kind gift from OSI 
Pharmaceuticals (Melville, NY). PI3K/mTOR inhibitor BEZ235 was purchased 
from AXON Medchem (Groningen, The Netherlands). PI3K inhibitor GDC-0941 
and mTOR inhibitor rapamycin were purchased from Chemdea (Ridgewood, NJ) 
and Calbiochem, respectively. 
 
siRNA  
ON-TARGETplus SMARTpools siRNA against EGFR, ERBB2, ERBB3, MET 
and a scrambled control were purchased from Dharmacon (Layfayette, CO). Cells 
were transfected with siRNA at a final concentration of 12.5 or 25 nM with 
RNAiMAX (Invitrogen) according to the manufacturer’s protocol. Cells were 
incubated with siRNA for 72 or 96 hr prior to analysis of cell viability.  
 
Cell Viability Assays 
Cells were plated in 96-well plates at 1000-2000 cells/well in 100 µl of medium 
containing 10% FBS. After 24 hr, cells were exposed to increasing concentrations 
of compounds. Each treatment was tested in triplicate. Cell viability was 
determined after 72 hr using the CellTiter-Glo Luminescent Cell Viability Assay 
Kit (Promega, Madison, WI) with a modification in the protocol in that the 
CellTiter-Glo reagent was diluted 1:3 with PBS. The relative luminescence units 
(RLU) were measured using the FLUOstar Optima plate reader (BMG Labtech 
GmbH, Germany) and relative cell number was calculated by normalization to the 
RLU of the control treated cells. 
   
Cell Cycle Analysis  
Cells were exposed to inhibitors or 0.1% DMSO for 24 hr and harvested. After 
washing with ice-cold PBS, cells were fixed in 70% ethanol at 4 ºC for at least 2 hr. 
Fixed cells were stained in PBS containing 10 g/mL RNase A and 20 g/mL 
propidium iodide (Sigma, St. Louis, MO) in the dark. DNA content analysis was 
performed by flow cytometry (FACSCalibur; Becton Dickinson, Mountain View, 
CA) with CellQuest and ModFIT LT software (Becton Dickinson). 





Genomic DNA was extracted from chondrosarcoma cell lines using DNeasy Blood 
& Tissue Kit (Qiagen, Valencia, CA) according to the manufacturer’s protocol. 
The coding sequences of selected genes in the PI3K/mTOR and RAS/MAPK 
pathways were amplified from genomic DNA by PCR with primers listed in the 
Table 8.1. PCR was performed in 50 μl reactions containing Platinum PCR 
SuperMix (Invitrogen), 200 ng DNA, 0.3 μM forward and reverse primers using 
GeneAmp® PCR System 9700 (Applied Biosystems, Carlsbad, CA). The PCR 
product was purified using Qiaquick PCR purification Kit (Qiagen), and sequenced 
using Big Dye Terminator V3.1 chemistry in combination with an Applied 
Biosystems 3730xl Sequencer. 
For chondrosarcoma primary tumor tissues, mutation analysis for PIK3CA (13) and 
NRAS was performed using DNA available from 89 chondrosarcomas. Hydrolysis 
probes assay was used to specifically screen for the PIK3CA c.1624G>A 
(p.E542K), c.1633G>A (p.E545K), and c.3140A>G (p.H1047R) and the NRAS 
c.35G>A (p.G12D), c.183A>T (p.Q61H), c.181C>A (p.Q61K), c.182A>T 
(p.Q61L), and c.182A>G (p.Q61R) hotspot mutations as described (13). Primer 
and probe sequences for NRAS mutation analysis are provided in Table 8.2. 
 
Tumor Xenografts in Nude Mice  
JJ012 cells (1 x 106) were suspended in PBS, mixed 1:1 with Matrigel (BD 
Biosciences), and subcutaneously injected into nude female mice (Nu/Nu, Charles 
River) in a final volume of 100 µl. Treatment began when tumors reached an 
average size of approximately 50 mm3. Mice were randomized into statistically 
identical cohorts ( 6 mice/group). BEZ235 was freshly prepared in 10:90 (v/v) N-
methyl pyrrolidone: polyethylene glycol 300 (Fluka #69118 and #81160), as 
described (14), and was administered daily at 35 mg/kg by oral gavage. Tumor 
xenografts were measured twice a week by ultrasound imaging (VisualSonic Vevo 
770, Toronto, Canada), and animal weight was recorded every 3-4 days. Following 
drug administration, tumors were harvested and fixed for histologic and 
immunohistochemical analysis or snap-frozen for immunoblot analysis. All 
procedures were performed according to protocols approved by the Institutional 
Animal Care and Use Committee of the Dana-Farber Cancer Institute.  
 
Tumor Xenograft Histology and Immunohistochemistry  
Haematoxylin and eosin staining as well as immunohistochemistry were performed 
on five-micron sections of formalin-fixed paraffin-embedded (FFPE) samples from 
tumors resected from mice. Tissue sections were deparaffinized, rehydrated, and 
microwaved in 10 mM citrate buffer (pH 6.0) in a 750 W microwave oven for 15 
min. Anti-phospho-S6 ribosomal protein (Ser 240/244) primary antibody (Cell 
Signaling, #2215) was added at a dilution of 1:100 and incubated overnight at 4 ℃. 
Sections were further processed with horseradish peroxidase-conjugated secondary 
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antibody. The reaction was detected by 3,3-diaminobenzidine and hematoxylin 
staining. Images were taken by using Olympus CX41 microscope with QCapture 
software (QImaging, Surrey, Canada). 
 
Tissue microarray immunohistochemistry 
Tissue microarrays (TMAs) containing 157 conventional chondrosarcomas and 25 
dedifferentiated chondrosarcomas were described previously (15, 16). All 
specimens were handled according to the ethical guidelines described in "Code for 
Proper Secondary Use of Human Tissue in The Netherlands" of the Dutch 
Federation of Medical Scientific Societies. TMAs contained 2 mm cores of all 
samples in triplicate. After de-waxing and rehydrating, TMAs were permeabilized 
with Tris-buffered saline (TBS)/0.5% Tween20 for 30 min at room temperature 
(RT) and washed several times in distilled water. For antigen de-masking, slides 
were immersed in citrate buffer (pH 6.0) and antigen retrieval was performed in a 
pressure cooker (Biocare Medical, UK) for 2 min at 125 °C followed by 10 min at 
85 °C. Non-specific binding was blocked in TBS/Tween20 (0.5%) and 10% goat 
serum for 1 hour at RT. Primary rabbit anti-pS6 antibodies (1:100, New England 
Biolabs, UK #4857) were incubated with the slides in a humidified chamber at 4 
°C over night. After washing 3 times, a secondary goat anti-rabbit Alexa 594 
antibody (1:300, Invitrogen, UK) was added. Nuclei were labeled with DAPI and 
slides were mounted with Prolong Gold Antifade (Invitrogen, UK).  Images were 
acquired with an Olympus Fluoview FV1000 confocal microscope and a 60x oil 
objective (NA: 1.35). Each image had a size of 2048 x 2048 pixels, a horizontal 
and vertical dimension of 211 µm x 211 µm and a thickness of 1.292 µm.  
 
Statistical Analysis  
Drug concentrations required to inhibit cell growth by 50% (IC50) were calculated 
by dose-response curve fitting with Prism version 5.0 (GraphPad Software). 
Comparisons between groups were made using the unpaired t-test. Differences in 
means ± SEM with p < 0.05 were considered statistically significant. 
 
  




Figure 8.1. Activation of multiple RTKs in chondrosarcoma cells. 
A. The phosphorylation status of 42 RTKs in chondrosarcoma cells under serum-depleted 
conditions was assessed by phospho-RTK arrays. Anti-RTK antibodies spotted on 
nitrocellulose membrane in duplicate were incubated with cell lysates followed by 
secondary anti-phosphotyrosine antibody detection. Positive controls are represented in the 
4 corners of each blot; negative antibody isotype controls and PBS control are represented 
in E13-20 and E21-22, respectively. The location and names of capture antibodies are listed 
in the first and second column of B. B. Qualitative heat-blot map of RTK array data. “+++”: 
RTK signal is higher than postive controls; “++”: signal is similar to positive controls; “+”: 
signal is lower than postive control but 5-fold higher than antibody isotype negative 
controls; “-“: low signal. C. Validation of phospho-RTK array data by immunoblot (IB) or 
immunoprecipitation (IP)/IB analysis. 
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20 H1047 F TGGGGTAAAGGGAATCAAAAG 1 TGACATTTGAGCAAAGACCTG 6 
R CCTATGCAATCGGTCTTTGC 
  
AKT1 2 E17 F 
M13-
















































F GAACCAAATGGAAGGTCACA 3 GAACCAAATGGAAGGTCACA 3 
R TGGGTAAAGATGATCCGACA 
  









BRAF 15 V600 F TCATAATGCTTGCTCTGATAGGA 3 TGCTTGCTCTGATAGGAAAATG  6 
R GGCCAAAAATTTAATCAGTGGA 
                    
§§M13 denotes the universal sequencing primer 5’-GTAAAACGACGGCCAGT-3’.  
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Table 8.2. Primers and reporters for NRAS mutation analysis 
Forward Primer 
Name Forward Primer Seq. Reverse Primer Name Reverse Primer Seq. 
NRAS35GA_F ATGACTGAGTACAAACTGGTGGTG NRAS35GA_R GGATTGTCAGTGCGCTTTTCC 
NRAS181CA_F GGTGAAACCTGTTTGTTGGACATAC NRAS181CA_R CCTGTCCTCATGTATTGGTCTCTCA 
NRAS182AT_F GGTGAAACCTGTTTGTTGGACATAC NRAS182AT_R GTATTGGTCTCTCATGGCACTGTAC 
NRAS182AG_F GGTGAAACCTGTTTGTTGGACATAC NRAS182AG_R TGGTCTCTCATGGCACTGTACT 
NRAS183AT_F GGTGAAACCTGTTTGTTGGACATAC NRAS183AT_R CCTGTCCTCATGTATTGGTCTCTCA 
    
Reporter 1 Name Reporter 1 Dye Reporter 1 Sequence Reporter 1 Conc. 
NRAS35GA_V VIC TTGGAGCAGGTGGTGTT 8 
NRAS181CA_V VIC CTGTACTCTTCTTGTCCAGC 8 
NRAS182AT_V VIC CAGCTGGACAAGAAGA 8 
NRAS182AG_V VIC ACAGCTGGACAAGAAG 8 
NRAS183AT_V VIC CACTGTACTCTTCTTGTCCAG 8 
    
Reporter 2 Name Reporter 2 Dye Reporter 2 Sequence Reporter 2 Conc. 
NRAS35GA_M FAM TTGGAGCAGATGGTGTT 8 
NRAS181CA_M FAM CTGTACTCTTCTTTTCCAGC 8 
NRAS182AT_M FAM ATACAGCTGGACTAGAAGA 8 
NRAS182AG_M FAM ACAGCTGGACGAGAAG 8 
NRAS183AT_M FAM ACTGTACTCTTCATGTCCAG 8 
      




Coactivation of RTKs in Chondrosarcoma Cells 
We employed phospho-RTK arrays to detect the phosphorylation status of 42 
RTKs in five human tumor-derived chondrosarcoma cell lines, and we observed 
that multiple RTKs were phosphorylated in cells under serum depletion conditions 
(Fig. 8.1A and B). For example, EGFR, MET, ERBB4, AXL, PDGFR, RON, and 
RET were phosphorylated in CS-1 cells. All four EGFR family members were 
phosphorylated in JJ012 cells. IGF1R, INSR, EGFR and EphA7 were 
phosphorylated in OUMS-27 cells.  
To further validate the phospho-RTK array data, we analyzed by immunoblot the 
expression and phosphorylation status of the 9 RTKs which were most strongly 
phosphorylated in the respective chondrosarcoma cell lines. As shown in Fig. 8.1C 
and Fig. 8.2A, the phospho-RTK array data were confirmed: EGFR (site Tyr1068) 
was highly phosphorylated in CS-1 cells and less so in the four other cell lines; 
ERBB2 (site Tyr1221/1222) and ERBB3 (site Tyr1289) were highly phosphorylated in 
JJ012 cells; phosphorylation of MET was detected in CS-1, JJ012, and SW1353 
cells, with the highest level in CS-1 cells; INSR  and IGF1R were highly 
phosphorylated in OUMS-27 cells; the highest phosphorylation level of AXL and 
EphA2 was observed in CS-1 and SW1353 cells, respectively; and phosphorylation 
of PDGFR was detected in CS-1 and CH-2879 cells.  
Moreover, most kinases remained constitutively phosphorylated under conditions 
of serum depletion at levels similar to that seen in the serum-containing media (Fig. 
8.1C). While the precise mechanism(s) of kinase activation remains unknown, it 
appears to be cell-autonomous and independent of exogenous growth factors.   
Taken together, the immunoblot data confirmed that RTKs are constitutively 
activated in chondrosarcoma cells, and that the patterns of activation vary among 
cell lines. 
 
Effects of RTK inhibition on the Growth of Chondrosarcoma Cells 
To explore the involvement of the above-noted highly activated RTKs on the 
growth and survival of chondrosarcoma cells, we applied small molecule inhibitors 
and/or siRNAs targeting corresponding RTKs to cells (Fig. 8.3). We examined the 
effects of the MET inhibitor PHA665752 (17) on MET signaling pathways and cell 
growth in the CS-1 cell line because of its high level of constitutive 
phosphorylation. MET phosphorylation at key residues in the kinase domain 
(Tyr1234/1235) was greatly suppressed by treatment with 200 nM PHA665752 in the 
presence of serum (Fig. 8.3A, left panel). Correspondingly, PHA665752 induced a 
dramatic reduction in cell number with 43% inhibition at 125 nM (Fig. 8.3B, left 
panel). We also applied MET siRNAs to exclude the possibility of off-target 
effects of the small molecule inhibitor. As shown in 8.2B, the expression of MET 
was dramatically decreased by MET siRNA. Cells transfected with MET siRNA 
had an obvious decrease (approximately 30%) in cell viability in comparison to 
control siRNA transfected cells after 72 hr (Fig. 8.2C). These results demonstrate 
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that MET is involved in the regulation of CS-1 chondrosarcoma cell growth. There 
was no significant effect of MET pathway inhibition in cell lines JJ012 and 
SW1353 that have low basal phospho-MET levels (Fig. 3B, left panel). In addition, 
we determined the effects of the EGFR inhibitor gefitinib and the anti-EGFR 
antibody cetuximab on the viability of CS-1 cells because of the high 




Effects of RTK inhibition in chondrosarcoma cells. 
A. Validation of phospho-RTK array data by immunoblot (IB) or 
immunoprecipitation (IP)/IB analysis. B. siRNA-mediated knockdown of RTK 
expression at 48 hr. C. siRNA-mediated knockdown of RTKs on growth of CS-1 
(at 72 hr) and JJ012 (at 96 hr) cells evaluated by CellTiter-Glo viability assay. 
Values represent mean ± SEM (n>3). ***, P<0.001, compared with scrambled 
siRNA-transfected cells. D. Effects of EGFR kinase family inhibitors on cell 
viability of JJ012 cells were evaluated by CellTiter-Glo viability assay at 72 hr. E. 
Effects of RTK inhibition on the signaling of PI3K/mTOR and MAPK pathways 
were evaluated by immunoblots.  
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In JJ012 cells, four members of the EGFR kinase family were phosphorylated. The 
irreversible EGFR/ERBB2 inhibitor BIBW-2992 (18) decreased phosphorylation 
of ERBB2 and ERBB3 (Fig. 8.3A, central panel), and inhibited cell growth in a 
dose-dependent manner with an IC50 of 0.38 ± 0.02 M (Fig. 8.3B, central panel). 
siRNA-mediated knockdown of ERBB3 also significantly reduced cell number 
(37.7% ± 6.1%) compared to control siRNA at 96 hr after transfection (P<0.001; 
Fig. 8.2B and 8.2C). However, the EGFR-specific inhibitors gefitinib and erlotinib 
only demonstrated mild effects as did siRNA mediated knockdown of EGFR and 
ERBB2 (Fig. 8.2C and 8.2D). These findings suggest that EGFR family kinases, 
and in particular ERBB3, are important regulators of the growth of JJ012 cells.  
In OUMS-27 cells, IGF1R and INSR are highly phosphorylated. Treatment with 
the IGF1R/INSR inhibitor PQIP (19, 20) decreased phosphorylation of IGF1R 
and INSR (Fig. 8.3A, right panel), and inhibited growth in a dose-dependent 
manner with an IC50 of 1.42 ± 0.08 M (Fig. 8.3B, right panel). These data suggest 
that the insulin receptor kinase family is involved in the growth of OUMS-27 cells.  
 
Effects of RTK Inhibition on the Activity of PI3K/mTOR and MAPK Pathways in 
Chondrosarcoma cells 
We further examined the effects of RTK inhibition on the PI3K/mTOR and MAPK 
pathways. In MET-dependent CS-1 cells, treatment with the MET inhibitor 
PHA665752 for 2 hr led to a dose-dependent decrease in the phosphorylation of 
AKT at Thr308 and Ser473, S6 at Ser235/236 and p44/42 MAPK at Thr202/Tyr204 (Fig. 
8.3A, left panel). In JJ012 cells, phosphorylation of AKT and S6 was partially 
reduced by BIBW-2992 treatment, but no effect on MAPK phosphorylation was 
observed (Fig. 8.3A, central panel). In OUMS-27 cells, IGF1R/INSR inhibitor 
PQIP treatment decreased AKT and S6 phosphorylation in a dose-dependent 
manner, with complete inhibition at 1.25 µM, but had no effect on MAPK 
phosphorylation (Fig. 8.3A, right panel). The inhibition of phosphorylation in the 
presence of the above inhibitors was continued for at least 24 hr, with the level of 
phosphorylation at 24 hr even somewhat lower (Fig. 8.2E). No significant 
inhibition on the phosphorylation of 4EBP1 was observed following the treatment 
of RTK inhibitors for 1 or 24 hr (Fig. 8.2E). 
 




Figure 8.3. Effects of 
RTK inhibition in 
chondrosarcoma cells. 
A. Effects of MET 
inhibitor PHA665752 (left 
panel, at 2 hr), 
EGFR/ERBB2 inhibitor 
BIBW-2992 (central 
panel, at 2 h) and 
IGF1R/INSR inhibitor 
PQIP (right panel, at 6 h) 
on the phosphrylation of 
RTKs and their 
downstream effectors 
were evaluated by 
immunoblot. B. Effects of 
RTK inhibitors on cell 
viability were evaluated 
by CellTiter-Glo assay at 72 hr.   
 
Chondrosarcomas have PI3K/mTOR Activation and are Sensitive to Inhibitors in 
vitro  
The above data suggest that RTKs are important mediators of chondrosarcoma cell 
growth. However, the heterogeneity of implicated pathways poses a considerable 
challenge to the clinical evaluation of any single tyrosine kinase inhibitor for the 
treatment of this disease. Targeting common pathways downstream of RTKs may 
instead be a method to inhibit cell growth irrespective of the particular upstream 
signaling molecule.  
We hypothesized that the PI3K/mTOR pathway might commonly mediate 
signaling from heterogeneous RTK activation and thus we examined the activity of 
this pathway in human primary chondrosarcoma tissue specimens. As an 
established surrogate of PI3K/mTOR pathway activity, we analyzed the S6 
phosphorylation status in chondrosarcoma tissue microarray samples by 
immunohistochemical staining. In total, 73 out of 106 (69%) conventional 
chondrosarcomas and 11 out of 25 (44%) dedifferentiated chondrosarcomas were 
positive (Table 8.3, Fig. 8.4). 
In order to determine whether PI3K/mTOR signaling and S6 phosphorylation were 
relevant to chondrosarcoma growth, we tested the effects of BEZ235, a dual 
PI3K/mTOR inhibitor (14). Treatment with BEZ235 potently inhibited the growth 
of all of the chondrosarcoma cell lines, with IC50 values below 10 nM (Fig. 8.8A, 
left panel). Cell cycle analysis showed a substantial increase in the proportion of 
cells in the G0/G1 phase of the cell cycle after treatment with the inhibitor (Fig. 
8.5A). No induction of apoptosis was observed (data not shown).  
 





Figure 8.4. S6 phosphorylation in chondrosarcoma clinical tissue microarray samples. 
Confocal images of immune-labeled sections with DAPI and anti-pS6 antibody in 
chondrosarcoma samples. Example images from central chondrosarcoma, peripheral 
chondrosarcoma and high grade areas of dedifferentiated chondrosarcoma display the 
sometimes sparse distribution and heterogeneity of cellular labeling in tumor regions. 
Positive controls are of breast carcinoma and normal spleen. Bar 20µm. 
 
We also tested the effects of the PI3K inhibitor GDC-0941 and the mTOR inhibitor 
rapamycin on cell growth. Each were significantly less potent than BEZ235, with 
GDC-0941 inhibiting the growth of chondrosarcoma cell lines with IC50 values of 
0.9-2.5 M, and rapamycin causing 22-49% growth inhibition at a concentration of 
1000 nM (Fig. 8.5B).  
Functionally important mutations in the PI3K/mTOR pathway have been reported 
as potential predictors of sensitivity to the treatment of PI3K/mTOR pathway 
inhibitors (21, 22). We sequenced selected hotspot sites, including PIK3CA (exon 9 
and 20), AKT1 (exon 2), and PTEN (exon 5). However, no mutations were detected 
in these five chondrosarcoma cell lines (data not shown). Moreover, PIK3CA 
hotspot mutations were absent in all 88 chondrosarcomas tested using hydrolysis 
probe assays (data not shown). 










A. Cell cycle analysis of 
JJ012 cells following 
24hrs treatment with 
BEZ235. B. Effects of 
PI3K inhibitor GDC-
0941 and mTOR 
inhibitor rapamycin on 
chondrosarcoma cell 
viability evaluated by 
CellTiter-Glo assay 
after 72 hr. Values 
represent mean ± SEM 
(n=3). C. Effects of 
BEZ235, GDC-0941 
and rapamycin 
treatment on the 
phosphorylation of 
AKT, S6, 4EBP1, and 
MAPK in JJ012 cells were evaluated by immunoblot. 
 
Sustained suppression of phosphorylation of S6 and 4EBP1, and feedback 
induction of AKT phosphorylation after prolonged treatment with BEZ235 in vitro  
We used the phosphorylation state of AKT, S6 [a major substrate of p70 S6 kinase 
1 (S6K1)], and 4EBP1 as markers to monitor the activity of PI3K/mTOR pathway 
inhibitors. The Thr308 site and Ser473 sites of AKT are regulated by PDK1 (a major 
downstream effector of PI3K kinase) and the mTORC2 complex, respectively.  
The mTORC1 complex catalyzes the phosphorylation of S6K1 and 4EBP1. (23-25)  
Following 2 hr treatment of JJ012 with BEZ235, the phosphorylation of S6 and the 
Ser65 site of 4EBP1 were suppressed at 1 nM and 30 nM, respectively, and the 
phosphorylation of AKT and the Thr37/46 and Thr70 sites of 4EBP1 was inhibited at 
100 nM (Fig. 8.5C). Following 24 hr treatment, the inhibition of S6 and 4EBP1 
phosphorylation was well sustained or even strengthened (Fig. 8.8B, left panel), 
while the initial inhibition on the AKT phosphorylation was dramatically reversed 
at 24 hr with an increase in phosphorylation level at the Thr308 site of AKT at 10 
and 100 nM. At 300 nM, BEZ235 treatment still potently inhibited the 
phosphorylation of Ser473 at 24 h, keeping AKT activity in a partially suppressed 
status, as phosphorylation of both Thr308 and Ser473 sites is required for full AKT 
activation (26, 27) (Fig. 8.8B, left panel). We further examined the effects of 
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BEZ235 treatment on the PI3K/mTOR signaling in the other four chondrosarcoma 
cell lines, and similar results were observed: the phosphorylation of S6, 4EBP1 and 
the Ser473 site of AKT, but not Thr308 site, were effectively inhibited by 300 nM 
BEZ235 treatment at 24 hr (Fig. 8.6A-8.6D). The effects of BEZ235 on MAPK 
phosphorylation were also examined, and a slight increase in its phosphorylation 
level was observed when JJ012 and SW1353 cells were treated with 100-1000 nM 
BEZ235 (Fig. 8.5B, Fig. 8.6B). 
In comparison to BEZ235, GDC-0941 effectively inhibited the phosphorylation of 
AKT at 300 nM, but required a much higher concentration (1000-10000 nM) to 
inhibit the phosphorylation of S6 and 4EBP1 (Fig. 8.5C). Following 24 h treatment 
with GDC-0941, the phosphorylation level of the Thr308 site of AKT remained 
suppressed. A slight induction of the phosphorylation signal of S6 and Ser473 site of 
AKT was observed in OUMS-27 and CS-1 cells, respectively (Fig. 8.6A and 
8.6D). 
Rapamycin treatment blocked S6 phosphorylation but only slightly decreased the 
phosphorylation of 4EBP1 at 10 nM (Fig. 8.5C, Fig. 8.8B). It has previously been 
demonstrated that mTORC1 inhibition can lead to feedback activation of PI3K in 
cancer cells (25). In SW1353 and OUMS-27 cells, we also observed a dramatic and 
lasting increase in the phosphorylation level of AKT at Thr308 and Ser473 following 
rapamycin treatment (Fig. 8.6B and 8.6D). However, in JJ012 cells rapamycin 
treatment enhanced the phosphorylation level of AKT only at Thr308, and not at 
Ser473 (Fig. 8.8B). There were no obvious changes observed in CS-1 and CH-2879 
















Figure 8.6. Time-dependent effects of PI3K/mTOR pathway inhibitors on the 
activation of AKT and MAPK signaling pathway in chondrosarcoma cells. 
A. Effects of BEZ235 (B), GDC-0941 (G), rapamycin (R), and DMSO control (C) on the 
phosphorylation of AKT, S6, 4EBP1, and MAPK in CS-1 (panel A), SW1353 (panel B), 
CH-2879 (panel C), and OUMS27 (panel D). Cells were evaluared by immunoblot at 1, 6, 
and 24 hr. 
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for pS6§ (%) 
Enchondroma 7 5 (71) 
Osteochondroma 6 5 (83) 
Conventional Chondrosarcoma 106 73 (69) 
Central Chondrosarcoma 80 58 (73) 
Grade I 37 27 (73) 
Grade II 30 20 (67) 
Grade III 13 11 (85) 
Peripheral Chondrosarcoma 26 15 (58) 
Grade I 14 9 (64) 
Grade II 9 5 (56) 
Grade III 3 1 (33) 
Dedifferentiated Chondrosarcoma 25 11 (44) 
§ pS6: phosphorylated S6 staining as performed on tissue microarrays 
 
In vivo effects of PI3K/mTOR inhibitor BEZ235 on chondrosarcoma tumor growth 
and PI3K/mTOR signaling 
The antitumor activity of BEZ235 was studied in a mouse xenograft model of the 
JJ012 cell line treated for 21 days with drug or vehicle control. As shown in Fig. 
8.7A, BEZ235 significantly suppressed tumor growth (p<0.01). No significant 
weight loss of the mice was observed (data not shown). Histologic analysis 
demonstrated a marked decrease in tumor cell viability as well as in the 
phosphorylation of S6 protein (Fig. 8.7B). We also explored the effects of short-
term (2 hr) and long-term (21 days+2 hr) treatment of BEZ235 on PI3K/mTOR 
signaling in JJ012 xenografts by immunoblots (Fig. 8.7C). The phosphorylation 
signal of S6 was diminished in all of the xenografts samples treated with 35 mg/kg 
BEZ235. The multiple phosphorylation sites of 4EBP1 were differentially 
dephosphorylated: phosphorylation of Ser65 site was suppressed, and 
phosphorylation of Thr70 and Thr37/46 sites were partially decreased, which may 
enable 4EBP1 to partially block the function of the eukaryotic translation initiation 
factor 4E (eIF4E), since the phosphorylation of Thr70 and Ser65 sites are critical for 
the release of 4E-BP1 from eIF4E (28, 29). BEZ235 treatment also decreased the 
phosphorylation of AKT at the Ser473 site, but the inhibition became less profound 
following the prolonged treatment of BEZ235. A slight increase in phosphorylation 








Figure 8.7. BEZ235 inhibits in vivo growth of JJ012 chondrosarcoma xenografts and 
reduced phosphorylation of S6 and 4EBP1 
A. JJ012 xenografts were treated with 35 mg/kg BEZ235 daily or with vehicle alone by oral 
gavage for 21 days. Tumor size was determined by ultrasound every 3-4 days. Values 
represent mean volume ± SEM (n>5). **, p<0.01, compared with respective control group 
treated with vehicle. B. Representative examples of hematoxylin and eosin staining in 
tumor xenografts 21 days after vehicle or BEZ235 treatment; and representative 
immunohistochemistry staining for phospho-S6 in tumor xenografts 2 hr after vehicle or 
BEZ235 treatment. Original magnification: 400×. C. After 21 days of BEZ235 (BEZ) or 
vehicle (Veh.) treatment, 6 mice were given an additional dose of vehicle or 35 mg/kg 
BEZ235 2 hr before the tumors were harvested. The phosphorylation levels of AKT, S6, 
4EBP1, and MAPK in those xenograft tumors were examined by immunoblots.      
 
BEZ235-induced hyperphosphorylation of IGF1R family kinases and feedback 
activation of AKT in chondrosarcoma cells 
Since it has been reported that rapamycin can induce feedback activation of AKT 
through RTK-dependent mechanisms (25), we used RTK arrays to explore the 
changes in RTK phosphorylation following 24 hr treatment with BEZ235. A 
common increase in the phosphorylation levels of IGF-1R and/or INSR was 
observed (Fig. 8.8C and 8.9A and 8.9B). We further checked the combinational 
effects of BEZ235 and the IGF1R/INSR inhibitor PQIP on AKT phosphorylation 
at the Thr308 site in OUMS-27 and SW1353 cells, and found that this remained 
suppressed following combination treatment with BEZ235 and PQIP for 24 hr (Fig. 
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8.8D). These data suggest that BEZ235 induces feedback activation of 
IGF1R/INSR, which further induces AKT phosphorylation in chondrosarcoma 
cells. 
 
Figure 8.8. Effects of PI3K/mTOR inhibitor BEZ235 and MEK Inhibitor ARRY-
142886 on chondrosarcoma cells in vitro.  
A. Dose-dependent reduction in chondrosarcoma cell number following 72 hr treatment 
with BEZ235 (left panel) or ARRY-142886 (right panel). Values represent mean ± SEM 
(n=3). B. Effects of rapamycin, BEZ235 (left panel, in JJ012 cells), and ARRY-142886 
(right panel, in SW1353 cells) treatment on the activation of AKT, S6, 4EBP1, and MAPK. 
C. The phosphorylation status of 49 RTKs in SW1353 cells was assessed by phospho-RTK 
arrays after 24 hr treatment with 0.1% DMSO (control) or 300 nM BEZ235. The location 
and names of capture antibodies are listed in Fig. 8.9B. The IGF1R kinase is highlighted 
with a rectangle. C. Combinational treatment with BEZ235 and IGF1R/INSR inhibitor 
PQIP prevented AKT from reactivation as evaluated by immunoblot at 24 hr. 






Figure 8.9. Feedback effects on phosphorylation of RTKs following 24hr 
treatment of BEZ235 in chondrosarcoma cells.  
A. The phosphorylation status of 49 RTKs was assessed by phospho-RTK arrays 
after 24 hr treatment with 0.1% DMSO (Control) of 300nM BEZ235. The positive 
controls are represented at A1-2, A23-24, adn F1-2; the PBS negative control is 
represented at F23-24. The location of capture antibodies for RTKs is listed in 
panel B. The changes in the phosphorylation level of IGF1R kinase family 
members were highlighted with a rectangle. B. The location of capture antibodies 











NRAS-Mutated Chondrosarcoma Cell Line is Sensitive to Inhibition of MAPK 
pathway  
In contrast to BEZ235, the MEK inhibitor ARRY-142886 (30) only inhibited the 
growth of SW1353, and had minimal effects on the other 4 chondrosarcoma cell 
lines (Fig. 8.5A, right panel). Sequencing of hotspot mutation-containing exons of 
HRAS, KRAS, NRAS (exon 2 and 3) and BRAF (exon 15) genes (31, 32) revealed a 
heterozygous c.181C>A (Q61K) mutation in NRAS in SW1353 cells (Fig. 8.10A). 
No mutation was found in these exons in the other four cell lines. 
We additionally performed hotspot mutation analysis for NRAS exons 2 and 3 in 
DNA from frozen chondrosarcoma clinical samples. NRAS mutations were found 
to be specific for a subset of conventional central chondrosarcomas: six samples 
(12%) harbored NRAS mutations, including 2 c.181C>A (Q61K) mutations, and 4 
c.182A>T (Q61H) mutations (Table 8.4). The other chondrosarcoma subtypes were 
negative.  
We examined the effects of ARRY-142886 on the MAPK and PI3K/mTOR 
pathways in SW1353 cells. Treatment with ARRY-142886 for 1 hr led to a dose-
dependent decrease in the phosphorylation of MAPK with complete inhibition at 
300 nM, but had no obvious effect on the phosphorylation of AKT, S6, or 4EBP1 
(Fig. 8.5B, right panel, Fig. 8.10B). With more prolonged treatment, a dramatic 
decrease in S6 phosphorylation and a partial inhibition of AKT phosphorylation 
were observed following 24 hr treatment with ARRY-142886 (Fig. 8.8B, right 
panel). The mechanism is unclear.  
We also examined the combinational effects of BEZ235 and ARRY-142886 on 
MAPK and AKT signaling pathways in SW1353 cells, and found stronger 
inhibition in comparison to BEZ235 treatment alone (Fig. 8.10C). 
Correspondingly, the combination of BEZ235 and ARRY-142886 had additive 
inhibitory effects on the cell viability in SW1353 cells (Fig. 8.10D). However, 
apoptosis was not observed following the combination treatment. 
  
  





Figure 8.10. Combinational effects of BEZ235 and MEK inhibitor ARRY-142886 in 
SW1353 cells with NRAS mutation. 
A. Sequencing was performed with forward or reverse sequencing primer. The top 
chromatogram is the mutant sequence of NRAS in SW1353 cells, and the bottom is a wild-
type sequence. B. Effects of MEK inhibitor ARRY-142886 on MAPK phosphorylation 
evaluated by immunoblot at 1hr. C. Effects of combination treatment with BEZ235 and 
ARRY-142886 on the signaling of PI3K/mTOR pathway and MAPK pathway analyzed by 
immunoblot at 24hr in SW1353 cells. D. Effects of combination treatment with BEZ235 
and ARRY-142886 on cell viability evaluated by CellTiter-Glo cell viability assay at 72 hr 










Sarcomas constitute a heterogeneous family of mesenchymal tumors with 
divergent lineages of differentiation. Some sarcomas have well-defined pathogenic 
genetic lesions, such as activating kinase mutations in gastrointestinal stromal 
tumors (GIST) or translocations that yield aberrant chimeric transcription factors in 
Ewing sarcoma, for example. Many other subtypes of sarcomas have no known 
dominant molecular pathogenic lesions to explain disease initiation, maintenance, 
or progression. Chondrosarcomas fall in this latter category (1, 4, 33) although 
recent reports indicate that approximately half have mutations in IDH1 or IDH2 
(34), which are considered to be an early event and of which the functional 
consequences remain to be established. Chondrosarcomas are notoriously resistant 
to conventional chemotherapeutic agents and currently no effective systemic 
therapies exist for metastatic or unresectable disease. A better molecular and 
biochemical understanding of this malignancy may yield novel and effective 
treatment approaches.  
We explored the potential role of receptor tyrosine kinases in driving 
chondrosarcoma cell survival and proliferation. We identified constitutive, serum-
independent activation of the MET, EGFR family, and IGF1R/INSR family kinases 
in multiple cell lines through as of yet unidentified mechanisms. Inhibition of RTK 
signaling by treatment with small molecule kinase inhibitors or by suppressing 
RTK expression with siRNA led to alterations in phosphorylation of downstream 
pathway members and a concomitant decrease in cellular proliferation. The 
incomplete block of cell growth suggests that other parallel pathways are also 
likely to be important.    
Consistent with our data demonstrating RTK activation, strong and common 
phosphorylation of the downstream signaling proteins AKT, MEK, and S6 kinase 
was previously demonstrated using kinase substrate peptide arrays and extracts 
from chondrosarcoma cell lines and primary cultures (35). Here, we have linked 
RTK activation in chondrosarcoma cells to PI3K/AKT/mTOR signaling by 
demonstrating that RTK inhibitors suppress AKT and S6 phosphorylation. 
Moreover, high-level phosphorylation of S6 was found in approximately 70% of 
chondrosarcoma tumors, suggesting that activation of the PI3K/AKT/mTOR 
pathway in cell lines is clinically relevant. We also identified functional mutations 
of NRAS in a chondrosarcoma cell line and in clinical samples; these may 
contribute to the activation of the MAPK signaling pathway. 
Notably, the heterogeneous pattern of RTK and NRAS activation among the 
varying human tumor-derived chondrosarcoma cell lines poses a challenge for the 
potential clinical development of tyrosine kinase inhibitors for this disease. 
Molecular profiling of signaling pathways in any given individual tumor might 
suggest a specific kinase inhibitor as a rational agent to test in that specific 
individual patient. Accordingly, such drugs could be studied in selected groups of 
patients, but this is a highly personalized and potentially cumbersome approach to 
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rare tumor subsets. An alternative approach may be to target shared downstream 
kinases, such as components of the PI3K/mTOR pathway. Indeed, the PI3K/mTOR 
inhibitor BEZ235 dramatically and potently blocked the growth of all 
chondrosarcoma cell lines in vitro and inhibited tumor growth in vivo. These data 
suggest that PI3K/mTOR pathway inhibitors, many of which are currently in 
clinical development (36-38), should be studied for their efficacy in the treatment 
of advanced chondrosarcoma.  
In chondrosarcoma cells, BEZ235 exhibited more potent inhibition on cell growth 
than the mTORC1 inhibitor rapamycin and PI3K inhibitor GDC-0941. A detailed 
comparison of the effects of these three inhibitors on PI3K/mTOR signaling 
showed that BEZ235 is a more potent inhibitor of the phosphorylation of S6 and 
4EBP1, important regulators of global protein synthesis and cap-dependent protein 
translation, respectively (39). Increases in the overall rate of protein synthesis as 
well as enhanced translation of oncogenes are often driven by the hyperactivation 
of RTKs and their downstream effectors, allowing uncontrolled growth and 
survival of cancer cells (40). The ability of BEZ235 to inhibit S6 and 4EBP1 
phosphorylation both in vitro and in vivo may account for its potent antitumor 
activity in chondrosarcoma as well as in other cancer types (41, 42). 
In the models presented here, the major effect of BEZ235 treatment was primarily 
cell cycle inhibition and a delay in tumor growth. A combination of BEZ235 and 
IGF1R/INSR inhibitor prevented AKT from reactivation, but still failed to induce 
apoptosis. High expression of BCL2 family members was recently shown to play 
an important role in chemoresistance of chondrosarcoma, and inhibition of BCL2 
was shown to repair the apoptotic machinery, rendering chondrosarcoma cells 
chemosensitive (43). Inhibition of BCL2 may further supplement the observed 
outcome of PI3K/mTOR blockade by inducing cell apoptosis.  
Recently, growth inhibitory effects of BEZ235 were reported in osteosarcoma, 
Ewing sarcoma, and rhabdomyosarcoma model systems (44). However, aside from 
their common mesenchymal origin, these sarcoma subtypes are generally 
chemosensitive and are unrelated to chemo- and radio-resistant chondrosarcomas, 
strongly differing in their biology and clinical behavior. 
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Chondrosarcoma     
Conventional 
Central 
50 2 (4) 4 (8) 6 (12) 
Grade I 13 0 (0) 0 (0) 0 (0) 
Grade II 28 2 (7.1) 1 (3.6) 3 (10.7) 
Grade III 9 0 (0) 3 (33.3) 3 (33.3) 
Conventional 
Peripheral 
17 0 (0) 0 (0) 0 (0) 
Dedifferentiated 
Chondrosarcoma 
10 0 (0) 0 (0) 0 (0) 
Clear Cell 
Chondrosarcoma 
9 0 (0) 0 (0) 0 (0) 
Mesenchymal 
Chondrosarcoma 
3 0 (0) 0 (0) 0 (0) 
 
 
In our study, an activating NRAS mutation was identified in 12% of clinical 
chondrosarcoma samples. Two of these 6 chondrosarcoma samples also contain an 
IDH1 R132C mutation (45). Similarly, SW1353 carries IDH2 (45) and NRAS 
mutations, indicating that these mutations are not mutually exclusive. SW1353 
cells were found to be sensitive to MEK inhibitors as well as to a PI3K/mTOR 
inhibitor. A combination of these two inhibitors had additive suppresion of 
SW1353 cell viability but did not induce apoptosis, consistent with reported effects 
of the combination in colorectal carcinomas with RAS mutations (46). 
Taken together, our study identifies the heterogeneity of RTK activation present in 
chondrosarcoma cell lines, and suggests that inhibition of the PI3K/mTOR 
pathway, a common signaling pathway downstream of RTKs, may be a rational 
therapeutic strategy for the treatment of advanced chondrosarcoma. Identification 
of NRAS mutations show that a subset may be particularly sensitive to MEK 
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Summary and concluding remarks  
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I. Chondrosarcoma from bench to bedside 
 
Chapter 1 emphasizes the need for translational research in chondrosarcoma. 
Model systems are needed to establish a bench to bedside pipeline and translate 
laboratory findings to new therapeutic strategies. The application of model systems 
and the importance of translational research in chondrosarcoma is illustrated in 
chapter 2 which reviews recent advances in pre-clinical chondrosarcoma research 
unraveling the role of EXT and IDH mutations in tumorigenesis as well as the 
therapeutic potential of targeting apoptosis and survival pathways. This thesis has 
shown the development of two model systems, both in vitro (cell lines, 2D and 3D 
culture)  and in vivo (orthotopic mouse models), to aid in the search for new 
therapeutic strategies in chondrosarcoma. These model systems were subsequently 
used to study the role of apoptotic and survival pathways in chemoresistance.  
As translational research is focused around the patient (fig 9.1), the collection of 
tumor material for frozen tissue, paraffin embedded tissue and cell culture is 
crucial. Frozen tissue can be used for DNA, RNA, and protein analysis, and 
paraffin embedded tissue is used for immunohistochemical analysis. When tissue 
microarrays (chapter 6- 8) are created,  immunohistochemical analysis of multiple 
tissues simultaneously is facilitated. Collection of cells for cell culture and the use 
of cell lines (chapter 3) are vital in chondrosarcoma translational research, as in 
vitro tumor cell behavior can be studied in 2D and 3D culture (chapter 5) , in 
response to drug treatment (chapters 5-8). Moreover, stable cell lines can be used 
for injection in mouse models (chapter 4), to generate xenografts. These in vivo 
models enable the evaluation of drug efficacy taking into account the 
microenvironment. If a drug proves to be safe and effective in the mouse models, 
the results can guide the design of clinical trials increasing the chance of a 
successful trial. Conducting large clinical trials is difficult, requiring large 
multicenter collaboration given the rarity of these tumors, and obtaining funding is 
challenging. Through combined European efforts, such as EuroBoNet and 
euroSARC, the study of larger patient groups and design of multicenter clinical 
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Figure 9.1. Chondrosarcoma from bench to bedside. Tumor material obtained from the patient can be used for several research purposes. 
Tissue embedded in paraffin can be used for protein expression and tissue microarrays are especially useful for the detection of proteins on 
multiple tumor tissues at once. Tissue microarrays are increasingly used for the identification of biomarkers. The isolation of fresh cells can 
be used for 2D and 3D cell culture to study in vitro tumor cell behavior and to possibly generate new cell lines. Frozen tissue can be used for 
DNA , RNA and protein analyses. Using cell culture models and siRNA screens, targets for treatment can be identified and compound 
screens can be performed. Compounds proven successful in vitro, can then be validated in the orthotopic mouse model, which will also allow 
for safety testing of combination strategies. Collaborative efforts such as EuroBoNet and euroSARC have enabled the collection of large 
databases for pre-clinical studies and are now facilitating clinical trials. For a rare malignancy such as chondrosarcoma, large cohort studies 
such as also performed in this thesis would have been impossible without the existence of such networks. 
Chapter 9                                                                                                      184 
 
II. Cell lines as model systems to study chondrosarcoma 
 
In order to establish representative models fully representing chondrosarcoma 
heterogeneity, in chapter 3 the existing cell line panel for chondrosarcoma was 
expanded. Growing chondrosarcoma cells in culture is a challenge, and often 
overgrowth of fibroblasts is observed. At the start of this thesis, four stable 
chondrosarcoma cell lines were available, all derived from conventional central 
chondrosarcoma. One more cell line derived from conventional central 
chondrosarcoma and two derived from dedifferentiated chondrosarcoma were 
generated, and over time four additional cell lines were developed by others (1). 
This panel is representing the genetic heterogeneity of chondrosarcoma as three 
cell lines harbor IDH1 mutations, two IDH2 mutations, and five TP53 mutations. 
Moreover, all show loss of p16 expression, not always due to CDKN2A 
mutations/chromosomal aberrations, emphasizing the role of p16 in progression 
(table 3 chapter 3). The importance of a cell line panel representing the full 
heterogeneity of chondrosarcoma is subsequently illustrated in both chapter 7 and 
chapter 8. In chapter 7, TP53 mutant cell lines were more sensitive to tyrosine 
kinase inhibition in combination with doxorubicin than TP53 wildtype cell lines. In 
chapter 8 receptor tyrosine kinase profiling revealed heterogeneity in receptor 
tyrosine kinase activation among the cell lines. For instance, only SW1353 was 
particularly sensitive to MEK inhibition, which was based on the presence of an 
NRAS mutation, which was subsequently found in 12% of conventional central 
chondrosarcomas. These results strongly emphasize the importance of a broad and 
extensive cell line panel, representing the full heterogeneity of chondrosarcoma.  
 
III. Orthotopic mouse model to study chondrosarcoma 
 
Cell lines can provide information about tumor cell behavior, however, during the 
development of new therapeutic strategies, information about the tumor 
microenvironment should also be taken into account. The natural niche for 
chondrosarcoma is in the bone, and the communication between healthy bone and 
tumor cells as well as the influence of blood supply and the immune system on 
tumor development and chemoresistance cannot be investigated using cell lines. A 
reliable mouse model, representing human chondrosarcoma, could aid in providing 
answers about in vivo tumor behavior and drug response, and bridge the gap 
between cell lines and clinical trials.   
As the natural niche for chondrosarcoma is in the bone, in chapter 4, 
orthotopicchondrosarcoma mouse models were created. A chondrosarcoma grade 
II cell line with IDH2 and TP53 mutations, and a chondrosarcoma grade III cell 
line wild type for IDH and TP53 were used. Rather than subcutaneous xenografting 
of tumor tissue or cell lines, luciferase transformed cell lines were injected in the 
tibiae. Therefore, tumor growth could be monitored throughout the duration of the 
experiment. Using doxorubicin, we show that this model is a valuable tool to 
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monitor in vivo tumor growth over time and will prove useful when testing new 
therapeutic strategies.  
 
IV. Apoptosis signaling in conventional chondrosarcoma and rare 
chondrosarcorcoma subtypes  
 
In chapter 5 2D and 3D cell culture models were used to explore the underlying 
causes of chemoresistance in conventional chondrosarcoma. We first established 
that resistance was not due to the extracellular matrix or multidrug resistance pump 
activity. As the literature showed high expression of the anti-apoptotic proteins 
Bcl-2 and Bcl-w in high grade conventional chondrosarcoma, the role of Bcl-2 
proteins in chemoresistance was further investigated in the cell lines using the BH-
3 mimetic ABT-737 (fig 9.2). Intermittent combination therapy with doxorubicin 
or cisplatin allowed for a dramatic reduction in concentrations used and induced 
apoptosis in all cell lines, indicating that Bcl-2 anti-apoptotic proteins are important 
in chemoresistance and that inhibition of Bcl-2 family members sensitizes 
chondrosarcoma cells for subsequent treatment with conventional 
chemotherapeutic agents.  
In chapter 6, the original hypothesis was to correlate the morphological 
resemblance of clear cell chondrosarcoma, dedifferentiated chondrosarcoma and 
mesenchymalchondrosarcoma with the different stages of the growth plate by 
studying proteins involved in growth plate signaling. To this end a tissue 
microarray study was performed, however, protein expression patterns in the 
different subtypes were not correlated to differentiation stages in the growth plate. 
Interestingly, in both dedifferentiated and mesenchymal chondrosarcoma, 
differences in protein expression could be observed between the cartilaginous 
components and the anaplastic components, indicating distinctive pathway 
activations in the respective malignant components. In all subtypes, strong 
expression of anti-apoptotic Bcl-2 family members was found, suggesting a 
specific upregulation of anti-apoptotic proteins in chondrosarcoma irrespective of 
subtype. For dedifferentiated chondrosarcoma, 2 cell lines were available, and 
combination treatment of ABT-737 with doxorubicin or cisplatin showed a 
reduction in cell viability, indicating a similar resistance mechanism in place as in 
conventional chondrosarcoma. The uniformity of inhibition of chondrosarcoma cell 
proliferation through the combination of Bcl-2 family inhibitors with 
chemotherapy indicates that this strategy is a strong therapeutic candidate for 
chondrosarcoma treatment.  
 
V. Survival pathways in conventional chondrosarcoma 
 
In chapters 7 and 8 increased kinase signaling was hypothesized to contribute to 
increased chondrosarcoma survival and as such to chemoresistance. As the Src 
pathway was previously found to be active in chondrosarcoma (2),  its role in 
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chemoresistance was investigated in chapter 7 . Moreover, since TP53 mutations 
are described to play a role in chemoresistance as well (3;4), a possible correlation 
between response and functional p53 was investigated. Cell lines with mutant TP53 
were found to be especially sensitive to the combination of doxorubicin with 
dasatinib (Src inhibition, fig 9.2). However, dasatinib as a single agent has been 
shown to overcome chemoresistance in other malignancies despite TP53 mutations 
(5;6). Thus, also in chondrosarcoma resistance mechanisms could be operable that 
can be overcome by dasatinib. Interestingly, Src inhibition was additionally found 
to uniformly inhibit migration across all cell lines, suggesting that chemoresistance 
and migration act through different pathways. 
In chapter 8, the chondrosarcoma cell line panel was used toinvestigate activation 
of receptor tyrosine kinases which further confirmed the heterogeneity of 
chondrosarcoma cell lines. Moreover, mutation analysis revealed an NRAS 
mutation in one cell line (SW1353) and in 12% of conventional chondrosarcomas. 
Downstream pathway analysis showed that despite heterogeneity in RTK 
activation, all cell lines showed activation of the PI3K/mTOR pathway (fig 9.2). 
Going back to human chondrosarcoma tissues using tissue microarrays, using pS6 
immunohistochemistry, mTOR pathway activation was confirmed in 69% of 
conventional and 44% of dedifferentiated chondrosarcomas. Using both cell lines 
and xenograft mouse models, dual PI3K/mTOR inhibitors were found to 
successfully inhibit chondrosarcoma tumor growth.  
In 2D cell culture, a combined strategy of dual PI3K/mTOR inhibitors with MEK 
inhibitors was found to be most successful, especially in NRAS mutated cells. 
However, in this study as well as in the literature, in RAS mutated cells such an 
approach does not lead to the induction of apoptosis.  
 
VI. Leads for new therapeutic strategies to overcome chemoresistance in 
chondrosarcoma 
 
Chemoresistance mechanisms in chondrosarcoma prove to be complicated. This 
thesis shows the activation of apoptosis pathways as well as survival pathways. In 
all cell lines inhibition of Bcl-2 family members with BH3 mimetics in 
combination with conventional chemotherapeutic agents leads to a dramatic 
reduction in cell viability. Src inhibition with dasatinib was found to be especially 
successful in TP53 mutant cell lines when combined with doxorubicin. In addition, 
circumventing the heterogeneity of upstream RTK activation, PI3K/mTOR 
activation was found to be a common downstream activation mechanism across 
cell lines. Moreover, preliminary data show that mTOR inhibition in combination 
with doxorubicin overcomes chemoresistance (van Oosterwijk et al, unpublished 
results), providing a third option for treatment in chondrosarcoma. Thus, using the 
bench to bedside pipeline, the importance of Bcl-2 family members, Src family 
kinases, and the PI3K/mTOR pathway in chemoresistance was demonstrated. 
Moreover, in vitro studies suggest a role for combination strategies, in which 
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inhibition of one of these three pathways renders the tumor cells sensitive to 





Figure 9.2. Interplay of survival and apoptosis pathways in chondrosarcoma. 
Activation of EGFR, IGF1R, and MET receptor tyrosine kinases (RTKs) were found using 
RTK profiling. Further investigation revealed activity of downstream PI3K/mTOR and 
MAPK pathways. Kinome profiling had previously revealed Src, PI3K, and AKT activity, 
and immunohistochemistry confirmed high mTOR signaling in human chondrasarcom 
tissues. The MAPK pathway was found to be activated in a subset of chondrosarcomas due 
to activating NRAS mutations, therefore downstream targeting with a MEK inhibitor is 
warranted. Active PI3K/mTOR, Src, and MAPK signaling pathways can lead to increased 
cell survival, but also promote resistance to apoptosis. Inhibition of apoptosis and 
upregulation of survival and proliferation can lead to chemoresistance, and targeting these 
pathways with inhibitors (shown in yellow) was found to successfully inhibit proliferation 
and overcome chondrosarcoma chemoresistance mechanisms. RAF and MEK can inhibit 
the transcription of the activating BH3 protein BIM, and PI3K can inhibit the sensitizing 
BH3 protein BAD. Lack of presence of these BH3 proteins leaves anti-apoptotic Bcl-2 
proteins free to sequester the pro-apoptotic proteins BAX and BAK, in which case 
apoptosis is inhibited. As upregulation of anti-apoptotic Bcl-2 proteins was found in 
combination with activation of these kinase pathways, a therapeutic approach targeting 
these pathways simultaneously is advised.  
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VII. Future prospects 
 
The orthotopic mouse model (chapter 4), can be used to explore the in vivo 
efficacy of the combination strategies that were shown here as in vitro data 
suggests these compounds are successful candidates for clinical trials. Future 
studies might explore the combination of dual PI3K/mTOR inhibitors with MEK 
inhibition in combination with BH-3 mimetics. This thesis shows the therapeutic 
potential of PI3K/mTOR inhibitors with MEK inhibitors (chapter 8) and of BH3 
mimetics (chapter 5&6), and recently such an approach was shown to induce 
apoptosis in RAS mutated cells (7). 
To further unravel the role of apoptosis and survival mechanisms in 
chemoresistance, in the final year a synthetic lethal siRNA screen with doxorubicin 
and cisplatin has been optimized and performed. The siRNA screen has been 
performed using the dharmacon libraries for ~80 apoptosis genes and a ~800 
kinases. The results of this screen will identify the key players in the pathways 
described in this thesis and will increase our understanding of the complicated 
nature of chemoresistance of chondrosarcoma. Moreover, in the future, a similar 
approach can be used to investigate the resistance to radiotherapy, which will 
provide answers as to whether this resistance is mediated by similar pathways or 
that a distinct resistance mechanism is in place. In the coming years, the results 
from the apoptosis and kinase screen will need to be validated using shRNA, and 
protein expression of identified genes will be examined on human chondrosarcoma 
tissue using tissue microarrays. Using 2D cell culture and the orthotopic mouse 
model, inhibitors will be evaluated for their efficacy targeting the key players 
identified. This project was designed to corroborate and expand on earlier findings, 
and the ultimate goal will be proceed to clinical trials. The completion of the bench 
to bedside pipeline as shown here will hopefully aid in the rapid clinical 
implementation of effective targeted therapy for chondrosarcoma.  
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I. De brug van basaal onderzoek naar therapie 
 
Het chondrosarcoom is een kwaadaardige kraakbeenvormende tumor in het bot en 
na het osteosarcoom de meest voorkomende kwaadaardige bottumor in de mens. 
Chondrosarcomen zijn resistent tegen conventionele radio- en chemotherapie. 
In hoofdstuk 1 wordt het belang van translationeel onderzoek naar 
chondrosarcomen beschreven. Modelsystemen zijn noodzakelijk om resultaten die 
gevonden zijn in het laboratorium te vertalen naar patiënten en indien mogelijk 
nieuwe therapieën te ontwikkelen. De toepassing van modelsystemen en het belang 
van de juiste vertaling van de resultaten wordt beschreven in hoofdstuk 2, waar 
ook recente resultaten in pre-klinisch onderzoek naar chondrosarcomen worden 
toegelicht. Uit onderzoek  wordt de rol van EXT en IDH mutaties in tumorgenese, 
alsook de mogelijkheden voor een gerichte therapie, duidelijk. In dit proefschrift 
wordt de ontwikkeling van twee modelsystemen, zowel in vitro (cellijnen, 2D and 
3D kweken) als in vivo (orthotopische muismodellen) beschreven, om het 
onderzoek naar nieuwe behandelmethoden voor chondrosarcomen te ondersteunen. 
Deze modelsystemen werden vervolgens gebruikt om de rol van apoptose- en 
overlevings signaaltransductiecascades in chemoresistentie te bestuderen. 
Aangezien het translationeel onderzoek zich richt op de patiënt, is het verzamelen 
van tumor materiaal (ingevroren, in paraffine of in celkweken) zeer 
belangrijk. Ingevroren materiaal kan worden gebruikt voor DNA, RNA en eiwit 
analyse.In paraffine bewaard weefsel kan worden gebruikt voor 
immunohistochemische analyse. Wanneer tissue micro-arrays (een paraffineblokje 
waarin meerdere kleine stukjes tumor van verschillende patienten worden 
geplaatst) worden gemaakt (hoofdstuk 6-8), kan gelijktijdig de 
immunohistochemische analyse van meerdere weefsels worden uitgevoerd. Het 
verzamelen van cellen voor celkweken en het gebruik van cellijnen (hoofdstuk 3) 
zijn essentieel voor het translationele onderzoek naar chondrosarcomen. Het invitro 
gedrag van tumorcellen kan worden bestudeerd in 2D en 3D kweken (hoofdstuk 5) 
evenals de reactie op medicijnen (hoofdstuk 5-8). Daarnaast kunnen stabiele 
cellijnen worden gebruikt voor injectie in muismodellen (Hoofdstuk 4) om 
xenograften te creëren. Deze invivomodellen maken het mogelijk om het effect van 
medicijnen te beoordelen waarbij rekening kan worden gehouden met 
omgevingsfactoren. Indien een behandeling veilig en effectief blijkt in 
muismodellen kan het resultaat gebruikt worden voor de ontwikkeling van 
klinische studies. Hiermee wordt de kans op succes verhoogd. Aangezien 
chondrosarcomenzeldzaam zijn is het alleen dankzij europese netwerken zoals 
EuroBoNet en EuroSARC mogelijk studies met grotere patientenpopulaties uit te 
voeren. 
 
II. Cellijnen als modelsysteem om chondrosarcomen te onderzoeken 
 
Om representatieve modellen te ontwikkelen, waarbij de grote verscheidenheid aan 
chondrosarcomen recht wordt gedaan, wordt in hoofdstuk 3 beschreven hoe het 
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bestaande cellijn-panel voor chondrosarcomen kan worden uitgebreid. Het kweken 
van chondrosarcoom cellen is lastig en leidt vaak tot een overmaat aan 
fibroblasten. Bij het begin van het onderzoek beschreven in dit proefschrift stonden 
vier stabiele chondrosarcoom cellijnen ter beschikking, welke allen afkomstig 
waren van conventionele centrale chondrosarcomen. Gedurende het onderzoek 
werd een additionele cellijn afkomstig van conventioneel centraal chondrosarcoom 
gegenereerd en tevens twee cellijnen afkomstig van gededifferentieerd 
chondrosarcoom. Daarnaast werden zes cellijnen ontwikkeld door andere 
onderzoeksgroepen (1). Deze cellijnen zijn representatief voor de genetische 
verscheidenheid van chondrosarcomenaangezien drie cellijnen IDH1 mutaties laten 
zien, twee cellijnen IDH2 mutaties en vijf TP53 mutaties. Bovendien treedt bij alle 
cellijnen onderdrukking van p16 op (hoodstuk 3, tabel 3). Het belang van een set 
cellijnen die representatief is voor de verscheidenheid van chondrosarcomen wordt 
duidelijk gemaakt in zowel hoofdstuk 7 als hoofdstuk 8. In hoofdstuk 7 wordt 
beschreven dat cellijnen metTP53 mutaties gevoeliger zijn voor tyrosine kinase 
inhibitie in combinatie met doxorubicine dan cellijnen zonder TP53 mutaties. 
Hoofdstuk 8 beschrijft het verschil in receptor tyrosine kinase activering tussen de 
verschillende cellijnen. Zo was bijvoorbeeld alleen de cellijn SW1353 bijzonder 
gevoelig voor MEK-inhibitie hetgeen verklaard kan worden uit de aanwezigheid 
van een NRAS mutatie. Deze mutatie was ook aanwezig in 12% van de 
conventionele centrale chondrosarcomen. Deze resultaten benadrukken het belang 
van een brede en uitgebreide set van cellijnen welke representatief zijn voor de 
onderlinge verschillen tussen de chondrosarcoom cellijnen. 
 
III. Orthotopische muis modellen ter bestudering van chondrosarcomen 
 
Hoewel cellijnen informatie kunnen verschaffen over het gedrag van tumorcellen, 
moet men voor de ontwikkeling van nieuwe therapeutische mogelijkheden ook 
rekening houden met de invloed van de omgeving op de tumorcel. De natuurlijke 
omgeving voor chondrosarcomenis het bot. De relatie tussen gezond weefsel en de 
tumorcel en de invloed van bloedtoevoer en het immuunsysteem op de 
ontwikkeling van tumorcellen kan echter niet worden bestudeerd bij het gebruik 
van cellijnen. Een betrouwbaar muismodel voor het menselijke chondrosarcoom is 
noodzakelijk om antwoorden te krijgen over de relatie tussen in vivo tumor gedrag 
en de respons op specifieke behandelingsmethoden. Tevens kan het een brug slaan 
tussen cellijn onderzoek en klinische studies. 
In hoofdstuk 4 wordt de ontwikkeling van een dergelijk orthotopischmuismodel 
beschreven. Hiervoor werden een graad II cellijn, met IDH2 en TP53 mutaties, en 
een graad III cellijn, wild type voor IDH en TP53, gebruikt.  
Luciferasegetransformeerde cellijnen werden in de tibiae geinjecteerd. Hierdoor 
kon de groei van de tumor in het bot gemonitordworden gedurende het beloop van 
het experiment.  
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IV. Apoptose signaaltransductie cascade in conventionele en zeldzame vormen 
van chondrosarcomen 
 
Hoofdstuk 5 beschrijft hoe 2D en 3D modellen kunnen worden gebruikt om de 
onderliggende oorzaken van chemoresistentie  in conventionele chondrosarcomen 
te onderzoeken. Als eerste is aangetoond dat de resistentie niet afhankelijk is van 
de extracellulaire matrix of van de multidrug resistentiepompen. Aangezien de 
literatuur een hoge activiteit van de anti-apoptotische eiwitten Bcl-2 en Bcl-w in 
hooggradige conventionele chondrosarcomen laat zien, is de rol van Bcl-2 eiwitten 
verder onderzocht in cellijnen met behulp van de Bcl-2 remmer ABT-737. 
Tussentijdse combinatie behandeling, gebruik makend van doxorubicine of 
cisplatine, liet een dramatische reductie in de gebruikte concentraties zien en 
veroorzaakte apoptose in alle gebruikte cellijnen. Dit toont aan dat Bcl-2 anti-
apoptotische eiwitten belangrijk zijn in chemoresistentie en dat inhibitie van Bcl-2 
eiwitten chondrosarcoom cellen gevoelig maakt voor behandeling met traditionele 
chemofarmaca. 
In hoofdstuk 6 werd onderzocht of de eiwitexpressie van de verschillende 
zeldzame subtypes(gedifferentieerd, mesenchymaal, en clear cell chondrosarcoom) 
overeenkwam met de verschillende stadia van de groeiplaat. Voor dit doeleinde is 
een tissue microarray(een paraffineblokje waarin meerdere kleine stukjes tumor 
van verschillende patienten worden geplaatst) gemaakt. In tegenstelling tot de 
verwachting, kwam de expressie van de eiwitten in de verschillende subtypes niet 
overeen met de verschillende stadia in de groeiplaat waarmee ze morfologisch 
overeenkwamen. In alle subtypes werd sterke expressie van de anti-apoptotische 
Bcl-2 eiwitten gevonden, suggestief voor een specifieke opregulatie van anti-
apoptotische eiwitten in chondrosarcomen, onafhankelijk van subtype. Van één van 
de zeldzame subtypes, gededifferentieerd chondrosarcoom, waren twee cellijnen 
beschikbaar. Combinatie behandeling met ABT-737 en doxorubicine of cisplatine 
liet een reductie in cel activiteit zien, wat wijst op eenzelfde resistentie 
mechanisme als in conventioneel chondrosarcoom. De overeenkomst die werd 
geobserveerd in de reactie op combinatie van Bcl-2 eiwit inhibitie en 
chemotherapie met betrekking tot een stop in cel proliferatie, suggereert dat deze 
strategie een sterke therapeutische kandidaat is voor de behandeling van 
chondrosarcomen.  
 
V. Overlevings signaaltransductie cascade in conventionele chondrosarcomen 
 
In de hoofdstukken 7 en 8 wordt onderzocht in hoeverre toegenomen kinase 
activiteit bijdraagt aan de overlevingskansen van chondrosarcoom cellen en 
eventuele resistentie tegen chemotherapie.  Eerder is beschreven dat de Src 
signaaltransductie cascade actief is in het chondrosarcoom (2) en de rol van dit 
mechanisme bij chemoresistentie wordt bestudeerd in hoofdstuk 7. 
Aangezien TP53 mutaties eveneens een rol spelen bij chemoresistentie (3;4) is ook  
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onderzocht in hoeverre deze mutaties de respons op therapie beïnvloeden. Cellijnen 
met gemuteerd TP53 bleken extra gevoelig voor de combinatie van doxorubine met 
Src inhibitie door middel van dasatinib (Src inhibitie). Het is echter aangetoond dat 
monotherapie met dasatinib ook in staat is chemoresistentie te overwinnen in 
andere kwaadaardige tumoren, ondanks TP53 mutaties (5;6). Dus ook in het 
chondrosarcoom kunnen mechanismen actief zijn die met behulp van dasatinib 
geblokkeerd kunnen worden. Tevens werd gevonden dat Src inhibitie de migratie 
blokkeert bij alle gebruikte cellijnen, hetgeen suggereert dat migratie en 
chemoresistentie volgens verschillende mechanismen verlopen. 
In hoofdstuk 8 is het panel van chondrosarcoom cellijnengebruikt om de activatie 
van tyrosine-kinase receptoren (RTK) te onderzoeken, welke de onderlinge 
verschillen tussen de verschillende cellijnen bevestigde. Daarnaast werd door 
mutatie analyse aangetoond dat één cellijn een NRAS mutatie bevatte (SW1353), 
welke kon worden bevestigd in 12% van de conventionele chondrosarcomen. 
 Ondanks verschillen in RTK activatie lieten alle cellijnen activatie van 
PI3K/mTOR zien. Activatie van het mTOR mechanisme kon worden aangetoondin 
69% van de conventionele en 44% van de gededifferentieerde chondrosarcomen. 
Zowel bij het gebruik van cellijnen als bij muismodellen werd aangetoond dat de 
tumorgroei succesvol kan worden afgeremd door het gebruik van PI3K/mTOR 
inhibitoren. 
In 2D celkweken bleek een gecombineerde aanpak van PI3K/mTOR remmers met 
MEK remmers het meest effectief, in het bijzonder in NRAS gemuteerde cellen. 
Echter, zowel in dit onderzoek als uit de literatuur blijkt dat bij RAS mutaties dit 
niet tot apoptose leidt. 
 
VI.Mogelijkheden voor nieuwe therapeutische strategieën 
 
Het is gebleken dat de mechanismen voor chemoresistentie in chondrosarcomen 
complex zijn. In dit proefschrift worden de rol van apoptose- en de overlevings 
signaaltransductie cascades in chemoresistentie onderzocht. In alle bestudeerde 
cellijnen leidde blokkering van Bcl-2 in combinatie met chemotherapie tot een 
duidelijke afname van de celgroei.Src-inhibitie door middel van dasatinib was met 
name succesvol in cellijnen met een TP53 mutatie indien dit gecombineerd werd 
met doxorubicine. Daarnaast werd aangetoond dat in alle cellijnen de PI3K/mTOR 
signaaltransductie cascade geactiveerd is, welke gebruikt kon worden om de 
verscheidenheid van de RTK activering te omzeilen. Bovendien laten voorlopige 
data zien dat mTOR afremming in combinatie met doxorubicine de mogelijkheid 
biedt om chemoresistentie te overwinnen (van Oosterwijk et al, ongepubliceerde 
resultaten). Dit biedt daarmee een derde mogelijkheid voor de behandeling van het 
inoperabele chondrosarcoom. Het belang van Bcl-2, Src-kinase en het PI3K/mTOR 
mechanisme als mogelijke aangrijpingspunten voor behandeling is daarmee 
aangetoond. Daarnaast kan op basis van in-vitro studies worden geconcludeerd dat 
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een combinatie van middelen succesvol kan zijn, met name in die gevallen waar 




Het orthotopische muismodel (hoofdstuk 4) kan worden gebruikt om in vivo de 
effectiviteit te onderzoeken van de combinatie van behandelmethoden die als 
mogelijke kandidaten uit in vitro onderzoek naar voren gekomen zijn. Toekomstig 
onderzoek kan zich dan richten op duale PI3K/mTOR inhibitie in combinatie met 
MEK afremming. Dit proefschrift laat de therapeutische mogelijkheden van zowel 
PI3K/mTOR gecombineerd met MEK-remmers (hoofdstuk 8) alsook van Bcl-2 
inhibitors zien (hoofdstuk 5 en 6). Recent is aangetoond dat een benadering 
waarbij deze therapieën gecombineerd worden leidt tot apoptose in cellen met 
RAS-mutaties (7). 
In het laatste jaar van het onderzoek beschreven in dit proefschrift is nog een 
"synthetic lethal siRNA screen", gebruik makend van doxorubicine en cis-platina, 
geoptimaliseerd en uitgevoerd om verdere opheldering van de rol van de apoptose- 
en de overlevings signaaltransductie cascade  bij chemoresistentie te verkrijgen. 
Hierbij is gebruik gemaakt van de Dharmacon bibliotheek (ca 80 apoptose genen 
en ca 800 kinases). Verwacht wordt dat op basis van deze screening het mogelijk 
zal zijn om de belangrijkste componenten voor de beschreven mechanismen te 
identificeren, wat tot een beter begrip van de onderliggende factoren zal leiden. In 
de toekomst zal deze methode ook worden gebruikt om de resistentie voor 
radiotherapie in het chondrosarcoom te onderzoeken. Dit kan dan inzicht geven in 
de resistentie voor radiotherapie en of dit op dezelfde mechanismen berust of dat 
hier een heel ander mechanisme een rol speelt. In de komende periode zullen de 
resultaten van apoptose en kinase screening gevalideerd moeten worden door 
middel van short hairpin RNAs (shRNA). Doormiddel van het introduceren van 
shRNA in een cel kan specifiek gen expressie worden onderdrukt. Hiermee 
geïdentificeerde targets kunnen vervolgens met gebruik van de pijplijn beschreven 
in dit proefschrift gevalideerd worden. In combinatie met de hier beschreven 
resultaten wordt hopelijk snel een weg gebaand naar implementatie van 
doelgerichte therapie voor inoperabel of gemetastaseerd chondrosarcoom. 
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